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ABSTRACT 
There are over 840,000 people in the UK with dementia, most of whom will 
experience Behavioural and Psychological Symptoms of Dementia (BPSD).  
Treatment options for BPSD are limited and often they have been managed with 
anti-psychotic medication, which increase mortality and the risk of stroke in people 
with dementia. Consequently, it is imperative to evaluate the impact that non-
pharmacological interventions such as physical exercise have on BPSD. This 
research seeks to address this matter by: exploring the current state of knowledge 
through a literature review; designing a simple, measurable and safe physical 
intervention for BPSD; devising, carrying out and reporting findings on a 
methodologically robust trial of exercise; and discussing its impact and future 
directions.  
A rapid appraisal of the literature showed that exercise programmes for people with 
dementia have often been poorly conceptualised and research methods had 
significant limitations; this was addressed with the design of EVIDEM-E. EVIDEM-E 
was a pragmatic, randomised, parallel group, single-blind, controlled trial that 
evaluated the effectiveness of exercise (planned walking) on the BPSD symptoms 
of 131 dyads (individuals with dementia and their carers). Physical exercise was 
delivered as an individually tailored regime of walking designed to become 
progressively intensive.  
Regular walking did not produce a statistically significant reduction in BPSD. This 
exercise, however, attenuated carer burden significantly. It is not clear whether this 
was because of the exercise per se, increased psychosocial interaction between 
carer and person with dementia, or a Hawthorne effect. Further research should 
focus on the mechanisms by which exercise may affect carers’ burden and whether 
reducing carer burden has long-term effects.  
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1 INTRODUCTION 
1.1 What is Dementia 
The word Dementia is derived from Latin (de=out from; mens= the mind) and 
means loss of mental abilities due to illness. Dementia is a syndrome that is defined 
as “progressive brain atrophy due to nerve cell loss leading to a characteristic 
worsening of memory and global intellectual deterioration without impairment of 
consciousness” (Rowley, 1994).  Dementia is almost always an irreversible process 
that damages areas of the brain that control thinking, memory, reasoning, 
personality, perception and language.  Some types of dementias are potentially 
reversible. The causes for these types of dementia can be: toxic reaction to 
medication, vitamin B12 deficiency, hormonal dysfunction, tumours and dietary 
deficiency. (Solomon and Budson, 2011). There are different types of dementia, 
which are discussed further in paragraph 1.1.3.  
1.1.1 Historical context 
King Lear, Act 4, Scene 7:60-70 
LEAR: "Pray, do not mock me: I am a very foolish fond old man; 
Four score and upward, not an hour more nor less;  
And, to deal plainly, I fear I am not in my perfect mind;  
Methinks I should know you, and know this man; 
Yet I am doubtful: for I am mainly ignorant. What place this is; and all the skill I have; 
Remembers not these garments; nor I know not where I did lodge last night; 
Do not laugh at me; for, as I am a man, I think this lady to be my child Cordelia." 
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William Shakespeare wrote King Lear around 1606. He portrayed what we now 
know as dementia about 300 years before Alois Alzheimer’s landmark description. 
Depictions of disorders of memory in older adults can be traced back to 2000-1000 
BC in Egyptian and Greek civilizations (Berchtold and Cotman, 1998). References 
to dementia-like conditions can also be found in Roman, Indian and Chinese 
medical texts. In India the complementary physicians called Ayurvedic used the 
Sanskrit term Smriti Bhransh to describe loss of memory (Mishra et al., 2013). Also, 
in some parts of South India, the word Chinan is used to refer to a condition 
associated with ageing, deterioration in memory, abnormal behaviour and 
incontinence. The Chinese used the words Zhi Dai Zheng for dementia and Lao 
Ren Zhi Dai Zheng for senile dementia (Zhang et al., 2006). 
The word ‘démence’ has existed in the French language since 1381 and implied a 
lack of ability to function on day-to-day basis. Apart from clinical implications 
‘démence’ was introduced in the legal system during Napoleon’s reign.  This is 
represented in Article 10 of the Napoleonic Code 1808: 'There is no crime when the 
accused is in a state of dementia at the time of the alleged act'.  
Medical use of the term dementia evolved throughout the 19th century and was 
used to describe a degenerative memory disorder often associated with old age, 
distinguishing it from other mental health problems such as depression or psychosis 
(Berchtold and Cotman, 1998). 
In 1907 Alois Alzheimer identified the ‘senile plaques’ and ‘neurofibrillary tangles’ 
that are common to the brains of people with Alzheimer's type dementia. Alois 
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Alzheimer was the first to identify and publish a clinical case of ‘pre-senile dementia’ 
(Figure 1.1), which was later named after Alzheimer by Kraepelin (1909/1910). The 
description below is a clear depiction of behavioural and psychological symptoms of 
dementia, which I will return to later (page 32).   
Definitions of dementia have become more medically specific in the last three 
decades. Currently the diagnostic criteria for dementia (American Psychiatric 
Association, 2013) refers to the multiple cognitive and intellectual deficiencies and 
decline involving memory, new and previously learnt information and problems with 
language, impairment of motor skills, inability to recognize familiar people or objects 
and impairments in planning, organizing and abstract reasoning. The process of 
ageing has been considered dominantly under the disciplines of biology and 
medicine (biomedicine) (Estes and Binney, 1989), which is being discussed further 
in the next section.   
“One of the first disease symptoms of a 51-year-old woman was a strong feeling of 
jealousy towards her husband. Very soon, she showed rapidly increasing memory 
impairments; she could not find her way about her home, she dragged objects to 
and fro, hid herself, or sometimes thought that people were out to kill her, then she 
would start to scream loudly. From time to time she was completely delirious, 
dragging her blankets and sheets to and fro, calling for her husband and daughter, 
and seeming to have auditory hallucinations. Often she would scream for hours and 
hours in a horrible voice.” 
Figure 1.1 Extract from: Alzheimer, 1907 
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1.1.2 Biomedicalization of dementia 
During this brief journey in the history of dementia, it is remarkable how its definition 
has changed but descriptions of the symptoms remain more or less the same. Our 
conceptualization of dementia has changed through time and it has been informed 
by very important medical discoveries. Development of medication for dementia 
helped bring dementia out of the shadows and foster discussion. However, it seems 
that the more is learned about dementia mechanisms and brain structural changes 
the more medical focus the definition takes and the further away it departs from 
important social and psychological factors. The biomedical model of dementia 
assumes there is a causal relationship between neuropathology and dementia. 
Kitwood (1989) and Lyman (1989) challenged the medical model of dementia as 
inadequate and as a way of medicalizing dementia by treating it strictly as a medical 
problem. The biomedical model describes the diagnosis of a disease process, 
attempts to explain its causation and offer (limited) management with 
pharmaceutical drugs. Thus, this account tends to lose sight of the person who 
suffers from the condition and overlooks essential social factors such as the carers 
and their wider social and family support systems.  
The loss of cognitive functions can bring about distress in individuals who suffer 
from it, and amongst the people who care for them, usually family members. Lyman 
argues that being given the medical label of ‘dementia’ with a prognosis of 
progressive deterioration brings about feelings of helplessness and despair (Lyman, 
1989). The labeling itself may limit the social engagements of those diagnosed and 
reduce social and functional expectations from carers, family and friends, thereby 
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imposing ‘learned helplessness’. ‘Learned helplessness’ is a condition when 
individuals believe they have no control over any situation, whatever they do 
(Seligman, 1991). Lyman (1989) suggests that while the biomedical model may be 
useful in terms of giving order to the care provided through introducing some 
predictability and control it can affect significantly the behaviour of the people 
diagnosed and their carers. Thus, activities which could be construed as “normal” 
such as walking may be interpreted by carers as signs of disease and be labeled or 
pathologised as ‘wandering’.  
Kitwood (1993) proposed a model of dementia, called the Theory of Personhood 
that takes into account individual differences, social and psychological factors as 
well as neurological impairment.  He puts forward the following equation: 
 SD = P + B + H + NI + SP 
SD stands for the clinical symptoms of dementia; P for individual’s personality 
characteristics such as coping styles towards change and loss and help seeking 
attitude; B refers to individual life stories in terms of losses, bereavement, and 
weakening of their lifelong support systems; H represents physical health; NI 
neurological impairment and SP social psychology and its effect on person’s values 
and wellbeing.  
Kitwood’s Theory of Personhood comprises a holistic, non-biomedical approach to 
the individual with dementia which alongside other psychosocial theories of BPSD 
(discussed in Paragraph 1.3.3) is a fundamental element of the EVIDEM-E study 
design as described in this thesis. The trial was carefully designed to tailor a non-
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medical intervention to each participant with dementia and their carer in order to test 
the hypothesis that physical activity would improve Behavioural and Psychological 
Symptoms of Dementia (BPSD) and carer burden. We used a rigorous approach, 
which is distinctive of pharmacological trials, to test a non-medical intervention. The 
evidence-base of dementia research is characterised by poor quality studies of non-
pharmacological interventions (Kverno et al., 2009; Thuné-Boyle et al., 2012).  
1.1.3 Dementia sub-types 
Dementia is an umbrella term for memory disorders and other cognitive changes in 
older adults, and is therefore a syndrome. Different types of dementia exist of which 
Alzheimer’s disease is the most common and therefore quite often it is used in lay 
language as a synonym for dementia.  
Primary neurodegenerative disorders: Alzheimer’s disease, along with 
Parkinson’s disease, Huntington's disease, Lewy Body dementia and a group of 
conditions referred to as Frontotemporal dementia (FTD), are conditions that result 
in progressive degeneration or death of nerve cells. 
Vascular disorders: Vascular dementia is caused as a result of conditions such as 
atherosclerosis, stroke or vasculitis that impair blood flow to the brain. 
1.1.4 Diagnostic criteria for dementia  
Dementia is difficult to recognise clinically in its early phase (Vernooij-Dassen et al., 
2005). The process usually includes taking medical and informant history, brain 
imaging, and neuropsychological testing, as well as other investigations depending 
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on the individual's presentation, as summarised in the Nice Guidelines (2006). The 
growing body of evidence about biomarkers has allowed them to be incorporated 
into the diagnostic research criteria, especially for Alzheimer’s disease (Dubois et 
al., 2007).  
A set of criteria is often used to help make an accurate diagnosis. There are two 
main criteria systems presently used: The International Classification of Diseases 
and Related Health Problems 10th Revision (ICD-10) (World Health Organization, 
1993), and the Diagnostic and Statistical Manual of Mental Disorders (5th Edition), 
also known as the DSM-V (American Psychiatric Association, 2013).    
The DSM-V outlines a detailed set of criteria for the diagnosis of dementia under the 
category of Major Neurocognitive Disorder (NCD). According to DSM-V a diagnosis 
is made when there is established cognitive impairment in addition to memory 
deficits that significantly affect social functioning and are characterised by gradual 
onset and irreversibility.  
The ICD-10 criteria is not worded as precisely as the DSM-V and has been 
criticised for being open to personal interpretations (Regier et al., 2013). 
Nevertheless, ICD-10 is widely used in both clinical and research settings  (Naik 
and Nygaard, 2008). We chose to use ICD-10 instead of DSM-V because of a focus 
on emotional, behavioural and motivational decline (Table 1.1).   
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Table 1.1 Criteria for dementia diagnosis according to ICD-10 and DSM-V 
Diagnostic Criteria ICD-10 DSM-V 
Memory impairment: recent or long term  X X 
Other cognitive disturbances 
aphasia  
apraxia  
agnosia  
executive functioning  
  
X 
Impairment of: 
abstraction  
judgement  
thinking  
planning/organizing  
 
 
X 
 
Preservation of awareness/consciousness X  
Decline in or change of : 
emotional liability  
irritability  
apathy  
coarsening of social behaviour  
 
X 
 
Duration 6 month or more X  
 
The accuracy of dementia diagnosis has been evaluated through post mortem 
identification of neuropathological sign especially senile plaques and neurofibrillary 
tangles. The diagnostic accuracy for Alzheimer’s disease has been reported to 
range from 65–96% with a specificity (the percentage of healthy people who are 
correctly identified as not having dementia)  of 23%–88% (Kazee et al., 1993; Lim et 
al., 1999; Varma et al., 1999). The positive predictive value (the chance that a 
person with diagnosis truly has dementia) has been reported as 80%-90% (Corey-
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Bloom et al., 1995). However these values vary on the setting where the diagnosis 
is made and the exact clinical and neuropathological criteria used. There are two 
established neuropathological diagnostic criteria: Braak and Braak's criterion that 
evaluates the density and distribution of neurofibrillary tangles and is mainly used in 
research settings, and the Consortium to Establish a Registry for Alzheimer's 
disease (CERAD) criterion that evaluates the highest density of senile plaques and 
is most frequently used in clinical outcome studies (Murayama and Saito, 
2004).  Thus, diagnosis made at special memory clinics have been reported to have 
higher positive predictive values than diagnosis made in the primary care (Corey-
Bloom et al., 1995). Neuropathological studies are susceptible to the selection bias 
because patients seen in a specialised memory clinic are more likely to receive an 
autopsy than those seen only in  primary care (Nelson et al., 2003). Dementia is 
under-diagnosed by primary care general practitioners, who interestingly often over-
estimate the prevalence of dementia syndromes (Turner et al., 2004). There is also 
a tendency to overestimate the prevalence of vascular dementia compared with 
Alzheimer’s disease in some countries (Maeck et al., 2008).  
Neuropsychological tests are standardized tests that measure a person’s memory, 
concentration, problem solving, mood and behaviour, and language skills. 
Neuropsychological testing can aid diagnosis of dementia, can help track its 
progression and can also assess the effectiveness of medications or other 
interventions. Nevertheless, their  reliability has been criticized because they may 
be influenced by respondent’s level of education, through misclassifying poorly 
educated individuals as demented or by missing dementia in well-educated people 
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(Mackinnon and Mulligan, 1998). Informant (carer) reports, on the other hand, may 
be influenced by non-cognitive factors, such as the affective state of the person with 
dementia and the informant, their personality and the quality of their relationship 
(Jorm, 1996). Dementia assessments are heavily dependent on linguistic and 
cultural factors therefore cognitive tests developed with a specific population may 
not be appropriate and reliable when used with individuals from different cultural 
and ethnic backgrounds (Rahman, 2015). The way dementia is considered in 
particular cultures affects how it is experienced, expressed and communicated to 
health professionals. Dementia in some cultures can be either highly stigmatised or 
be seen as normal ageing (Seabrooke and Milne, 2009). Azam (2007) has reported 
that in some South Asian countries dementia is considered as a form of madness 
and that in most South Asian languages no word for dementia exists. Furthermore, 
in some South Asian cultures dementia may be seen as punishment for past life 
actions (Mackenzie, 2006). These cultural differences make it more difficult for 
dementia to be diagnosed accurately and in a timely way in ethnic minority 
communities.  
1.1.5 Prevalence and incidence rates of dementia 
Life expectancy is increasing especially in industrialised societies (Figure 1.2) and is 
expected to continue to rise. This has brought about an increase in the prevalence 
of dementia.  
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Figure 1.2 Life expectancy at birth, UK, from period life tables, 1980-82 to 2008-10 (Office 
for National Statistics 2011) 
It has been estimated that more than 24.3 million people worldwide live with 
dementia, and 4.6 million new cases are diagnosed each year (Ferri et al., 2005). 
The prevalence of dementia is expected to double between 2001 and 2040 (Ferri et 
al., 2005). 
Alzheimer’s Society Report (2014) indicates that currently there are 850,000 people 
in the UK living with dementia. It also claims that 163,000 new cases of dementia 
occur in England and Wales each year, which means a new case arises every 3.2 
minutes. Approximately 6% of people aged over 65 years have some form of 
dementia (Lobo et al., 2000), with the population prevalence rising to 20% in those 
aged over 80 years (Katz et al., 2012). However, recent epidemiological studies 
suggest that the incidence of dementia may be falling and that prevalence figures 
are inflated by as much as 25% (Matthews et al., 2013).  Mathews et al. (2013) 
suggest that later-born populations have a lower risk of prevalent dementia than 
those born in the past century.  
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In recent years, in UK, the number of people being diagnosed with dementia has 
come under political as well as scientific attention. In 2013 UK hosted the first ever 
G8 summit on dementia. The political impetus centred around the perceived 
blockages in the dementia diagnosis pathway namely: 
 Lack of health seeking behaviour by people with dementia and their families 
 Lack of recognition in primary care and acute hospitals 
 Lack of awareness of referral pathways when clinicians did identify dementia.  
In 2011 in England just 42% of individuals estimated to have dementia were being 
diagnosed, therefore the government set an objective on dementia diagnosis 
according to which two thirds of the estimated number of people with dementia 
should receive a diagnosis by 2015 (Department of Health, 2012a). A year later 
(2012) dementia diagnosis had risen to 59% and the government issued a specific 
mandate to NHS England for 2015/16 that included a commitment to improve 
diagnosis (Department of Health, 2013a). As a consequence of these campaigns 
the proportion of people in UK diagnosed with dementia exceeded 66% of expected 
prevalence in 2015 (Alzheimer’s Society, 2015).    
1.1.6 The impact of dementia 
The Dementia Report (2014) reveals that dementia costs the UK economy about 
£26 billion a year, which is more than the cost of cancer and heart disease 
combined. Thus, dementia has been described as “the greatest medical challenge 
of the 21st century" (Alzheimer’s Research Trust, 2010). Investments in dementia 
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research, however, remain relatively modest. Combined government and charitable 
investment in dementia research, in 2010, was 12 times lower than spending on 
cancer research. Over £590 million is spent on cancer research each year, while 
just £50million is invested in dementia research. The discrepancy between 
dementia costs and research investments may partly be explained by the lack of 
awareness about the degree of the problem and dearth of statistics. On the other 
hand, this may represent a vicious circle where the less attention dementia gets, 
less research is carried out and consequently less evidence about the depth of the 
problem that dementia represents is available. This vicious circle can perpetuate the 
stigma  Dementia seems to have been out of the public awareness for a long time, 
but recently the Department of Health (2009) and consequently the Dementia 
Report (Lakey et al., 2012) have focused on raising awareness and transforming 
the dementia services in order to provide a more effective system of diagnosis and 
treatment of the condition. Government funding of dementia research across the 
National Institute for Health Research (NIHR) and the Medical Research Council 
(MRC) has increased by nearly a third (31%) in 2010/11. The prime minister has 
promised to double UK government investment in dementia research from £66 
million in 2015 to £122 million in 2025, and similar increases are expected from  the 
commercial and charitable sectors (Department of Health, 2012b, 2013b). 
There are 6.5 million people in the UK who provide unpaid care and support to older 
people with dementia (Office of National Statistics, 2011). This number is predicted 
to reach 9 million by 2037 (Buckner and Yeandle, 2011). According to the Dementia 
Report (2010) 25 million people or 42% of the UK population know someone close 
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to them who has been diagnosed with dementia. Carers are typically partners, 
relatives and family members and the majority of them are women (Office of 
National Statistics, 2011). The Alzheimer’s Research Trust (2010) reports that 1.4 
million of these carers provide more than 50 hours per week unpaid care, thereby, 
saving the UK economy £8 billion per year.  
Caring for people with dementia comes at a price for the carers. Carers of people 
with dementia experience more physical and mental health problems (Moise and 
Schwarzinger, 2004; Pinquart and Sörensen, 2007) and get more distressed 
(Schulz and Martire, 2004; The Princess Royal Trust for Carers, 2011) than their 
counterparts who look after older people without dementia. Despite the fact that 
carers bring huge savings to the economy, 75% of them report that they are worse 
off financially as a result of caregiving (Carers UK, 2008). Carers have reported that 
because of their caring responsibilities they have had reduced income or working 
hours, missed out on the chance of a promotion, or were forced to give up work 
(Carers Week, 2013).  
Caring for a person with dementia has a profound impact not just on individual 
families but on the society as a whole. Thus, caring for a person with dementia 
costs the UK economy about £27,647 per year. This is more than the combined 
cost of care for or people with cancer, stroke and heart disease (cancer-£5,999, 
stroke £4,770 and heart disease £3,455 per year) (Carers Week, 2013).   
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1.2 Behavioural and Psychological Symptoms of Dementia 
Behavioural and psychological symptoms of dementia (BPSD) are also known as 
neuropsychiatric or non-cognitive symptoms and are common and distressing 
features of the condition. Psychological symptoms can include anxiety, depressed 
mood, hallucinations and delusions while behavioural symptoms refer to aberrant 
motor behaviour, verbal and physical aggression, screaming, restlessness, 
agitation, swearing, wandering, apathy, culturally inappropriate behaviours, 
disinhibition and hoarding (Desai and Grossberg, 2001). Unlike cognitive functioning 
of people with dementia that progressively deteriorates, BPSD symptoms typically 
fluctuate over the course of dementia (Ballard and Howard, 2006; Lawlor, 2004).  
1.2.1 Phenomenology, prevalence and incidence of BPSD 
Although non-cognitive symptoms of dementia have historically been described as 
core features of the condition (Table 1.2) they have not been given the appropriate 
recognition until the last twenty years. The term Behavioural and Psychological 
Symptoms of Dementia was introduced in 1999 by the International Psychogeriatric 
Association (IPA) which has been at the forefront of raising awareness about BPSD 
and has been publishing and updating educational packs for the management of the 
symptoms.  
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Table 1.2 Common Behavioural and Psychological Symptoms of Dementia (Grossberg and 
Desai, 2003) 
Symptoms  
Aggression 
Verbal 
 
Physical 
Screaming  
Cursing 
Agitation 
Hitting 
Biting 
Kicking 
Scratching 
Grabbing  
Non-aggressive behavioral 
symptoms 
Verbal 
 
 
 
Physical 
Repetitive questioning 
Complaining 
 
Wandering 
Pacing 
Hoarding 
Rummaging 
Hiding 
Taking other people’s belongings 
Shadowing 
Resistance to care 
Intrusiveness 
Mannerism  
Thought and perception 
 
Delusions 
Hallucinations 
Illusions 
Misperceptions  
Mania 
Affect-Mood Depression 
Anxiety 
Apathy 
Irritability 
Elation 
Persecution  
Sleep disturbances Insomnia 
Increased daytime napping 
Sundowning 
Sexual Hypo-sexuality (inhibited sexual excitement) 
Hyper-sexuality (increased sexual urges) 
Sexual disinhibition 
Appetite Poor food intake 
Hyperphagia (excessive hunger) 
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It is estimated that over 90 percent of people with dementia are likely to experience 
BPSD such as changes of personality and behaviour (Aalten et al., 2003; Overshott 
et al., 2004) and sleep disruption (Boeve et al., 2002). People with dementia are 
four times more likely to experience BPSD than older adults without dementia 
(Lyketsos et al., 2000). Prevalence estimates for BPSD vary because of the 
heterogeneity of sample populations studied, diverse settings and type of dementia, 
different study designs, sample sizes, different instruments used to measure the 
symptoms and the different definitions used for BPSD (Aalten et al., 2007; Finkel et 
al., 1996; Ikeda et al., 2004; Lyketsos et al., 2002a; Savva et al., 2009). The 
prevalence of BPSD is more common in nursing homes than in community settings 
(Australian Medicines Handbook, 2006). 
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Table 1.3 BPSD point prevalence in adults with dementia1  
 
 
Symptoms 
Aalten  
et al.  
(2003) 
 
Netherlands 
(n = 199) 
Benoit  
et al.  
(2003)  
 
France 
(n = 255) 
Byrne 
 
(2003) 
12 European 
Countries 
(n = 138) 
Saz  
et al.  
(2009) 
 
Spain 
(n=223) 
Lyketsos  
et al.  
(2002b)  
 
USA 
(n=362) 
Savva  
et al. 
 (2009) 
 
UK 
(n=587) 
Steinberg  
et al.  
(2008)  
 
USA 
(n=408) 
Weighted 
mean2 
 
 
 
(n= 2,172) 
Apathy 59.3 63.5 48.9 46.7 35.9 50.3 51 50 
Depression  57.3 42.7 45.3 38.2 32.3 20.5 47 37 
Agitation  28.6 44.3 30.9 44.4 30.3 Not 
reported 
24 33 
Sleep  18.1 12.9 12.9 43.3 27.4 42 Not reported 30 
Irritability  39.7 25.0 31.7 17.9 27 28.8 27 28 
Delusions  34.7 24.7 19.4 26 18 Not 
reported 
38 28 
Anxiety  39.2 46.3 33.8 39.3 21.5 8.9 32 27 
Aberrant 
Motor 
Behaviour  
 
34.7 
 
29.8 
 
18.7 
 
Not reported 
 
16 
 
Not 
reported 
 
29 
 
25 
Appetite  24.6 24.3 12.9 28.4 19.6 Not 
reported 
Not reported 22 
Hallucinations 13.1 7.8 7.9 5.4 10.5 15.1 24 14 
Disinhibition  12.6 13.3 14.4 Not reported 12.7 Not 
reported 
15 14 
Euphoria  7.0 9.8 5.0 Not reported 3.1 9.5 1 6 
                                            
1 This table was adapted from Robert et al. (2005) with additional data (Savva et al., 2009; Saz et al., 2009; Steinberg et al., 2008) added and 
calculated (http://www.rapidtables.com/calc/math/weighted-average-calculator.htm) by the candidate. 
2 Overall mean taking into account the relative contribution of the size (n) of each study. 
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The above table (Table 1.3) presents findings from six, large, cross-sectional, 
population based studies that have reported prevalence of BPSD worldwide. The 
variability between the reported prevalence rates may be due to differences 
between study designs, utilized measures, geographical and cultural settings, 
population samples and severity of dementia. Thus, Benoit et al. (2003) reported 
on individuals with Alzheimer’s disease only, while all the other studies included 
different dementia types. Aalten et al. (2008) and Benoit et al. (2003) recruited 
patients from specialized memory clinics where BPSD prevalence is expected to 
be higher, as opposed to the other studies that recruited community based 
samples. Another characteristic of Benoit et al. (2003) is that it reported on 
individuals with moderate/severe dementia only (MMSE 11-20) who may 
experience more BPSD symptoms than individuals with mild dementia. All but two 
of the above studies i.e. Savva et al. (2009) and Saz et al. (2009) have utilized the 
Neuropsychiatric Inventory to measure BPSD. The other two studies used the 
Geriatric Mental State Interview (Copeland et al., 2009), which uses a different 
taxonomy to the NPI, therefore some data is missing from these two studies. In 
spite of the high level of heterogeneity between the reported studies, the reported 
prevalence estimates of BPSD are consistent between studies. Apathy, depression 
and agitation are the most frequent symptoms followed by sleep problems, 
irritability, delusions and anxiety. Participants seem less likely to experience 
hallucinations, disinhibition and euphoria.    
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1.2.1.1 Depression 
The World Health Organisation (2014) defines depression as “.... a common 
mental disorder, characterized by sadness, loss of interest or pleasure, feelings of 
guilt or low self-worth, disturbed sleep or appetite, feelings of tiredness, and poor 
concentration.” 
Depression frequently co-exists with dementia. This can exacerbate the effects of 
dementia, making it even harder for affected people to remember things, leading to 
increased confusion and anxiety. It may also cause behavioural changes such as 
walking aimlessly, aggression, social withdrawal and reduced appetite (Alzheimer 
Society, 2008).  
1.2.1.2 Anxiety 
Up to 71 percent of people with dementia show signs of anxiety (Ballard, Neill, et 
al., 2000; Chemerinski et al., 1998; Lyketsos et al., 2001; Wands et al., 1990). In 
older adults without dementia, anxiety is associated with reduced quality of life, 
functional limitations, poorer physical health and reduced activities (de Beurs et al., 
1999; Wetherell et al., 2004). Until recently, little attention has been paid to anxiety 
symptoms in dementia despite their high prevalence. This may be due to difficulties 
in defining anxiety in this population because of the overlap between symptoms of 
anxiety, agitation, depression and dementia. However, there is some evidence that 
anxious mood is associated with poorer quality of life and behavioural disturbances 
in dementia, even after controlling for depression (Seignourel et al., 2008). 
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1.2.1.3  Apathy 
Apathy refers to a loss of motivation and is marked by diminished initiation 
(difficulty in initiating purposeful activity), poor persistence, lack of interest, 
indifference, low social engagement and blunted emotional response (Landes et 
al., 2001). The incidence of apathy increases with the severity of dementia and is 
the most common behavioural disturbance with reported prevalence rates as high 
as 80 percent (Onyike et al., 2007) with an average mean prevalence across 
studies of 56 percent (Robert et al., 2005). Apathy is also associated with 
decreased function (Yeager and Hyer, 2008). Patients with apathy are nearly three 
times more likely than those without to be impaired in dressing, bathing, 
transferring from bed to chair, using the toilet, walking or eating (Freels et al., 
1992). Apathy and depression have some overlapping characteristics, like loss of 
interest or pleasure from activities and both are associated with functional and 
cognitive decline. As a result, these conditions can be conflated and many patients 
are perceived as having apathy and depression simultaneously (Onyike et al., 
2007; Robert et al., 2006).  
1.2.1.4 Aggression/Agitation  
It is important to note that aggressive behaviours and agitation may be a sign of 
pain and discomfort (Husebo et al., 2011). It is therefore imperative to rule out pain 
before engaging the person in interventions to reduce BPSD. Indeed, the aetiology 
of aggression in dementia is complex but includes feeling frightened or humiliated; 
feeling frustrated at being unable to understand others or make themselves 
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understood; the physical effects of dementia eroding judgement and self-control; 
boredom; physical discomfort or pain and; loss of inhibitions and decreased 
awareness of rules about appropriate behaviour (The Alzheimer’s Society, 2008). 
Behaviour can be seen as a form of communication and establishing what the 
person with dementia is trying to communicate may prevent them from feeling 
frustrated and acting aggressively. However, dealing with aggressive behaviour 
can be difficult and multiple solutions such as consistent routine, regular 
stimulation or use of music may be required (Desai and Grossberg, 2001). 
1.2.1.5 Repetitive behaviours 
The aetiology of repetitive behaviours include: memory loss causing the person not 
to remember that they have already asked a question; perseveration (repetition of 
a particular response) due to frontal lobe damage; side effects from medication 
resulting in repetitive movements or restlessness, and; psychotropic medication 
causing the person to have akathisia (inner restlessness) or tardive dyskinesia 
(repetitive body movements)  (The Alzheimer’s Society, 2010). 
There may also be environmental causes such as: separation from the carer which 
leads to the person with dementia to repeat questions about their whereabouts; 
misrepresentation of sounds or sights, which may cause anxiety; overwhelming 
stimuli (e.g. movement, noise); inability to judge time causing the person to think 
the carer has been away for a long time; misunderstanding what is happening, 
causing the person to constantly ask questions; inability to express needs such as 
hunger, thirst, or needing to go to the toilet. 
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1.2.2 BPSD and types of dementia 
BPSD does not occur uniformly and different dementia types are characterised by 
specific BPSD symptoms (Kar, 2009).  
 People with Alzheimer’s disease (AD) have been said to present with 
depression symptoms in the early stages of the condition and sometimes low 
mood symptoms can precede cognitive impairment (Geerlings et al., 2000). 
BPSD symptoms become more frequent with the severity of dementia 
(Steinberg et al., 2008) in AD. Other common BPSD symptoms reported for AD 
are apathy (Benoit et al., 2003), anxiety, phobias  (Chiu et al., 2006) and 
agitation (Lyketsos et al., 2001). 
 Lewy body dementia (DLB) is said to be characterised by the presence of 
visual hallucinations, which are less prevalent in other dementia types (Chiu et 
al., 2006). Delusional misidentification and hallucinations can happen in the 
early stages of DLB (Ballard et al., 2014) and worsen over the course of 
dementia.  Anxiety and aggression have also been reported as the most 
common BPSD symptoms followed by depression, apathy, agitation and sleep 
disorders (Borroni et al., 2008; Chiu et al., 2006). DLB is marked by motor 
disabilities such as muscle jerking, loss of dexterity, limb stiffness and a 
shuffling gait (Gnanalingham et al., 1997). These symptoms cause balance 
problems for people with DLB and put them at increased risk of falls compared 
to people with other dementia types (Ballard et al.; Härlein et al., 2009).    
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 People with vascular dementia (VaD) are reported to be primarily affected by 
affective disturbances such as depression and apathy (Kindermann et al., 
2002; O’Brien et al., 2003). Kar (2009b) argues that people with VaD, who 
unlike people with other dementia types maintain a significant degree of insight 
for a long time during the course of the condition, react to the awareness of 
their prognosis by experiencing depression and anxiety symptoms.  
 The most prominent aspects of Frontotemporal dementia (FTD) are verbal 
outbursts and inappropriate activities (Chiu et al., 2006; Mendez et al., 1998).  
Inappropriate activities have been reported as disinhibition and complex 
compulsive behaviours (time consuming preoccupation with ideas and/or 
activities such as wandering, pacing and/or hoarding) which often occur at the 
early stages of the condition and precede cognitive deterioration (Rosso et al., 
2001). Another unique feature of FTD is a change in appetite and major dietary 
changes (Miller et al., 2001).   
The above descriptions provide an overview of the distinct features of BPSD in 
different dementia types. However, these characteristics can become indistinct in 
cases of mixed aetiology and any people with any type of dementia can experience 
any of the BPSD symptoms (Desai and Grossberg, 2001). The variety of 
symptoms across dementia subtypes encouraged us to design an intervention for 
people with dementia of any type, rather than for a specific sub-type. We will return 
to this topic on ‘EVIDEM-E trial design and methods’ Chapter (3) on page 106. 
Notwithstanding the differentiation of dementia subtypes and the importance of this 
in terms of management and prognosis the study group felt that clinicians 
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particularly in primary care would not place too much emphasis on subtype. We 
therefore thought it was important in terms of generalizability of the study to include 
all subtypes. 
1.2.3 Methods for screening and diagnosing BPSD  
A number of scales have been developed as tools to assess BPSD (Table 1.4, 
Table 1.5). However, only some of these tools are validated and widely used at 
present. Most of the measures are developed specifically for people with 
Alzheimer’s disease, therefore symptoms typical to other dementia types such 
as hallucinations and disinhibition are not included (e.g. BEAM-D, BEHAVE-AD, 
BSSD, Pittsburgh Agitation Scale). Some of the more widely used instruments 
are: the Neuropsychiatric Inventory which screens for a wide range of 
behavioural and psychological symptoms; The Cohen-Mansfield Agitation 
Inventory (CMAI), which focuses on aggression and agitation behaviours; The 
Behavioral Pathologic Rating Scale for Alzheimer’s Disease (BEHAVE-AD) 
which is used in detecting delusions and sleep disturbances; and The 
Consortium to establish a Registry in AD (CERAD) Behavioural Scale, which like 
the NPI, rates a range of non-cognitive symptoms of dementia.  
Table 1.4 presents the set of measures that were not considered to be used as 
a primary outcome for EVIDEM-E and the reasons for their exclusion. The main 
reasons for not considering these instruments were that: they screened for 
specific symptoms only such as sleep (Leeds Sleep Evaluation Questionnaire), 
depression (Dementia Mood Assessment Scale, Cornell Scale for Depression in 
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Dementia); or the scales were not validated for people with dementia (Brief 
Psychiatric Rating Scale, Sandoz Clinical Assessment – Geriatric).Table 1.5  
displays a more detailed analysis of the BPSD measures considered for use in 
this trial and their psychometric properties.   
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Table 1.4 Excluded measures 
Measure Reason for exclusion 
Blessed Dementia Scale (Blessed et al., 
1968) 
Used as a dementia diagnostic tool rather than as a measure of BPSD. The rate consists 
of 22 items that evaluate performance of everyday activities, changes in habits and 
changes in personality interests and drive. Not BPSD specific.   
Brief Agitation Rating Scale (BARS) (Finkel 
et al., 1993) 
Assesses agitation and physical aggression in elderly nursing home residents. This scale 
is not dementia or BPSD specific.  
Brief Psychiatric Rating Scale (BPRS) 
(Overall and Gorham, 1962) 
Developed to evaluate symptoms’ change in psychiatric patients. Not validated with 
dementia patients.  
Cohen-Mansfield Agitation Inventory 
(CMAI) (Cohen-Mansfield et al., 1989) 
Developed to measure agitation and aggression in nursing home residents. Primarily 
useful with severely demented institutionalised patients. It does not assess the full BPSD 
spectrum.  
Cornell Scale for Depression in Dementia 
(Alexopoulos et al., 1988) 
Designed to assess depression only in dementia patients.   
Dementia Behavior Disturbance Scale 
(DBD) (Baumgarten et al., 1990)  
Assesses challenging behaviour in Alzheimer’s patients. It does not include psychological 
symptoms such as apathy and depression and is not validated for different dementia 
types just AD.  
Dementia Mood Assessment Scale 
(DMAS) (Sunderland et al., 1988)  
Designed to assess depression only in dementia patients, omits other symptoms. 
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Measure Reason for exclusion 
Dysfunctional Behavior Rating Instrument 
(DBRI) (Molloy et al., 1991)  
Assesses challenging behaviour such as demanding, acting out, withdrawing, psychotic, 
paranoid, disruptive, repetitive, and inappropriate behaviours. It does not include 
psychological symptoms such as depression, anxiety, apathy, irritability, dishinibition.  
Global Assessment of Psychiatric 
Symptoms (GAPS) (Raskin and Crook, 
1988) 
Developed to evaluate psychiatric symptoms in geriatric psychiatric inpatients. It is not 
validated for dementia patients and it does not cover a wide range of BPSD symptoms.  
Irritability/Apathy Scale (Burns et al., 1990)  This scale measures Irritability (5 items) and Apathy (5 items) only.  
Leeds Sleep Evaluation Questionnaire 
(Parrott and Hindmarch, 1980) 
This questionnaire assesses sleep disturbances only.  
Sandoz Clinical Assessment – Geriatric 
(SCAG) (Shader et al., 1974)  
This assessment is developed to assess psychopathology for and with geriatric 
populations and is not validated for people with dementia.   
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Table 1.5 Characteristics of measures that were considered for use as the primary outcome in Evidem-E 
Measure Population Informant Frequency Severity Reliability Validity Comments 
Behavioral and 
Emotional 
Activities 
Manifested in 
Dementia (BEAM-
D) (Sinha et al., 
1992) 
45 Alzheimer 
Disease (AD) 
outpatients 
Patient/ 
carer 
Present/ 
absent 
4 point 
scale 
indicating 
severity 
and 
intensity 
of 
behaviour 
Interrater reliability 
for target 
symptoms r=0.95 
and for inferred 
behaviours 
r=0.85 
Test-retest 
not reported 
Has 
construct, 
content 
and 
convergen
t validity  
 
Omits apathy, and 
disinhibition. 
Assesses symptoms 
characteristic of AD 
outpatients only, not 
other dementia types.  
Excluded 
Behavioral 
Pathology in 
Alzheimer’s 
Disease Rating 
Scale (BEHAVE-
AD) (Reisberg et 
al., 1987) 
57 AD 
outpatients mild 
to severe 
carer No 
frequency 
measure 
Ratings 
differ for 
each item 
Interrater  reliability 
for item severity 
ratings         
 r= 0.76-1.00 
Test-retest 
R=0.96 
Has 
content and 
construct 
validity 
when 
compared 
with patient 
records 
Excludes apathy, 
irritability and 
disinhibition. Developed 
with AD outpatients 
only, no other 
dementias included. 
Excluded 
Behavioural 
Syndromes Scale 
for Dementia 
(BSSD) 
(Devanand et al., 
1992) 
Based on 
interviews of 
carers of 106 
AD patients 
Carer and 
clinician 
Most 
items are 
not rated 
for 
frequency 
There are 
no 
guidelines 
for 
severity 
Interrater interclass 
correlation 
coefficients for 
scores on five 
domains range 
from 
r= 0.76-0.95   
Has 
content 
and 
construct 
validity 
 
Excludes anxiety and 
depression symptoms. 
Assesses symptoms 
characteristic of AD 
outpatients only, not 
other dementia types. 
Excluded 
 
Caretaker 
Obstreperous 
Behavior Rating 
Assessment 
 
Developed on 
25 community 
dwelling and 
nursing home 
 
carer 
 
0-4 scale  
 
Severity 
measured 
as impact 
on carer  
 
Interrater 
r=0.73-0.99; 
Test-retest  
r=0.73-0.95 
 
Validation 
studies 
have not 
been 
 
Excludes apathy, 
anxiety, depression, and 
hallucinations. 
Complicated scoring and 
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Measure Population Informant Frequency Severity Reliability Validity Comments 
(COBRA) 
(Drachman et al., 
1992) 
patients with mix 
dementias  
4 point 
scale 
 reported small study sample size. 
Excluded 
 
CERAD Behavior 
Rating Scale for 
Dementia (Tariot 
et al., 1995) 
Developed from 
literature review 
and expert 
pannel. Piloted 
in 303 AD 
outpatients 
carer 4 point 
scale 
Not 
measured 
Interrater 
k=0.77-1.00 
 
Test-retest  
r=0.70-0.89 
 
Has 
content 
and 
construct 
validity 
The frequency rating 
does not distinguish 
between symptoms that 
happen several times 
daily and once every two 
days. It does not provide 
assessment of severity. 
These properties limit its 
usefulness in assessing 
subtle changes.  
Excluded  
Gottfries-Bråne-
Steen Scale 
(Gottfries et al., 
1982) 
Long-term 
nursing home 
residents (only 
30% with 
dementia) 
Nurses, 
psychiatrists, 
psychologists 
Not 
measured 
7 point 
scale 
Interrater for three 
subscales: 
motor-  
0.83-0.93; 
cognitive- 0.81-0.97; 
emotional- 
0.57-0.87 
No test-retest 
reliability reported 
Not 
validated 
with 
dementia  
patients  
Not validated for 
dementia patients. 
Informants have to be 
highly trained 
professionals.  
Excluded 
 
Manchester and 
Oxford 
Universities 
Scale for the 
Psychopathologi
cal Assessment 
 
32 dementia 
patients 
 
carer 
 
3 point 
scale 
1-less 
than once 
a week to 
3-four or 
 
3 point 
scale 
1-mild to 
3-severe 
 
Interrater 
k=0.56-1.00 
 
Test-retest 
K=0.43-0.93 
 
Has face 
validity  
 
Small sample size. 
Content and construct 
validity information 
absent. Not widely 
used. 
Excluded 
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Measure Population Informant Frequency Severity Reliability Validity Comments 
of Dementia 
(MOUSEPAD) 
(Allen et al., 1996)  
more 
times a 
week 
Neurobehavioral 
Rating Scale 
(NRS)  
(Levin et al., 
1987) 
HIV positive, 
head injury and 
dementia 
patients 
patient Present- 
absent 
6 point 
scale 
0-‘not 
present to 
6-
‘extremly 
severe’ 
Reliability not 
reported for 
dementia patients 
Has 
construct 
and content 
validity for 
AD and 
vascular 
dementia.  
Observer rated, 
requires clinical 
expertise and training. 
Frequency rating does 
not distinguish between 
high and low rate of 
symptom occurrence.  
Excluded 
Neuropsychiatric 
Inventory (NPI) 
(Cummings et al., 
1994) 
Elderly 
dementia 
patients 
carer 4 point 
scale 
1-less 
than once 
a week  
to 4- 
several 
times a 
day 
3 point 
scale  
1-‘mild’ to 
3-‘severe’ 
Interrater 
r=0.53-0.98 
(frequency); 
r=0.51-1 
(severity)  
 
Test-retest 
k=0.79-0.86 
Has 
construct 
and content 
validity and 
convergent 
validity with 
HAM-D and 
BEHAVE-
AD. 
Validated for 
telephone 
interviewing.  
Use of screening 
questions minimizes 
time of administration. 
Includes wide range of 
BPSD. Widely used in 
clinical trials. Has been 
validated for telephone 
interviewing.  
Included 
Pittsburgh 
Agitation Scale 
(Rosen et al., 
1994) 
AD psychiatric 
inpatients or 
nursing home 
residents 
Direct 
observation 
of behaviour 
Not 
measure
d 
4 point 
scale 
different 
criteria for 
each 
domain 
Interrater 
r=0.82 
 
No test-retest 
reliability reported  
Has 
construct, 
content and 
internal 
validity for 
AD 
psychiatric 
Requires constant 
observation and 
evaluates only disruptive 
behaviours. It does not 
provide assessment of 
frequency. Not validated 
for other dementias, just 
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Measure Population Informant Frequency Severity Reliability Validity Comments 
inpatients 
and nursing 
home 
residents 
only.  
AD. 
Excluded 
Revised Memory 
and Behavior 
Problems 
Checklist  
(Teri et al., 1992)  
201 geriatric 
outpatients with 
possible 
depression or 
cognitive 
impairment 
(roughly half 
had AD) 
carer 4 points 
scale 
0=none 
to 
4=daily 
Not 
measured 
Interrater 
r=0.86 
 
Test-retest 
r=0.88  
Has 
construct, 
content and 
convergent 
validity in 
depression, 
cognition, 
carers’ 
burden and 
carers’ 
depression.  
It does not measure 
severity of symptoms. 
The scale omits core 
symptoms such as 
apathy, appetite and 
perceptual 
disturbances.   
Excluded     
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1.2.3.1 The Neuropsychiatric Inventory 
The NPI was chosen in preference to other measures because it includes a 
broader range of BPSD symptoms. The NPI is an established, validated measure 
that is widely used in similar research studies, which makes the study findings 
more easily comparable with other research results. This measure is the only 
instrument that includes commonly experienced personality change such as apathy 
and irritability. Furthermore, the NPI incorporates symptoms that are rare in AD but 
common in other dementia types, such as euphoria and disinhibition (as in 
frontotemporal dementias), making the tool valid for a wide range of dementias. 
Another strength of the NPI is that it attempts to avoid symptom overlaps. For 
example, to avoid overlap when assessing symptoms of depression and dementia 
the authors have included in the depression/dysphoria scale just the key emotional 
aspects of depression such as sadness and tearfulness (Cummings and 
McPherson, 2001). Ease of scoring is also one of the positive features of NPI, as it 
takes account of both frequency and intensity of behaviours. However, its intensity 
scoring has been criticized because it is based on carers’ subjective interpretation 
of how difficult symptoms seem to be for the patient, whereas frequency ratings 
have been described as more objective reports (Gallo et al., 2009). The NPI is 
flexible and easy to administer even by less clinically experienced professionals 
without affecting scale validity or reliability (Fernandez et al., 2008). Being reliant 
on carers’ reports, NPI assessment does not require the input of individuals with 
dementia and can be inclusive of everyone with dementia no matter what stage of 
dementia they are at (Connor et al., 2008).  
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The main psychometric features of the NPI are described below: 
 Content validity of an instrument refers to the degree to which it includes all the 
items necessary to represent the concept being measured. A Delphi panel3 
evaluated the content validity of each domain of the NPI as well assessed 
(Cummings et al., 1994). A score of 1 meant that the domain was well 
assessed and a score of 4 meant that the domain was poorly assessed. The 
mean scores ranged from 1.2 (disinhibition) to 2.0 (aberrant motor behaviour).  
 Test re-test reliability assesses the agreement between results of the same 
measure that is being repeatedly tested. The measure is reliable when there is 
close agreement over repeated tests given that the variables being measure 
remain the same. The NPI has optimal test-retest reliability for both frequency 
(Cohen’s Kappa = 0.79) and severity (Cohen’s Kappa = 0.86) testing, and 
overall Cohen’s Kappa = 0.88. The NPI validation study (Cummings et al., 
1994) included telephone interviewing in its assessment suggesting that the 
NPI can be used as a telephone interview.    
 Inter-rater reliability indicates how well different raters agree in the way they 
administer and score an instrument. The inter-rater reliability of the NPI has 
been reported to very good with correlations ranging from 0.53 (irritability) to 
                                            
3 A Delphi panel is a board of experts who participate in a reiterative process of 
evaluation and/or discussions that usually involves several rounds that aims to 
achieve convergence of opinions.    
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0.98 (hallucinations) for the frequency measure, and from 0.51 (anxiety) to 1 
(hallucinations) for the severity testing (Cummings et al., 1994).  Overall inter-
rater reliability coefficients have not been reported.  
 The internal consistency of a measure is concerned with the extent to which 
items comprising the measure fit together. Cummings et al. (1994) reported a 
high level of internal consistency reliability (Cronbach’s alpha = 0.88). 
 The NPI has good concurrent validity with other similar measures such as 
BEHAVE-AD and the HDRS with all correlations reaching 0.05 significance 
level; and good convergent validity (individual items of the NPI have been 
subjected to convergent validity studies with MRI, PET and other studies) 
(Cummings et al., 1994).  
Although Cummings did not provide a conceptual framework for the design of the 
NPI, the tool can be considered as grounded on the biomedical model whereby the 
disease leads to certain symptoms (behaviours) and a specific measure such as 
NPI is applied to determine the symptoms’ response to treatment. The NPI 
quantifies the problematic behaviours of individuals with dementia, and their carers’ 
distress. The measure fails to consider the meanings of these behaviours and 
possible alternative triggers such as changes to physical or psychosocial 
environments or the quality of the relationship between the person with dementia 
and their carer. This may lead to detection biases because of the arbitrary 
attribution of behaviours as neuropsychiatric symptoms. On the other hand, 
determining the cause of problem behaviours in people with dementia can be a 
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very complicated and time consuming process, and avoiding identification of the 
underlying meaning of the non-cognitive symptoms can make them  easier to 
capture (Lai, 2014). Further information about the NPI domains and how the scale 
is scored is provided in paragraph 3.4.1, pp 134. 
1.2.4 Impact of BPSD  
The development of BPSD is associated with a worse prognosis and faster rate of 
dementia progression (Paulsen et al., 2000). Untreated BPSD brings about 
reduction in the quality of life for the person suffering from the condition and 
causes significant distress (Chan, 2007; Cohen-Mansfield, 1995; Finkel et al., 
1996). Once symptoms are ameliorated functional impairment may partially 
resolve, reducing patient and carer distress and improving quality of life.  
BPSD symptoms increase carer stress (Ornstein and Gaugler, 2012) and have a 
negative effect on their quality of life (Ballard, Lowery, et al., 2000). Behaviours that 
challenge carers especially depression and low-mood are reported to have a 
consistent and powerful negative impact on the psychological health of carers 
(Hooker et al., 2002). Behavioural and Psychological Symptoms of Dementia 
cause distress for carers and can contribute to the breakdown in care at home 
leading to relocation to a care home (Banerjee, 2003; Donaldson et al., 1998; 
Finkel, 2000; Lawlor, 2002). Specific BPSD symptoms such as sleep disturbances 
(i.e. nightly restlessness and wandering) also contribute to carer distress (Hope et 
al., 2001) and are predictors of relocation to a nursing or residential home (Schur 
and Whitlatch, 2003) because of the increased burden that is placed on the carer 
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(Lindsay and Anderson, 2004). Caring for dementia comes at a financial cost for 
family carers who reduce working hours to look after their family members, which 
inevitably results in lower incomes for carers (Covinsky et al., 2001).  
Untreated BPSD can also cause stress to nursing staff in residential facilities 
(Draper et al., 2000; Rodney, 2000) and increase financial costs (Cohen-Mansfield, 
1995; O’Donnell et al., 1992; Smith et al., 2005).   
Several studies indicate that treatment of BPSD with antipsychotics almost doubles 
the risk of mortality for patients (Banerjee, 2009; Food and Drugs Administration, 
2011) and increases by 9-fold risk of stroke in the first four weeks (Kleijer et al., 
2009). The following section will discuss this topic further.  
1.3 Aetiology of BPSD 
Different theoretical frameworks have been proposed to explain the aetiology of 
BPSD. These theories are divided into two major groups, neurobiological and 
psychosocial, and have driven various and distinct interventions for BPSD that will 
be discussed in detail in the following sections.  
1.3.1 Neurobiological/genetic theories of BPSD 
The neurobiological/genetic theories of BPSD are predominant within medicinal 
research and practice, and assert that BPSD are the direct cause of cognitive 
decline, brain dysfunction, imbalance of neurotransmitters and genetic 
characteristics (Kar, 2009). Thus, agitation in people with dementia has been 
linked to frontal lobe dysfunction (Boyle and Malloy, 2004; Senanarong et al., 
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2004). People with BPSD have been reported to have lower metabolism and 
perfusion in the frontal and temporal lobes than those without BPSD (Hirono et al., 
2000). Boyle and Malloy (2004) have claimed that apathy is triggered by an 
interaction between cholinergic deficiency and neuropathological changes in frontal 
brain regions. Agitation and psychosis are reported to be specifically correlated 
with a high burden of neurofibrillary tangles (Barber et al., 1995; Tekin et al., 2001). 
Parnetti et al. (2001) suggest that specific brain regions that regulate emotional 
activities (parahippocampal gyrus, dorsal raphe, locus coeruleus) and cortical 
hypometabolism contribute to BPSD. Genotypes such as transmitter receptor 
polymorphisms of the serotoninergic, cholinergic, and dopaminergic systems have 
also been proposed as predisposing factors for BPSD (Assal et al., 2004; Holmes 
et al., 1998; Nacmias et al., 2001; Sukonick et al., 2001). Irritability and aberrant 
motor behaviour in Alzheimer’s  have been associated with dopamine transporter 
gene 3’-untranslated region variable number tandem repeat polymorphism (DAT1 
3’-UTR VNTR) (Pritchard et al., 2008). Pritchard et al. (2007) also reported that 
serotonin transporter SERT may cause susceptibility to the development of 
psychosis and aggressive symptoms.  
While this specific framework is very useful in understanding possible mechanisms 
of BPSD and in planning specific pharmacological interventions, there are a few 
pitfalls to be aware off, especially if this approach is considered in isolation to other 
psychological and social factors. Pharmacological therapies have significant 
limitations such as serious adverse side effects (discussed further in the following 
section), interaction between drugs and limited efficacy (Hersch and Falzgraf, 
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2007).  Psychotropic medicines can have sedating effects which may contribute to 
further cognitive decline, non-compliant behaviour, restlessness and dyskinesia 
(Lindsey, 2009).  The neurobiological approach disregards possible psychosocial 
or environmental factors influencing the expression of particular BPSD symptoms, 
which may serve as signals to communicate particular needs (Cohen-Mansfield, 
2001). Cohen-Mansfield (2001) argues that medication may instead conceal the 
real need by eliminating important signal symptoms. Furthermore, there is a 
tendency to interpret an association with a cause: for example just because 
dopamine levels go up or down it does not necessarily mean that dopamine 
causes the symptoms associated with it.  
1.3.2 Conventional treatments for BPSD  
Conventionally, a pharmacological approach has dominated the clinical 
management of BPSD. Common forms of treatments include mood stabilisers, 
anxiolytics, hypnotic and antipsychotic medications and more recently, 
cholinesterase inhibitors. Antipsychotic medications (e.g. haloperidol, risperidone, 
olanzapine) have been overly used to manage behavioural problems such as 
agitation and aggression (Ballard, Hanney, et al., 2009; Banerjee, 2009) but there 
are long-standing concerns that treating aggressive behaviour with 
pharmacological methods suppresses behaviour without addressing its cause (The 
Alzheimer’s Society, 2008; The Royal College of Psychiatrists, 2006). Evidence is 
also beginning to accumulate suggesting that excessive sedation with 
antipsychotics may reduce symptoms such as restlessness and aggression at the 
expense of the person's mobility and coherence, with the perverse consequence of 
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accelerating the rate of decline of cognitive capacity and quality of life for the 
person with dementia (Ballard, Hanney, et al., 2009; Schneider et al., 2006). Other 
side effects of antipsychotics include excessive sedation, dizziness and 
unsteadiness, which can lead to increased falls and injuries, as well as 
parkinsonism and restlessness.  
Use of antipsychotics in dementia increases the likelihood of stroke and premature 
death which has led the health authorities of both the United States (Food and 
Drugs Administration, 2011) and the UK (National Institute for Health and Clinical 
Excellence, 2006) to issue guidance directing clinicians to avoid the use of these 
drugs in dementia (Ballard, Hanney, et al., 2009; Banerjee, 2009). In the UK, the 
NICE/SCIE guidelines encourage clinicians to treat BPSD with non-
pharmacological methods in the first instance, unless the patient is severely 
distressed and there is an immediate risk of harm to themselves or others (Clark, 
2011). 
In 2012, an audit of prescriptions of antipsychotic drugs by GP practices in England 
reported that antipsychotic prescriptions for people with dementia reduced by 52 
per cent between 2008 and 2011 (Health and Social Care Information Centre, 
2012).  
Other pharmaco-therapeutic interventions are sometimes used but may present 
similar challenges to antipsychotics. Cholinesterase inhibitors may in fact worsen 
BPSD symptoms (Howard et al., 2007). Memantine is another option but is 
relatively high cost (McShane et al., 2006). Hypnotic and anti-depressants may 
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potentially worsen symptoms or have negative side effects (Boeve et al., 2002; 
Glass et al., 2005). Further, most classes of medication are designed for short term 
use (especially hypnotics, anxiolytic medications). Long-term psychosocial 
strategies may be a better way to achieve the best quality care possible for people 
with dementia and those whom support them. Therefore, non-pharmacological 
alternatives are now being considered as first-line management of BPSD (Hersch 
and Falzgraf, 2007).  
1.3.3 Psychosocial theories of BPSD 
As Kitwood (1989) proposed, individual differences, social and psychological 
factors need to be taken into account alongside neurological impairment in order to 
provide effective, holistic, individualised interventions for BPSD. Three 
psychosocial models of BPSD have been proposed by Cohen-Mansfield (2000): 
 The unmet needs model 
 Learning/behavioural model 
 Environmental vulnerability/reduced stress-threshold model  
The Unmet Needs model suggests that the dementia process affects both the 
ability of the person with dementia to use the environment appropriately to meet 
their needs and their ability to communicate their needs effectively (Algase et al., 
1996; Cohen-Mansfield, 2000; Hancock et al., 2006). These impaired abilities, in 
interaction with longstanding habits and personality, physical and mental states 
and unfavourable environmental conditions, can give rise to BPSD (Figure 1.3).  
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Figure 1.3  Unmet needs model (Cohen-Mansfield, 2000) 
According to this model BPSD can result from unmet needs as a way of:  
 meeting a specific need (e.g. pacing to provide stimulation when bored) 
 communicating a need ( e.g. repetitious verbalisations to communicate an unmet 
need) 
 as an outcome of having an unmet need ( e.g. screaming when in pain or 
constipated) 
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According to the unmet needs model an imbalance in the interaction between 
personality, physical and mental health and environmental circumstances results in 
BPSD.  
Premorbid personality problems have been correlated with a higher incidence of 
BPSD. Thus, premorbid neuroticism has been correlated with anxiety (Archer et 
al., 2007), delusions, aggressiveness and affective disturbance (Low et al., 2002). 
Poor physical and mental health especially pain and discomfort have a two way 
interaction with unmet needs (Cohen-Mansfield, 2000). Symptoms like agitation 
and aggression can be a way of communicating distress and physical pain. For 
example, Hurley et al. (1992) reported an increase of verbal challenging 
behaviours when people with dementia experienced fevers. A positive association 
has also been reported between aggression and urinary tract infections (Huffman 
and Kunik, 2000). Sleep disturbances and fatigue have been related to increased 
agitation in dementia (Cohen-Mansfield and Marx, 1990). Mental health problems 
can be both a cause and effect of unmet needs.  Affective disorders, for instance, 
have been associated with increased agitation in nursing home residents with 
dementia (Volicer et al., 2012).  Agitation on the other hand, can develop as result 
of loneliness or limited social contact (Cohen-Mansfield and Werner, 1995, 1997; 
Salzman et al., 2008).  
Environmental circumstances are essential to this social constructionist model of 
BPSD and include both the physical and the social context of the environment. 
Social constructionism is a theoretical approach according to which our realities 
are shaped through our experiences and our interactions with others (Burr, 2003). 
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Physical environments can be under-stimulating or over-stimulating for people with 
dementia. BPSD symptoms result when the balance between under and over-
stimulation is compromised (Kovach et al., 2004). Overstimulation such as 
excessive noise and large number of staff can cause irritation and agitation (Cleary 
et al., 1988). On the other hand, monotonous environments that do not offer 
activities and frequent stimulation can also result in agitated behaviours (Cohen-
Mansfield et al., 1992).   
The Learning/Behavioural model assumes that BPSD happen as the direct result 
of conditioning. The basis of conditioning is that a reward following a particular 
response acts as a reinforcer and increases the likelihood that the response will be 
repeated. This model proposes an ABC paradigm= Antecedents -> Behaviour -> 
Consequences; where particular BPSD symptoms that are related to specific 
antecedent stimuli are reinforced by certain consequences.  For example: under-
stimulation in a nursing home (bored, lonely) -> triggers agitation in a person with 
dementia -> staff engage more and try to calm and pacify the resident, which fulfils 
the social need of the person with dementia; on the other hand this attention 
reinforces agitated behaviours. According to this model many challenging 
behaviours are learned through reinforcement by carers, therefore behaviour 
change can only happen when reinforcement contingencies are modified. This 
model relies on the assumption that learning occurs with dementia, however 
impaired learning is one of the most prominent features of the condition. Cohen-
Mansfield (2000) suggests that the fundamental element of this model is not direct 
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learning but fulfilment of social needs through increased attention or provision of 
attention.  
The Environmental Vulnerability/Reduced Stress-Threshold model suggests 
that a person’s needs and abilities need to match the environmental demands 
(Cohen-Mansfield, 2000). Lawton's (1982) seminal work conceptualized the role of 
an individual's home environment on physical functioning performance through a 
‘press-competence’ model, according to which an individual with a given 
competence interacts with an environmental condition having a given “press” or 
demand. Lawton and Simon (1968) postulated that individuals with lower 
competence are more sensitive than those with higher competence to the 
demands of their environment. If environmental demands are either too strong or 
too weak in relation to the individual’s level of competence, negative mood and 
problematic behaviour may occur (Tomey and Sowers, 2009). A related hypothesis 
is the ‘Reduced Stress Threshold’, according to which individuals with dementia 
gradually lose their coping abilities and consequently perceive their environment as 
increasingly stressful (Hall, 1994). Cohen-Mansfield (2000) drew into these earlier 
frameworks to develop the Environmental Vulnerability model which brings 
together the ‘press-competence’ and ‘reduced stress threshold’ models. This 
model maintains that considering the decreased level of competence of people 
with dementia their likelihood of being disturbed by the environment increases. 
Therefore, environmental stimuli that are inappropriate and exceed the individual’s 
threshold for tolerating stress results in negative mood and challenging behaviours 
(BPSD).  
 63  
 
The three psychosocial models described above may be complementary and are 
not mutually exclusive.  Different models may also account for different BPSD 
symptoms in different individuals. These models have provided the grounding for 
different non-pharmacological interventions for BPSD, which will be described in 
detail in the next section.  
1.3.4 Non-pharmacological interventions for BPSD 
The growing recognition of the importance of BPSD symptoms and the rising 
concern regarding their treatment with antipsychotic drugs have triggered a surge 
of interest in developing and applying non-pharmacological interventions as 
treatments for BPSD. Table 1.6 presents my summary of non-pharmacological 
interventions for BPSD. The main headings represent the category under which 
individual interventions have been included. Most of the individual therapies may 
be categorised under more than one heading, for example reduced sensory 
stimulation can be classified as sensory manipulation as well as environment 
manipulation and social contact. However, for ease of description individual 
interventions have been categorised under one heading.  
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Table 1.6 Non-pharmacological therapies for BPSD 
 
 
 
 
Sensory manipulation/ 
relaxation 
 
Massage/touch 
Aromatherapy 
Music  
Snoezelen therapy/multi-sensory stimulation 
--------------------------------------------------------------- 
Decreased sensory stimulation 
--------------------------------------------------------------- 
Balancing arousal control excesses 
 
 
Social contact 
 
Pet therapy 
Reminiscence therapy 
Simulated Presence Therapy 
 
 
Psychological 
therapies and emotion 
oriented approaches 
 
Differential reinforcement (behavioural) 
Reality orientation/ Cognitive stimulation therapy  
Validation therapy  
 
 
 
Environmental 
interventions 
 
Stimulus control 
Signposting 
Use of Mirrors 
Wandering areas 
Enhanced environments  
Light therapy 
 
Training and 
psychoeducation for 
carers 
 
Educational programmes for staff and family carers 
 
 
Structured activities 
 
Recreational activities  
Physical activities (outdoor walks, Tai Chi, strength and 
flexibility training, etc.) 
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1.3.4.1 Sensory manipulation 
Sensory manipulation treatments are primarily used with people with moderate to 
severe dementia and have been focusing on both stimulation enhancement and 
reduction. Stimulation enhancement approaches have been used to provide 
meaningful stimulation, reduce anxiety/agitation and improve mood and are based 
on the ‘unmet needs’ and ‘environmental vulnerability’ models, which propose that 
BPSD may result from periods of sensory deprivation (Cohen-Mansfield, 2001). 
Massage therapies have included hand massage with essential oils (Kilstoff and 
Chenoweth, 1998; Kim and Buschmann, 1999; Rowe and Alfred, 1999), electrical 
nerve stimulation (Scherder et al., 1995) and craniosacral therapy4 (Gerdner et al., 
2008). All these studies, apart from Scherder et al. (1995) have indicated decrease 
on agitation, wandering and fidgety behaviours, however, they are quite small with 
samples varying from 14-30 participants and the methodologies used are not 
robust (not blinded, no control group)  (Kverno et al., 2009).  
Aromatherapy involves the use of essential oils such as lavender, thyme and 
melissa (lemon) balm for treatment of agitation in people with dementia. These oils 
have been applied in different ways such as by diffusion in communal areas 
(Holmes et al., 2002), bedside diffusers (Lin et al., 2007), applied to the skin 
(Ballard et al., 2002) and as sachets (Snow et al., 2004). Most of these studies 
have reported significant reduction in agitation and excellent compliance with the 
intervention (Douglas, 2004). The study from Ballard and colleagues (2002) is a 
                                            
4 An alternative medicine approach that aims to relieve pain and tension by gentle 
manipulations of the skull. 
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randomised controlled trial (RCT) that reported not only significant reductions in 
agitation but also excellent compliance with the intervention. However, the 
intervention itself was more than just aromatherapy as it also involved increased 
social contact whereby Melissa balm was applied twice a day on participants’ faces 
and arms, which may also be considered as massage. Therefore, the benefit of 
aromatherapy is still under investigation and it has been reported as one of the 
fastest growing complementary therapies (Burns, 2002; Forrester et al., 2014).  
Music interventions have been quite heterogeneous, ranging from listening to 
music for relaxation and anxiety reduction (Holmes et al., 2006; Sung et al., 2010), 
during mealtimes (Chang et al., 2010; Hicks-Moore, 2005) or bath-times (Clark et 
al., 1998), to dancing, singing, playing musical instruments, or participating in 
composition and improvisation sessions (Cohen-Mansfield, 2001; Ledger and 
Baker, 2007; Sherratt et al., 2004). All of the above studies reported some benefits 
in terms of decreased agitation, reduction of aggressive behaviours and grater 
positive engagement. The main disadvantage of music intervention studies is that 
most of them have very small sample sizes (ranging from 10-46 participants); have 
employed within-participants experimental design; and use direct observational 
methods which are susceptible to rater bias and Hawthorne effect. Therefore the 
chance of obtaining significant results is reduced and the findings remain 
inconclusive (Vasionytė and Madison, 2013). White noise (environmental sounds) 
has also been used to induce relaxation and sleep, and consequently reduce 
verbal agitation and wandering (Burgio et al., 1996). Different music interventions 
feed into different psychosocial theories. For example listening for relaxation is 
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based on the unmet needs and environmental vulnerability hypotheses; music use 
during bath and mealtimes is based on the above mentioned hypotheses as well 
as the learning/behavioural theory.  
Multi-sensory stimulation (MSS) or Snoezelen therapy, which is also considered 
as an emotion-oriented approach, combines relaxation and exploration of sensory 
stimuli such as lights (e.g. fiber optics), sounds and tactile sensations (cushions, 
vibration pads). This therapy is usually delivered in dedicated rooms and sessions 
are tailored to individual needs (Douglas, 2004). Multi-sensory stimulation is 
primarily used to reduce apathy in people with advanced dementia. Baker et al. 
(2001) examined the effects of MSS on 25 participants with moderate to severe 
dementia through an RCT and found significant reduction in dysphoric mood. 
However, when the same authors (Baker et al., 2003) ran a second, bigger trial 
(n=65) they did not find any significant differences between the control and 
intervention arms. The cost and complexity of MSS rooms can be a barrier to using 
them especially as evidence in their favour is not very robust.  
Decreased sensory stimulation interventions are based on the ‘reduced stress 
threshold’ model, which suggests that BPSD can result as a consequence of over 
or inappropriate stimulation. This approach has been applied in care or residential 
homes where the levels of over-stimulation are higher than family homes. Two 
small studies (Cleary et al., 1988; Meyer et al., 1992), with samples of 11 
participants each, explored benefits of “quiet” interventions in agitation symptoms.  
Meyer et al. (1992) introduced a ‘quiet week’ which included turning off the 
television, lowering voices and reducing fast movement by staff at a day centre, 
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and found a significant decrease in agitated behaviours. Cleary et al. (1988) took a 
more holistic approach by removing sources of stimulation such as TVs, radios and 
telephones as well as by manipulating the environment (introducing: smaller tables 
for eating and activities or neutrally painted walls), educating carers and training 
staff. These authors also reported decrease in agitation.  Overall, there is limited 
evidence about the effectiveness of these interventions on BPSD.  
Kovach et al. (2004) has taken a noteworthy approach to the subject of stimulation 
and its relationship to BPSD. These authors propose a model called Kovach’s 
Model of Imbalance of Sensoristasis, which describes the importance of keeping in 
balance sensory-stimulating and sensory-calming activities as this imbalance can 
give rise to or exacerbate agitation in advanced dementia. This model is consistent 
with Cohen-Mansfield's (2000) environmental vulnerability/reduced stress-
threshold model. 
1.3.4.2 Social Contact 
The next group of interventions include interventions that focus on real or 
stimulated social contacts and are based on the ‘unmet needs’ model of BPSD. 
Several studies suggest beneficial effect of pet therapy on agitation and verbal 
aggression (Churchill et al., 1999; Fritz et al., 1995, 1996; Zisselman et al., 1996).  
Reminiscence therapy (RT) uses materials (e.g. old newspapers, photographs 
and household items), music and art to stimulate memories and enable people to 
relive past experiences that are highly significant to them. This approach was 
originally but unsuccessfully utilised as an intervention for improving cognitive 
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symptoms of dementia, but it has been shown to improve level of psycho-social 
wellbeing of people with dementia (Brooker & Duce, 2000; Lai, Chi, & Kayser-
Jones, 2004; Woods, Spector, Jones, Orrell, & Davies, 2005). Reminiscence 
therapy is flexible and can be adapted to groups as well as individual needs. 
However, there is limited evidence of a significant impact of RT in BPSD (Woods et 
al., 2005).  
Simulated presence therapy is grounded in the unmet needs and environmental 
vulnerability theories and entails use of videos or audio recordings of family 
members sharing conversations and memories with the person with dementia. This 
intervention has been used in care and residential homes. Two studies have 
reported reduction in physical and verbal agitation and greater frequency of happy 
expressions during treatment, however, these benefits do not seem to last beyond 
exposure time (Camberg et al., 1999; Garland et al., 2007).  
1.3.4.3 Psychological therapies and emotion oriented approaches 
Differential reinforcement aims to reduce or eliminate maladaptive behaviours by 
using positive reinforcement in a structured way to increase desirable behaviour 
and is based on the ‘learning/behavioural model’. Rogers et al. (1999) applied 
behavioural rehabilitation to reduce disruptive behaviour in nursing home residents 
with dementia. Doyle and colleagues (1997) also used reinforcement of quiet 
behaviour and environmental stimulation to decrease noise-making in 12 long-
term-care residents with severe dementia. There have not been any reports of 
more recent interventions of differential reinforcement.  
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Reality orientation (RO) is based on the idea that impairment in orientation and 
confusion prevent people with dementia from functioning well and is supported by 
the environmental vulnerability and the unmet needs models. RO facilitates re-
orientation through: reminding people with dementia of facts about themselves; 
and through environmental manipulation (such as using signposting, clocks, 
calendars, newspapers, television, pictures, personal belongings). The efficacy of 
RO has been criticised by several authors who found RO classes non-efficacious 
(Hanley et al., 1981); with little long-term effect (Hitch, 1994); or argued that RO 
can have a negative effect on mood through reminding people of their prognosis 
(Baines et al., 1987; Goudie and Stokes, 1989). Dietch and colleagues (1989) 
claimed that insensitive use of RO through incessantly correcting and challenging 
people with dementia could result on demeaning and confrontational experiences 
for this vulnerable population. However, more recent reviews (Spector, Davies, 
Woods, & Orrell, 2000; Spector, Orrell, Davies, & Woods, 2001)  have been quite 
favourable to RO and its outcomes. In fact it seems as though, after a loss of 
interest for this approach in the nineteen eighties, interest in RO has been 
reawakened (Spector et al., 2001; Woods, 2002) under the new term Cognitive 
stimulation therapy (CST). 
Cognitive stimulation therapy, unlike RO, is grounded in person-centred care 
(Kitwood, 1997) and its key principles are to appropriately and sensitively use 
multi-sensory stimulation to re-orient people with dementia and strengthen 
relationships with carers (Spector, Orrell, & Goyder, 2013). This approach is 
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predominantly used in group of patients with mild to moderate dementia, as 
participants need to be able to carry out meaningful conversations and participate 
in group activities.    
Validation therapy (VT) is based on the Rogerian humanistic psychology 
argument that BPSD symptoms are strategies used by people with dementia to 
avoid stress, boredom and the painful reality of their condition (Hitch, 1994). 
Validation therapists propose that empathic communication with individuals with 
dementia is essential rather than their orientation to the present. Neal and Barton 
Wright (2003) evaluated validation therapy through a Cochrane review and 
concluded that evidence about the efficacy of validation therapy is insufficient.  
1.3.4.4 Environmental interventions 
Environmental interventions include modifications of the factors that may cause or 
exacerbate BPSD such as: excessive noise (reduced stress threshold model), lack 
of routine (unmet needs model), inadequate lighting (environmental vulnerability 
model), confusing surroundings, and excessive demands by staff in residential 
settings (learning/behavioural model) (Gauthier et al., 2010). Many of these 
approaches have focussed exclusively on assisted-living facilities. Some of the 
environmental interventions include: 
Enhanced environments - Several non-randomised trials have investigated the 
effect of environment manipulation on agitation symptoms and exit-seeking 
behaviours of people with dementia in residential settings. Different approaches 
entailed: painting two dimensional grids on the floor in front of exit doors (Chafetz, 
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1990; Hewawasam, 1996; Hussian and Brown, 1987); painting murals over 
doorways (Kincaid and Peacock, 2003); and placing blinds and cloth barriers over 
doors or door handles (Dickinson et al., 1995; Namazi et al., 1989). Chafetz (1990) 
concluded that the two-dimensional grid is ineffective, however, the other authors 
reported on reduced exiting behaviours and ambulation.  
Wandering areas/ Removal of restraints – A few authors have criticised the 
reduced autonomy in institutionalised patients, and have argued that these settings 
exacerbate or even cause BPSD. Two studies found that unlocking exit doors in a 
residential home, and release from mandatory confinement in an acute unit 
reduced agitation as well as both physical and verbal aggression (McMinn and 
Hinton, 2000; Namazi and Johnson, 1992).  
Light therapy – Light therapy has been utilised to improve circadian rhythms, 
which are impaired in people with dementia (Vitiello and Borson, 2001). This 
approach is supported by the ‘unmet needs’ model as it attempts to improve sleep 
(Mishima et al., 1994; Okawa et al., 1991) and consequently reduce agitation 
(Lovell et al., 1995; Lyketsos et al., 1999). The above studies have reported 
benefits on sleep and agitation, but other studies have reported no effect (Koss 
and Gilmore, 1998; Thorpe et al., 2000). Overall, the support for this approach 
remains inconclusive as the reported studies are small non-RCTs (Cohen-
Mansfield, 2001; Forbes et al., 2014; Skjerve et al., 2004).   
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1.3.4.5 Training and psychoeducation programmes for carers 
This approach focuses on improving carers’ knowledge of dementia and BPSD, 
improving communication with people with dementia, and on providing potential 
management strategies for BPSD.  Reduced agitation has been reported after 
training staff on communication skills (McCallion et al., 1999), empathy (Williams, 
1994), tailored and focused care (Matteson et al., 1997; Mentes and Ferrario, 
1989; Wells et al., 2000). Psychoeducation interventions with family carers have 
also resulted in improved mood (Hébert et al., 2003) and decreased or delayed 
institutionalisation (Eloniemi-Sulkava et al., 2001; Mittelman et al., 1996). All the 
above studies report improved outcomes immediately after the intervention, 
however this effect ceases not long afterwards, indicating that educational 
programmes should be of an ongoing nature rather than a one-off intervention 
(Livingston et al., 2005).  
1.3.4.6 Structured activities  
Recreational activities such as sewing, dancing, games, playing instruments 
have been reported to have a positive effect on agitation (Aronstein et al., 1996) 
and wandering behaviours (Groene, 1993; Kolanowski et al., 2009). These 
findings, however, are based on a small number of non-randomised studies.    
Physical activities include various types of physical exercises such as outdoor 
walks (Calkins et al., 2007; Detweiler et al., 2008), Tai Chi (Tadros et al., 2013), 
strength and flexibility training (Steinberg et al., 2009), walking, cycling, chair 
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based exercise (Heyn et al., 2004). These interventions will be covered at length in 
the Literature Review chapter.  
1.4 Exercise and its putative mechanisms of improving BPSD 
1.4.1 Working definition of exercise 
The terms physical activity and exercise have been used interchangeably to 
describe interventions that involve bodily movements (Caspersen et al., 1985). 
Caspersen and colleagues (1985) have argued that although these concepts have 
common elements, they are quite distinct from each other. They state that even 
though both physical activity and exercise involve bodily movements that result in 
consumption of energy, exercise differs because unlike physical activity it is a 
planned, structured, and repetitive action for the purpose of improving health. This 
classic definition of exercise has been recently validated (Chodzko-Zajko et al., 
2009) and is still being widely used in research, particularly in dementia studies 
(Bowes et al., 2013; Cedervall, 2014; Farina et al., 2014; Law et al., 2014), 
therefore it was decided to be applied in the conceptualization  and design of the 
intervention in Chapter 3. 
1.4.2 How exercise interventions might effect BPSD 
According to BPSD theories the most fundamental elements that give rise to these 
symptoms are physical and mental health status and environmental circumstances 
(Cohen-Mansfield, 2000).  
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1.4.2.1 Physical health 
Physical wellbeing is strongly associated with physical activity, absence of which is 
established as a major risk factor for ill health and mortality (Kokkinos, 2012; Lee et 
al., 2010; Scarmeas et al., 2011). Increased physical activity levels can improve 
general cardiovascular health (Balady et al., 2004), can reduce the risk of high 
blood pressure (Rossi et al., 2012), some types of cancer (Meyerhardt et al., 
2006), osteoporosis and fracture risk (Rizzoli et al., 2009) and Type 2 diabetes 
(Knowler et al., 2002). Improved cardiovascular system and general physical 
health is characterized by lower arousal at rest which can induce relaxation, and 
positive engagement.  
Physical activity has been strongly related to pain and discomfort caused by 
physical conditions such as arthritis, constipation, musculoskeletal diseases, 
cancer and vascular diseases, on a two way interaction as both cause and effect of 
these health problems (Dukas et al., 2003; De Schryver et al., 2005). For instance, 
physical inactivity can be a sign of experiencing pain or constipation but these 
conditions can also result from prolonged periods of immobility creating thus a 
vicious circle of inactivity and ill-health (Plooij et al., 2012). Physical pain often 
results in low mood, apathy, irritation and aggression, which can be wrongly 
diagnosed as BPSD and subsequently treated with antipsychotics (Ballard, 
Corbett, et al., 2009; Husebo et al., 2011). In order to address this issue NICE 
guidelines state that the first step to treating BPSD is to assess and treat any 
contributory physical or mental health problems (Clark, 2011).  
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Physical activity can improve strength and balance, and help to counteract the fear 
of falling (Allan et al., 2009). Improved physical function contributes in maintaining 
muscle strength and joint flexibility and reduces the risk of osteoporosis (a disease 
that affects the bones, making them weak and more likely to break) (Borer, 2005; 
Rizzoli et al., 2009). This can be a way of helping people maintain 
independence for longer by reducing their dependency in activities of daily living. 
Functional independence is essential for individuals’ maintenance of self-efficacy, 
sense of control, self-esteem and ability to participate in social activities, all of 
which are strongly linked with depressive symptoms (Boström et al., 2014; Yang, 
2006). 
1.4.2.2 Cognitive decline 
Exercise has been reported to be an important and effective protective factor 
against cognitive decline and subsequently of BPSD (Ahlskog et al., 2011; Laurin 
et al., 2001). BPSD such as apathy, agitation, disinhibition, irritability, and aberrant 
motor behaviour worsen with the progress of dementia (Tanaka et al., 2015).  
Ahlskog and colleagues (2011) describe regular exercise as ‘neuroprotective 
therapy’. Recent studies suggest that exercise may have positive effects on brain 
neuroplasticity, which is a fundamental mechanism for learning, memory, and 
cognition (Ahlskog et al., 2011; Vaynman et al., 2004). Exercise has been reported 
to result in increased size of hippocampus and improved memory (Erickson et al., 
2011; Morra et al., 2009). Functional brain MRI studies have reported significantly 
improved cognitive networks after exercise (Ruscheweyh et al., 2011; Voss et al., 
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2010). The cognitive decline is critical for development of BPSD and regular 
exercise may provide a buffering effect.  
1.4.2.3 Depression and anxiety 
Exercise has been reported to improve mental health, specifically depression and 
anxiety in general population (Craft and Perna, 2004; Gogulla et al., 2012) as well 
as in individuals with dementia (Conn, 2010; Dunn, 2010). Cooney and colleagues 
(2013) carried out a Cochrane review of exercise interventions for depression and 
concluded that exercise was more effective than antidepressants and 
psychological therapies alone in reducing depressive symptoms. The mechanisms 
underlying the antidepressant effects of exercise can be multifactorial including 
physiological and psychological elements. The ‘thermogenic’ model is one of the 
earlier physiological hypotheses, which claims that exercise brings about increases 
in the temperature of specific brain regions that can lead to relaxation and 
reduction in muscular tension and improvement of anxiety and depression (Szabo 
et al., 2013).  
Another putative physiological model is the ‘monoamine’ hypothesis, according 
to which exercise leads to an increase of brain neurotransmitters (e.g., serotonin, 
dopamine, and norepinephrine) that are reduced in individuals with depression 
(Tang et al., 1981). Although animal models back up this theory (Dishman, 1997), 
no studies involving humans have been reported so far due to the use of invasive 
procedures necessary in obtaining samples such as spinal taps for cerebrospinal 
fluid.  
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The ‘endorphin’ hypothesis is another influential physiological model, which 
proposes that exercise has a positive effect on depression due to increased 
release of β-endorphins following exercise. According to this theory, β-endorphins 
act as internal psychoactive agents that can trigger feelings of euphoria and 
improve mood (Craft and Perna, 2004). This model has been criticized because 
peripheral endorphin levels may not necessarily reflect endorphin activity in the 
brain and even if they do they are not necessarily directly associated with a change 
in mood or feelings of depression (Farrell et al., 1982). It remains unclear if 
elevations in β-endorphins are directly linked to a reduction in depression. 
Several psychological mechanisms have also been proposed. They include the 
‘self-efficacy’ and the ‘distraction’ hypotheses. Craft and Perna (2004, pp108) 
define self-efficacy as the “belief that one possesses the necessary skills to 
complete a task as well as the confidence that the task can actually be completed 
with the desired outcome obtained”. Bandura (1997) describes that individuals with 
low self-efficacy often experience negative self-evaluations, negative ruminations, 
and faulty styles of thinking, which lead to depression and anxiety. Self-efficacy 
can be enhanced through improving feelings of mastery by promoting self-
monitoring behaviours, goals’ setting, and utilization of social support. Exercise 
interventions include all these elements as individuals learn to monitor exercise 
behaviours, set short and long-term exercise goals, and receive positive support 
from trainers and other carers. The relationship between exercise and self-efficacy 
in depressed patients has not been studied extensively and findings have been 
equivocal (Craft, 2005).  
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The distraction hypothesis suggests that exercise serves as a distraction from 
worries, anxiety, and depressing thoughts. This hypothesis is based on the styles 
theory proposed by Morrow and Nolen-Hoeksema (1990) according to which 
negative thinking leads to negative attributions about the self and the world, and 
prevents individuals from behaving in a manner that elicits positive reinforcement. 
Exercising can break this cycle through keeping individuals focused on training 
goals or somatic changes such as their breathing, heart rate, sore muscles and by 
providing positive reinforcement by meeting exercise goals and receiving social 
rewards from carers and trainers.  
1.4.2.4 Sleep problems 
Poor or inadequate sleep is a risk factor for depression (Riemann and Voderholzer, 
2003). Although sleep problems increase with age, people with dementia have 
been reported to experience more difficulties than their peers without dementia  
(Grace et al., 2000; Prinz et al., 1982). Physical inactivity may be related to sleep 
disturbances and ‘sundowning’ (symptoms of agitation that are observed in some 
people with dementia during late afternoon and evenings) (Loprinzi and Cardinal, 
2011). Exercise can improve sleep by promoting daytime activity. Daytime activity 
reduces sedentary behaviour and results in increased social contact, light 
exposure, timely suppression of melatonin secretion, and stronger circadian 
rhythms (Ancoli-Israel et al., 2003; McCurry et al., 2005).  
 
 80  
 
1.4.2.5 Environmental factors 
Physical and social environmental factors, such as lack of social interaction, 
enclosed spaces, isolation, visual and auditory sensory deprivation may all 
contribute to or cause BPSD (Hersch and Falzgraf, 2007). Regular exercise 
outdoors can be a way of counteracting all the above (Thuné-Boyle et al., 2012).  
1.4.2.6 Delusions and hallucinations 
There is a paucity of research on plausible mechanisms by which exercise might 
affect psychotic symptoms such as delusions and hallucinations. This was taken 
into account during the design of EVIDEM-E (Chapter 3).  
It can be concluded that aetiology of BPSD may be described as the result of a 
complex interplay of psychological, social, and biological factors. Considering 
these factors at isolation can result in ineffective and even unsafe treatments.  It 
has been recommended that BPSD is managed through a combination of non-
pharmacological approaches and careful use of pharmacological interventions 
(Clark, 2011). As discussed earlier, non-pharmacological interventions for BPSD 
are based on three main psychosocial theories: ‘The unmet needs model’, the 
‘Learning/behavioural model’ and the ‘Environmental vulnerability/reduced stress-
threshold model’. These interventions, unlike pharmacological therapies, vary 
greatly in their approach, population target, dose, and treatment objectives (Hersch 
and Falzgraf, 2007). Exercise interventions, for example, have been quite 
heterogeneous involving different activity types, frequencies, intensities, duration, 
and settings. Nevertheless, exercise interventions have the hypothetical potential 
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to affect BPSD, especially  as they are already established as effective 
interventions for physical health and mood disorders in the general population 
(NICE, 2009).  
1.5 Barriers to exercising and theories of behavioural change 
Despite the multiple potential benefits of exercising it is difficult to induce 
individuals to start exercising and adhere to exercise regimens (Resnick et al., 
2000; Salmon et al., 2003). Key barriers to participating in physical activity for the 
general population are pre-existing  health problems (physical health conditions, 
medication intake; deteriorated physical abilities), cultural issues, environmental 
factors, demographic factors (lower socioeconomic status, living alone); 
psychological factors (worse cognitive ability, depressive symptoms), stress and a 
lack of time (Picorelli et al., 2014; Rasinaho et al., 2007; Schutzer and Graves, 
2004). People with dementia, especially those living in residential care facilities, 
face additional barriers including stigma, staff availability, negative attitudes about 
the capability of people with dementia and a culture of risk aversion in care of older 
people (Benjamin et al., 2014; Tak et al., 2012). 
Introducing exercise regimens in a person’s life means initiating significant lifestyle 
and behavioural changes. Therefore, being able to predict and influence health 
behaviour is essential in order to achieve and maintain compliance with the 
intervention. Different theories have proposed various putative models of health 
behaviour change. I will describe the four most influential theories of behavioural 
change, which are based on Bandura’s social cognition theory of behaviour: 
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 The Health Belief Model 
 The Theory of Reasoned Action 
 The Theory of Planned Behaviour 
 Trans-theoretical model (Stages of change) 
 The Health Belief Model (HBM) suggests that social, economic and 
environmental factors guide individual’s perceptions about the likelihood of threat 
to their health if they do not engage in the particular behaviour (e.g. exercise or 
smoking cessation), and the perceived expectations if they do. If individuals do not 
accept the diagnosis or the severity of their illness, or do not think that the health 
behaviour will be feasible and/or beneficial they will not change their behaviour 
(Strecher and Rosenstock, 1997). Tanner-Smith & Brown (2010) reported weak 
support for the HBM’s ability to explain and predict perceptions of risk. Armitage & 
Christian (2003) concluded that the model offers poor construct definition and weak 
predictive validity of the HBM’s core psychological components. This model has 
been criticised for its limitation in considering “contextual constraints”. Thus, even if 
perceived health-threat susceptibility and severity may be high, if one is struggling 
with critical issues such as poverty, actions to assure health are not undertaken as 
this is not perceived as a high priority in the hierarchy of needs (Tanner-Smith and 
Brown, 2010). Although descriptions of the HBM include demographic and 
socioeconomic variables, reviews of its practice indicate that these elements have 
not been utilised effectively (Taylor et al., 2007). This can be another factor that 
may explain HBM’s low ability to predict perceptions of risk. 
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The Theory of Reasoned Action (TRA) proposes that behaviour change can be 
predicted by a person’s intentions (Fishbein and Ajzen, 1975). According to this 
theory, intentions are determined by the person’s attitude towards the behaviour, 
and beliefs regarding carers’ support of the behaviour. For example, people may 
believe that exercising will improve BPSD symptoms; however, they may also feel 
that it is painful, tiring and can cause falls. The pros have to outweigh the cons for 
behaviour to change. People are influenced by significant others whose opinions 
are valued (Schutzer and Graves, 2004). For example, if a man believes that his 
wife wants him to exercise, and he values her opinion, he would be more likely to 
engage in exercise. The Theory of Reasoned Action has been criticised because it 
neglects the social factors that affect human action (Werner, 2004).  
To overcome TRAs limitations  Ajzen (1991) proposed a new model called The 
Theory of Planned Behaviour (TPB). This model is very similar to the original 
TRA, with the added element of perceived behavioural control that is driven by 
perceived self-efficacy and self-confidence. Perceived behavioural control is an 
individual perception about the feasibility for a specific behaviour to be performed 
(such as exercising). TRA and TPB have some limitations in predicting behaviour 
(Werner, 2004). The first limitation is that intention determinants are not limited to 
attitudes, subjective norms, and perceived behavioural control. There may be other 
emotional factors, which these two models overlook, such as fear, mood and 
negative or positive feeling that influence behaviour. Empirical studies have 
reported that only 20% - 40% of the variance of behaviour could be explained 
using TRA or TPB (Ajzen, 1991; Werner, 2004). However, when compared to 
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HBM, the TRA and the TPB have been described as more parsimonious (they 
have fewer, more precisely defined, components)  in design (Taylor et al., 2007).  
The Transtheoretical model (TTM). Unlike the previously mentioned models that 
focus only on the mechanisms of behaviour change, TTM takes account of both 
processes as well as stages of change by including a temporal dimension 
(Prochaska and DiClemente, 1983; Prochaska and Velicer, 1997). This model 
assumes that for a healthy behaviour to be adapted or an unhealthy one to be 
eliminated certain consecutive stages have to occur. According to this model 
people progress through five phases related to their willingness to change: pre-
contemplation (not ready), contemplation (getting ready), preparation (ready), 
action, and maintenance. Different intervention strategies have to be applied at 
each level in order to help people progress to the next stage.  Progression through 
the stages can occur in a linear fashion, but nonlinear progression is also common 
and so is regression from later stages to earlier ones  (Burkholder and Nigg, 2002).  
Several reviews have reported that TTM based approaches applied in exercise 
promotion are no more likely to be effective than alternative (rationally designed) 
interventions in achieving desired behavioural change outcomes (Adams and 
White, 2005; Riemsma et al., 2002; Taylor et al., 2007). Van Sluijs and colleagues 
(2004) reviewed 29 trials concerning the effect of stages-of-change-based 
interventions in primary care on smoking, physical activity, and dietary behaviour. 
They concluded that TTM application was effective on dietary behaviour but not 
smoking cessation and physical activity. Several authors have questioned the 
internal validity of the TTM, and have raised concerns about misclassifications in 
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self-report of stages of change (Adams and White, 2005; Riemsma et al., 2002; 
Taylor et al., 2007). Marshall and Biddle (2001) carried out a meta-analysis of 71 
papers concerning the application of the TTM to physical activity. They concluded 
that stage membership is associated with different levels of activity and 
perceptions of self-efficacy. However, they were unable to confirm whether 
physical activity changes can be staged, or should be regarded as positioned on a 
continuum. This model, same as the other models described,  has also been 
criticised for not including measures of health related social, economic and 
environmental variables (Buchan et al., 2012; Taylor et al., 2007).  
Models of behaviour change are applied in the field of health promotion for 
interventions that are evidence based. These models have been utilised in the 
fields of smoking cessation, physical activity, diet and HIV risk control. TPB and the 
TTM appear to be the most extensively employed models and they can both 
predict health related behaviour with greater effect than the HBM and TRA (Taylor 
et al., 2007). This effect however remains quite low with this model explaining just 
20-40 per cent of observed behaviour (Armitage and Conner, 2000). The body of 
evidence relating to the effectiveness of health behaviour change interventions 
based on all of the above models is varied and remains inconclusive (Taylor et al., 
2007). The design of EVIDEM-E intervention (described in Chapter 3) was 
primarily pragmatic and not theory based, although elements of the above theories 
such as carer’s perception of self-efficacy were fundamental to the study design 
and in the recruitment of dyads.  
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The following chapter will explore current (time limitations apply) evidence about 
the effect of exercise on BPSD.   
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2 LITERATURE REVIEW 
A rapid appraisal method, which adopted a critical interpretive approach (Dixon-
Woods et al., 2006) was carried out in order to synthesise the evidence of exercise 
on improving BPSD (Thuné-Boyle et al., 2012). Critical interpretive synthesis is an 
adaptation of meta-ethnography and grounded theory techniques, which involves 
an iterative approach of refining the research question by using theoretical 
sampling. Papers are searched and selected through this iterative process. Quality 
of selected papers is assessed using relevance in terms of contribution to theory 
development rather than methodological characteristics (Gough, 2007).  
The critical interpretive approach is ingrained in qualitative methods and draws on 
interpretive synthesis methods (Noblit and Hare, 1988). Dixon-Woods and 
colleagues (2006) argue that the Critical Interpretive Synthesis is more useful than 
the Systematic Review, when exploring complex questions. They claim that 
Systematic Reviews are well-fitted to test theories through aggregative synthesis, 
but the Critical Interpretive Synthesis enables generation of theories that are 
grounded in research and hold stronger explanatory power. Using a critical 
interpretive approach, we synthesized the evidence of physical activity on 
improving BPSD and proposed a research agenda. 
2.1 Aims and objectives 
The purpose of the literature review was to synthesize the evidence in order to 
understand the efficacy of exercise programs for people with dementia in relation 
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to various outcomes: psychological, behavioural, and mood and sleep disturbance. 
Three questions were addressed: 
1. Does exercise improve symptoms of BPSD? 
2. How has exercise been conceptualized and do some aspects of it (e.g. type and 
duration) provide better results than others? 
3. What are the main limitations and methodological shortcomings of current 
research in this area? 
2.2 Inclusion/Exclusion criteria 
Although the aim of this review was to be as inclusive as possible with the current 
relevant literature, we nevertheless recognize the importance of setting boundaries 
about which papers to include. This review was carried out during the period June 
2010 - May 2011, therefore papers published beyond this date are not included in 
this review. The search was limited to English language publications about human 
subjects only. Studies and review articles that met the following criteria were 
selected: 
2.2.1 Inclusion Criteria 
The individual studies and reviews that were included in the review met the criteria 
below: 
 Individual studies that measure the efficacy of exercise in improving BPSD. 
We used Caspersen et al's. (1985) classic definition of exercise as planned, 
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structured, and repetitive activity for the purpose of improving health 
(paragraph 1.4.1). 
 Review articles that examine intervention studies assessing the efficacy of 
exercise in improving BPSD.  
 Papers should have been published in peer-review journals using relevant 
keywords appearing in the title or abstract. 
2.2.2 Exclusion Criteria  
Studies were excluded because they: 
 examined the efficacy of exercise on cognitive impairment only.  
 had a primarily pharmacological focus. 
 were single case reports, observational studies or qualitative studies.  
 Individual studies that reported combined interventions (i.e. combining 
exercise with another psychosocial intervention) were excluded as these are 
unable to establish the absolute effect of exercise. This criteria was not 
possible to apply to reviews as they covered a mix of interventions, which 
would have meant excluding all reviews.    
2.3 Database search  
Medline, Embase, PsychInfo and PubMed were searched using a combination of 
keywords: 
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1. physical activity and dementia/Alzheimer’s disease 
2. exercise and dementia/Alzheimer’s disease 
3. non-pharmacological interventions and dementia 
4. exercise, sleep disturbance and dementia/Alzheimer’s disease 
5. exercise, apathy and dementia/Alzheimer’s disease 
6. exercise, aggression and dementia/Alzheimer’s disease 
7. exercise, wandering/repetitive behaviours and dementia/Alzheimer’s disease 
8. exercise, depression/mood and dementia/Alzheimer’s disease 
Other sources were also searched including reference lists and book chapters. 
Seven hundred and twenty-three articles were screened through evaluating their 
titles and abstracts. Articles were excluded because of reasons outlined in the 
exclusion criteria. The majority of excluded papers were studies of pharmacological 
interventions. Other initial exclusions encompassed studies that were unrelated to 
dementia or were not BPSD specific. For example papers about physical exercise 
interventions for cognitive symptoms of dementia were excluded. Unfortunately, 
specific details on numbers of papers excluded for each particular reason were not 
recorded. Sixteen studies fitted the inclusion criteria. Of these, 10 were review 
articles and 6 were additional papers not included in these reviews. No publications 
were included twice. The search process is described in Figure 2.1 as a Prisma 
diagram (Liberati et al., 2009).  
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Each paper included in the reviews was examined to assess their inclusiveness. 
Table 2.1 describes the reviews and Table 2.2 describes the individual articles 
explored. 
Number of 
records identified 
through 
database search: 
N = 723 
 
Number of 
records 
identified 
from other 
sources: 
N = 0 
 
  
  
 
Number of records 
after duplicates 
removed: 
N = 513 
  
    
 
Number of records 
screened: 
N = 513 
 
Number of records 
not fitting inclusion 
criteria: 
N = 424 
    
 
Number of full-text 
articles accessed for 
eligibility: 
N = 89 
 Number of full-text 
articles excluded:  
N= 73 
Reasons: 
1. Articles covered 
in reviews (71) 
2. Articles not 
published (2) 
    
 
Number of studies 
included in the 
qualitative synthesis: 
Reviews: N= 10 
Research articles: 
 N= 6 
  
 
Figure 2.1 PRISMA flowchart describing the search process of finding articles examining 
the efficacy of exercise on BPSD (Thuné-Boyle et al., 2012)
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Table 2.1 Summary of reviews included 
Reviews No. of 
trials 
BPSD outcomes 
assessed 
Types of exercise explored Effect of exercise 
Deschenes & McCurry 
(2009) 
 
0 Sleep any type of exercising Concluded that no controlled trials examining the effect of 
exercise on sleep have been conducted thus far. 
Eggermont & Scherder 
(2006)  
 
27 Mood and sleep. Various; walking, sport activities, 
aerobics, strength, flexibility and 
sit stand repetitions. 
Sustained walking benefits depression and agitation. 
Exercise beneficial to the quality of sleep.  
Forbes et al. (2009)  4 Behaviour and 
depression. 
aerobic, strength, balance 
training, walking, hand movement 
No conclusions possible. 
Heyn et al. (2004)  
 
9 Behaviour. Functional, endurance, 
recreational, mobility (walking), 
isotonic and aerobic (incl. 
strength and flexibility) exercises.  
Exercise training improved behaviours. Not able to 
establish which type of training exercise were the most 
beneficial. 
 
McCurry et al. (2000)  0 Sleep any type of exercising No studies fitting the inclusion criteria found. 
Overshott et al. (2004) 
 
2 Agitation, apathy, 
depression, 
sleep. 
daytime physical activities and 
exercises    
Exercise reduces agitation. Exercise was not discussed in 
relation to depression, sleep or apathy.  
Robinson et al. (2006)  
 
1 Wandering physical exercise No robust evidence to recommend the use of exercise to 
reduce or prevent wandering in people with dementia. 
Shub et al. (2009)  3 Sleep aerobics, endurance activities, 
strength training, balance, 
flexibility training 
Exercise improved sleep. Should walk for 30 minutes a day 
in natural light. 
 
(Siders et al., 2004) 9 Wandering walking, outdoor activities Taking methodological limitations into account, there 
appears to be some evidence that structural activities 
reduces wandering during the day and night.  
Vital et al. (2010)  
 
4 Depression strength and flexibility exercises, 
walking, balance training 
Two studies presented reductions in depression while the 
other two did not. 
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Table 2.2 Additional papers not included in the reviews displayed in Table 2.1 
Author, 
year & 
country 
Design Recruitment Participants 
and sample 
size 
Exercise 
intervention 
Follow-up 
time scale 
Outcome variable(s) & 
measurement 
Findings 
Aman & 
Thomas 
(2009) 
USA 
Prospective 
between 
group 
design. 
A special needs 
unit of two nursing 
homes. 
50 residents 
with dementia 
(SLUMS < 20); 
40 = Exercise 
group; 
10 = control 
group (those 
who refused 
exercise). 
30 minutes of 
exercise three 
days a week; 15 
min aerobics and 
15 min resistance. 
 
3 weeks Depression; Cornell 
Scale of Depression, 
agitation;  the 
Pittsburgh Agitation 
Scale; Cohen/Mansfield 
Agitation Inventory 
Improvements in 
agitation after three 
weeks. 
Edwards 
et al. 
(2008)  
USA 
 
Repeated 
measures 
design pilot 
study. 
Two nursing 
homes. 
36 residents 
with dementia 
Mainly chair 
based exercise 
but some walking, 
3 times a week for 
30 minutes over 
12 weeks.  
 
3 and 12 
weeks 
Affect (anxiety, 
depression and anger); 
the Philadelphia 
Geriatric Center 
Apparent Affect Rating 
Scale. 
Immediate short 
term effect on 
reducing anxiety 
only. Long-term 
effect on reducing 
both anxiety and 
depression. 
Hokkanen 
et al. 
(2003)  
Finland 
 
RCT pilot Dementia nursing 
home. 
Four people 
with dementia 
16 sessions of 
dance and 
rhythmic 
movement lasting 
30-45 min, once a 
week. 
16 weeks Depression and apathy; 
The Neuropsychiatric 
Inventory (NPI). 
No reduction in 
depression or 
apathy. 
 
Regan et 
al.  
(2005) 
UK 
 
Between 
group 
design 
Through the 
community mental 
health team, the 
Alzheimer’s 
Society, via 
memory clinics, 
224 participants 
with 
Alzheimer’s 
disease (MMSE 
>20) 
Any; participants 
were divided into 
absent, moderate 
or vigorous 
exercise groups. 
N/A Depression; the Cornell 
Scale for Depression in 
Dementia. 
Lack of exercise was 
an independent 
predictor of 
depression 
(association, not 
causation) p<0.001. 
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Author, 
year & 
country 
Design Recruitment Participants 
and sample 
size 
Exercise 
intervention 
Follow-up 
time scale 
Outcome variable(s) & 
measurement 
Findings 
through care 
homes, day 
hospitals and 
inpatients units. 
 
Steinberg 
et al. 
(2009) 
USA 
RCT Recruited from the 
John Hopkins 
Comprehensive 
Alzheimer 
Program, the 
department of 
psychiatry, 
Baltimore  
27 home 
dwelling 
patients with 
Alzheimer’s 
(MMSE>10): 
14=intervention  
13=control. 
Daily programme 
of aerobic, 
balance and 
flexibility, and 
strength training, 
shown to patients 
and carers, to be 
done at home. 
Control = home 
safety 
assessment.  
 
6 and 12 
weeks 
Depression and apathy. 
Neuropsychiatric 
Inventory, the Cornell 
Scale for Depression in 
Dementia. 
A trend towards 
worse levels of 
depression in the 
exercise group. 
Volicer et 
al. (2006) 
USA 
Repeated 
measures 
design 
Two dementia 
special care units 
at different 
locations. 
90 veterans 
with dementia 
provided with 
long-term care 
(MMSE 0-19) 
Continuous 
meaningful 
activities, e.g. 
moving from the 
table to a circle, 
moving chairs, 
marching to 
music, going from 
one area to 
another.  
 
12 weeks Agitation, sleep 
disturbance, use of 
psychotropic 
medications. 
Not clear what 
measures were used. 
Decreased agitation, 
improved sleep and 
a reduced use of 
psychotropic 
medication. 
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2.4 Exercise as treatment for BPSD 
The benefits of exercise for healthy older adults are well documented and are 
linked to improved physical and psychological outcomes including the prevention of 
heart disease, stroke, diabetes, falls, depression, cognitive decline and dementia 
(Elward and Larson, 1992; Mather et al., 2002). Exercise may enhance sleep and 
contribute to an increased quality of life via promotion of relaxation, and 
maintenance of daytime wakefulness (Montgomery and Dennis, 2002). Currently, 
the literature contains several reviews (Table 2.3) examining the efficacy of 
exercise in dementia (Deschenes and McCurry, 2009; Eggermont and Scherder, 
2006; Forbes et al., 2008; Heyn et al., 2004; McCurry et al., 2000). These reviews 
examine different outcomes, different modalities of exercise, different aspects of 
behavioural and psychological symptoms and use different inclusion criteria. 
Consequently, heterogeneity in the reviews makes it difficult to draw definitive 
conclusions about the role of exercise in managing BPSD, and difficult to do a 
meta-analysis.  
Heyn et al (2004) carried out meta-analysis of exercise in dementia and reported 
data on 30 trials of exercise. The authors reported on trials that included strength, 
cardiovascular or flexibility regimes; and analysed for functional, cognitive or 
behavioural outcomes. A significant positive effect of exercise on behavioural 
outcomes was reported (Effect Size = 0.54; 95% Confidence Interval = 0.36-.72). 
However these trials do not provide a full picture of the effectiveness of exercise on 
BPSD for a number of reasons. There was considerable heterogeneity in terms of 
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the interventions, and exercise was often combined with other behavioural 
interventions. Thus, it is difficult to isolate the impact that exercise has had on 
behavioural outcomes. Some regimes were quite complex and require a high 
degree of physical fitness that would preclude many older adults with complex 
physical problems and moderate or profound dementia from performing them. 
Moreover, they were potentially unsustainable without the support of trained 
therapists. Finally, the relatively high cost of delivery and specialist input required 
may prevent the interventions being used more widely. Most trials included in the 
analysis were relatively small, with only two of the eight studies that reported 
effects on behaviours having samples in excess of 100 participants. 
Table 2.3 Overall summary of the efficacy of exercise in BPSD 
Symptom 
Effects of exercise 
Anxiety An immediate short term effect of chair based exercise and some 
walking on anxiety was found, which was maintained at 12 weeks 
(Edwards et al., 2008). 
Depression 
 
Forbes et al. (2009) was not able to make any conclusions about 
the efficacy of exercise on depression as few studies fitted their 
very robust inclusion criteria.  
The findings of other studies are contradictory. There is no 
improvement in depressed mood  after doing 30 minutes of 
aerobic exercise three times a week for three weeks (Aman and 
Thomas, 2009). However, sustained walking benefits depression 
(Eggermont and Scherder, 2006)  but only in the long term 
(Edwards et al., 2008), with fewer depressive symptoms after three 
months (Logsdon et al., 2005). Comprehensive exercise as well as 
walking for 16 weeks reduces depressed mood where the effect of 
comprehensive exercise was superior to walking (Williams and 
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Symptom 
Effects of exercise 
Tappen, 2008).  
Apathy 
 
One pilot study with a small sample size found no effect of daily 
aerobics, flexibility and strength exercises on apathy after three 
months (Steinberg et al., 2009). 
General 
behaviour 
 
 
Exercise training improved behaviours (Heyn et al., 2004) but the 
type of behaviour is not specified and it is not clear which type of 
training exercise were the most beneficial. Large effect size 
studies had more frequent exercise sessions per week while 
medium effect size studies delivered the longest exercise training.   
Repetitive 
behaviour 
No studies available. 
 
Aggression
Agitation 
 
Improvements in agitation were demonstrated after three weeks of 
aerobic exercise (Aman and Thomas, 2009). Sustained walking 
benefits agitation (Eggermont and Scherder, 2006; Overshott et 
al., 2004) and meaningful exercise decreases agitation (Volicer et 
al., 2006). Chair based exercise had no effect on anger in the short 
or long term (Edwards et al., 2008).  
Wandering 
 
Some limited evidence shows that exercise (walking and structural 
activities) reduces wandering during the day and night (Siders et 
al., 2004). 
Sleep 
disruptions 
 
Some evidence that exercise (e.g. walking) improve sleep (Shub et 
al., 2009; Volicer et al., 2006) although (Deschenes and McCurry, 
2009) concluded that no robust controlled trials examining the 
effect of exercise on sleep have been conducted thus far. 
 
2.4.1 Type of exercise 
The reviews of studies described varied approaches to the concept of exercise. For 
example, Shub et al. (2009) included studies using exercise protocols ranging from 
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walking to more comprehensive programmes such as aerobics, endurance 
activates, strength training, balance and flexibility training, and concluded that 
walking is the most feasible and effective activity. Heyn et al. (2004) included 
studies examining walking, cycling, chair based exercise, flexibility and weight 
training but did not compare effectiveness between different modalities. Siders et 
al. (2004) only mentions dancing as exercise and argues that exercise had been 
poorly operationalized in studies. Forbes et al. (2008) reviewed studies examining 
aerobics, walking, ‘meaningful’ exercise and flexibility but could not carry out an 
analysis to determine a dose-response between the type, frequency, and intensity 
of physical activity due to the small number of trials included in the review. Vital et 
al. (2010) included studies examining walking, aerobics, strength and flexibility 
training but also concluded that there is no consensus on what is the most effective 
modality. The papers included in Eggermont and Scherder’s (2006) review 
evaluated seated exercise, walking, aerobics, music training, sit to stand 
repetitions, and strengthening and flexibility exercises where the effect of walking 
was superior to the other modalities. Some reviews failed to mention how exercise 
had been conceptualised in the studies they reviewed (Deschenes and McCurry, 
2009; McCurry et al., 2000; Robinson et al., 2006). 
Exercise was also conceptualised in different ways in the individual papers 
included in this review. Some studies evaluated chair based exercises and walking 
(Edwards et al., 2008) while others explored aerobics (Aman and Thomas, 2009; 
Steinberg et al., 2009), dance and rhythmic movement (Hokkanen et al., 2003) or 
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‘meaningful’ activities such as marching to music, moving from a table to a circle 
and walking from one area to another (Volicer et al., 2006).  
Most of the reviews and individual papers included in this review either did not 
address or are inconclusive about identifying the most effective type of exercise as 
therapy for BPSD. Eggermont and Scherder’s (2006) recognise that walking is 
more efficacious than other forms of exercise and Shub et al. (2009) identify 
walking as the most feasible form of exercise.   
2.4.2 Frequency and duration of exercise 
Heyn et al. (2004) coded studies with regards to the intensity, frequency and length 
of the intervention but were unable to demonstrate a significant finding for these 
training characteristics. Eggermont and Scherder (2006) provided clear details of 
the frequency and duration of the exercise interventions when available. They 
found that higher frequency of exercise (daily or several times a week) was related 
to better outcome (sleep) irrespective of duration. Siders et al. (2004) also describe 
the frequency and duration of studies but do not discuss these in any detail while 
Forbes et al. (2008) were unable to examine the effect of frequency and intensity of 
exercise due to the small number of trials. Shub et al. (2009) concluded that: 
“Patients with dementia and carers should be instructed to walk for exercise daily 
for 30 minutes, preferably outside in natural light”. Others made no mention of 
frequency or duration of exercise (Robinson et al., 2006). 
Of the individual papers, when reported, duration of exercise varied from a daily 
programme of exercise (Steinberg et al., 2009) to 30 minutes, three times a week 
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(Aman and Thomas, 2009; Edwards et al., 2008) and 30-45 minutes once a week 
(e.g. Hokkanen et al., 2003). This limited evidence indicates that exercise should 
be carried out daily or several times a week for it to be effective.  
Heyn et al. (2004) reported that the mean duration of exercise interventions that 
reached a large effect size was 14.5 weeks and a medium effect size was 23.4 
weeks. However, these effect sizes applied to mixed outcomes including 
cardiovascular, functional and behavioural aspects. Consequently, we could not 
draw a conclusion about the most effective duration period for our intervention.    
2.4.3 Place of exercise 
The studies included in the reviews by Eggermont and Schreder (2006) and Siders 
et al. (2004) were conducted in care homes, although one study included in Siders 
et al. (2004) was conducted outside. Other reviews (Deschenes and McCurry, 
2009; Heyn et al., 2004; McCurry et al., 2000; Overshott et al., 2004; Robinson et 
al., 2006; Shub et al., 2009) provided little information about the place of exercise 
as did Forbes et al. (2009) due to not being able to assess difference between 
these. 
Of the individual studies, most took place within care homes (e.g. Aman and 
Thomas, 2009; Edwards et al., 2008; Hokkanen et al., 2003; Volicer et al., 2006). 
Steinberg et al. (2009) however, carried out their intervention outside the care 
home setting where participants exercised within their own home. 
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2.4.4 Design 
Some of the review papers included some form of quality criteria to the designs of 
the studies included (Eggermont and Scherder, 2006; Robinson et al., 2006) 
and/or only included papers using RCTs with a non-intervention control group (e.g. 
Forbes et al., 2009; Heyn et al., 2004). In the review by Forbes et al. (2009) studies 
had follow-up times ranging from seven weeks to three months but the effect of 
exercise at follow-up was not examined due to lack of trials. Deschenes and 
McCurry (2009) concluded that no controlled trial had been conducted to examine 
the effect of exercise on sleep. Heyn et al. (2004) and Robinson et al. (2006) also 
point out the absence of blinding procedures and the lack of long-term follow-ups in 
studies while Siders et al. (2004) highlights a lack of RCT designs and a lack of 
control group included in studies. Other reviews (e.g. Overshott et al. 2004; Shub 
et al. 2009) only mentions the importance of conducting RCT studies but fail to 
critically examine the methodology of papers under review. 
Of the individual papers, only two studies (Hokkanen et al. 2003; Steinberg et al. 
2009) used a randomised controlled trial design. However, both of these were pilot 
studies. The others used either a repeated measures design (Edwards et al., 2008; 
Volicer et al., 2006) or a between group design (Aman and Thomas, 2009; Regan 
et al., 2005). Of those using a between group design, the control group consisted 
of those who refused to exercise (Aman and Thomas, 2009) and those who simply 
did not exercise (Regan et al., 2005). In these studies the groups would almost 
invariably be different at the start and consequently any differences observed are 
likely to be due to the pre-existing differences. In Steinberg et al.’s (2009) RCT 
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study, the control group were given a home safety assessment only. Follow-up 
times also varied from three weeks (Aman and Thomas, 2009) to 16 weeks 
(Hokkanen et al., 2003). 
2.4.5 Sample size 
The meta-analysis by Heyn et al. (2004) excluded research papers using less than 
five participants and mentions the problem of small sample size in current studies 
using an RCT design. Eggermont and Scherder (2006), Forbes et al. (2009), 
Siders et al. (2004) and Vital et al. (2010) also provided clear details of sample size 
and made similar comments with regards small sample size and low power of 
studies.  
The sample size in the individual studies was small overall, with only two studies, 
which were not RCTs, having 90 participants or more (Regan et al., 2005; Volicer 
et al., 2006). Steinberg et al. (2009) is the largest RCT with 27 participants. The 
remainder had samples ranging from four to 50 (e.g. Aman and Thomas, 2009; 
Hokkanen et al., 2003).  
2.4.6 Cognitive disability and diagnosis 
Eggermont and Scherder (2006) only included studies where participants had an 
MMSE (Mini-Mental State Examination) score of 24 or less and although they 
describe the diagnosis of participants within each study, these were not discussed 
further. Heyn et al. (2004) included papers where participants had MMSE scores of 
less than 26 or a pre-existing diagnosis of dementia. Seventy-five percent of the 
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studies reported the MMSE score. The type of dementia diagnosis affecting the 
participants was described but not discussed further. Siders et al. (2004) report 
that cognitive disability and type of dementia was rarely described. Indeed, Forbes 
et al. (2009) also highlight the lack of homogeneity in terms of diagnosis and 
severity of disease in current studies. Some reviews (e.g. Vital et al., 2010) only 
included patients with Alzheimer’s disease while others (e.g. Overshott et al., 2004; 
Shub et al., 2009) did not discuss diagnosis or cognitive status.  
Many of the individual studies ignored the potential importance of diagnosis type 
(e.g. Edwards et al., 2008; Hokkanen et al., 2003; Volicer et al., 2006) although 
most reported the MMSE or SLUM (Saint Louis University Mental Status) scores 
used as an inclusion criterion and describe the diagnosis of their participants (e.g. 
Aman and Thomas, Edwards et al., 2008; 2009; Regan et al., 2005; Steinberg et 
al., 2009). However, two studies did have a homogenous sample (only people with 
Alzheimer’s disease; Regan et al., 2005; Steinberg et al., 2009).   
2.4.7 Limitations of the literature review 
The major limitation of this literature review is that it completely relied on previously 
published research that was identified using the critical interpretive approach, the 
search methodology described in paragraph 2.3 and the appropriateness of these 
studies given the inclusion/exclusion criteria. This review was carried out within 
very limited time frames and its conduct and the trial design phase overlapped. 
Therefore, a few aspects of the trial design were not primarily informed by these 
findings, but by decisions taken at Advisory and Steering Committee meetings.  
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Single studies that investigated combined interventions were excluded from the 
review, however the reviews included did incorporate combined interventions. For 
example an RCT by McCurry and colleagues (2005) was not included on the 
review because the intervention included both walking and a sleep hygiene 
programme. The review was restricted to English papers only. This review was 
sent for publication in May 2011, consequently it did not include papers that were 
published beyond this date. As a result relevant reviews such as the one by Tadros 
et al (2013), which explores the effectiveness of Tai Chi on BPSD were not 
included.  
2.5 Summary 
There are plausible mechanisms for reduction of BPSD using exercise as therapy 
(Cooney et al., 2013). However, exercise programmes for people with dementia 
have been poorly conceptualised and it is unclear which aspects of exercise (e.g. 
type and duration) provide better results than others. We need to understand 
further what behavioural and psychological symptoms responds best to what type 
of exercise/intervention, how exercise may work, for whom and under what 
circumstances. At the conclusion of the review there appeared to be some 
indication that walking is a feasible exercise that can help reduce depression 
(Edwards et al., 2008; Eggermont and Scherder, 2006; Williams and Tappen, 
2008), aggression and agitation (Overshott et al., 2004) wandering (Siders et al., 
2004) and sleep disturbances (Shub et al., 2009; Volicer et al., 2006). However, 
evidence that exercise has a role in improving apathy and repetitive behaviours 
appeared to be completely lacking. The beneficial effect of duration and frequency 
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of exercise was also unclear although some studies suggested that walking for at 
least 30 minutes, daily or several times a week may enhance outcome (Eggermont 
and Scherder, 2006; Heyn et al., 2004; Shub et al., 2009). Indeed, studies 
examining the effect of daily exercise had more favourable outcomes. However, 
the methodological shortcomings of current work in this area are substantial and 
future studies need to focus on conducting robust longitudinal trials of well-defined 
exercise interventions appropriate for people with dementia. The EVIDEM-E trial 
was designed to measure and clarify the effect of such a well-defined exercise 
intervention.  
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3 EVIDEM-E TRIAL DESIGN AND METHODS 
3.1 EVIDEM  
EVIDEM-E was one out of five components of the EVIDEM program. EVIDEM 
stands for “Evidence-based Interventions in Dementia: Changing practice in 
dementia care in the community: developing and testing interventions from early 
recognition to end of life”. EVIDEM was a £2 million program of research funded by 
the National Institute for Health Research (NIHR) under grant code RP-PG-0606-
1005. It was a consortium of academic and NHS professionals who conducted five 
research projects, from 2007-2013, that explored the trajectory of dementia 
process, from diagnosis to end-of-life care (Table 3.1). EVIDEM-E (exercise) was 
one of those five projects, which aimed to determine the effectiveness of physical 
exercise delivered through a program of incremental walking for treating 
behavioural and psychological symptoms of dementia compared with treatment as 
usual.  
The program was hosted by Central & North West London NHS Foundation Trust 
(CNWL). It commenced in 2007 and reached its conclusion in 2013.
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Table 3.1 Description of the other EVIDEM projects 
Study title Aims Design Findings 
 
EVIDEM-ED:         
A cluster-
randomised 
controlled trial to 
improve early 
diagnosis and 
clinical 
management of 
dementia in 
primary care 
To test a customised educational 
intervention developed for general 
practice, promoting both earlier 
diagnosis of dementia and concordance 
with management guidelines. 
The intervention was tested 
in an unblinded cluster 
randomised controlled trial 
(RCT) with a pre- and post-
intervention design, with two 
arms: usual care compared 
with the educational 
intervention. 
Case detection rates were unaffected by 
the intervention. Carers’ recall of advice 
given suggested that a large minority had 
not received the information recommended 
by the National Institute for Health and 
Clinical Excellence (NICE) dementia 
guidelines. 
 
EVIDEM-C: 
Promoting 
continence and 
managing 
incontinence with 
people with 
dementia living at 
home 
To investigate (1) the incidence of the 
problems for people with dementia living 
in their own homes; (2) the published 
evidence for management; (3) the 
experience; and (4) the strategies and 
issues faced by people with dementia, 
their carers and the professionals trying 
to support them, as well as the feasibility 
of testing different designs of continence 
pads and tools to aid primary care 
nurses in tailoring their advice, 
management and support. 
This qualitative study had 
four interlinked phases: 
1. 1. Reviewed the evidence 
about prevalence and 
effective interventions.  
2. 2. Explored the experiences 
and strategies used by 
people with dementia and 
their carers to manage 
incontinence, and the 
impact and consequences 
of that incontinence.  
3. 3. Tested the feasibility of an 
identified intervention.  
4. 4. Developed educational 
resources. 
5.  
This study suggested that there are 
strategies and responses that primary care 
professionals and others can utilise to 
encourage greater openness, thereby 
lessening the taboo of incontinence within 
the stigma of dementia. It remains to be 
seen if these approaches, combined with 
more emphasis of effective containment of 
excreta, will influence decisions about 
relocation of people with dementia to care 
homes. 
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Study title Aims Design Findings 
 
EVIDEM-EoL: 
Quality of care at 
the end of life 
 
 1. To characterise dementia residents 
living in care homes and describe their 
respective pathways to death, including 
a survival analysis to identify indicators 
of the end of life. 
 2. To describe the care and support 
needs of this population, and of their 
carers. 
 3. To establish how care home staff and 
NHS primary care practitioners define, 
assess and provide end-of-life care for 
this population. 
 4. To describe how different contexts 
and models of care in care home 
environments influence experiences of 
end-of-life care. 
 5. To identify the treatments and 
interventions received and services and 
resources used, leading up to death. 
  
This study used a 
prospective, mixed-
methods design including 
case notes analysis, 
interviews, mapping of 
service use and economic 
evaluation. 
This study tracked care 
received by 133 dementia 
residents over 18 months in 
six residential care homes, 
including medication review 
and economic evaluation. 
Just over 20% of the resident cohort died. 
There were no significant differences 
between those who died and those still 
alive in terms of sex, age, care home, 
duration of prior residence or a formal 
diagnosis of dementia. Sedative load was 
not significant but inappropriate prescribing 
was. Phase 2 used a co-design approach 
[Appreciative Inquiry (AI)] with three of the 
six care homes that built on existing 
relationships and expertise and, when 
appropriate, end-of-life care tools. The 
intervention was evaluated in terms of its 
ability to address the different types of 
uncertainty. AI did not increase resource 
use and there was a reduction in hospital 
costs. 
EVIDEM-MCA: 
Implementing the 
Mental Capacity 
Act 2005 (MCA) 
 
1.  
2. To identify the implementation issues 
arising from the introduction of the MCA 
in the services working with people with 
dementia and their carers over a 5-year 
period, in community settings (including 
care homes) 
3. To explore and make recommendations 
about continued professional 
development programmes about the 
MCA, and their links to adult 
Qualitative design: The 
study was designed as four 
phases to reflect the 
trajectory of the dementia 
syndrome: (1) pre 
diagnosis; (2) post 
diagnosis; (3) living with 
dementia after diagnosis; 
and (4) towards the end of 
life. Tailored, semi-
structured topic guides were 
Baseline interviews indicated limited 
awareness, knowledge and understanding 
of the MCA but by follow-up these had 
grown. The need for training to be a 
continuous process informed by 
supervision, rather than one-off events was 
identified. An ‘information merry-go-round’ 
for people seeking advice and information 
was found. Some ‘well’ older people had 
made financial plans but appeared reluctant 
to think about HSC preferences and 
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Study title Aims Design Findings 
safeguarding training and practice. 
4.  
 
developed to explore the 
research questions at each 
phase.  
choices. Principles of the MCA, such as 
‘best interests’ decision-making, were 
useful for carers to apply when deciding for 
their relatives. Few professionals are aware 
of offences under the MCA and lack 
confidence in distinguishing criminal acts (ill 
treatment and wilful neglect) from poor 
care. 
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3.2 Evolution of the trial design 
Study design was the first component of the EVIDEM-E project since the original 
grant proposal was very general and unspecified. The development of the protocol 
was the first task of the project team. This allowed the candidate to play an 
unusually large role in trial design. The design was developed through interactions 
between the study team and the steering group, which was comprised of: consultant 
psychiatrist, physiotherapist, occupational therapist, exercise therapist, assistant 
clinical psychologists, voluntary sector representatives and two carers.  
The EVIDEM-E study was designed as a pragmatic, randomised, controlled, single-
blind, parallel-group trial (Schulz et al., 2010). The parallel group design is 
commonly used when comparing two treatments (Turner, 2013). Participants were 
randomly allocated to either intervention or control group and remained in their 
allocated group throughout the trial. Cluster randomisation was discussed when 
recruitment from care homes was considered (Campbell et al., 2000). Clustered 
randomisation of care homes would have controlled for contamination effects. 
Contamination happens when behaviour of a participant in a specific arm of the trial 
may be influenced by another participant in the opposite arm of the same trial 
(Torgerson, 2001). The same members of staff might support participants on either 
arm of the trial; therefore contamination across participants could have increased. 
However, considering the small expected number of recruitments from care homes, 
it was decided to randomise participants individually. 
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Randomised controlled trials (RCT) are considered as “The most scientifically 
rigorous method of hypothesis testing available in epidemiology” (Last, 2001). 
During the last 50 years the effect of an intervention has been tested though RCTs 
rather than in observational studies because RCTs provide the most clear and 
unbiased evaluation of effect. Randomisation is one of the most powerful elements 
of RCT design as it removes selection bias and enables distribution all variables 
which might have an effect on outcomes equally between intervention/control 
groups. The process of randomisation was completely removed from the study team 
and was assigned to external, independent researchers. Randomisation enables 
distribution of potential confounders equally and avoids selection by perceived 
likelihood of favourable / unfavourable outcome. Blinding is another fundamental 
element of RCTs that minimises information bias during outcome assessments. 
Unfortunately, an intervention like exercise cannot be received blindly by 
participants who are bound to know their arm allocation. Hence, this study was 
single-blind with the researcher being blind to participants’ allocation. The data 
analysis was also conducted blindly by the researcher.  
EVIDEM-E was a pragmatic trial with explanatory elements. Patsopoulos (2011) 
maintains that there is a continuum between pragmatic (effectiveness) and 
explanatory (efficacy) trials and these concepts are not dichotomous. Efficacy trials 
determine the outcome of an intervention under ideal circumstances. Effectiveness 
trials measure the degree of effect under “real world” clinical settings. EVIDEM-E 
employed limited exclusion criteria, included a large sample size and utilized a 
simple intervention which was delivered in real life routine conditions that were not 
 112  
 
optimal. However, the intervention was delivered by a single exercise therapist, and 
there were formal follow-up meetings with participants. These two elements are 
characteristic of explanatory trials. The design effects on study’s internal and 
external validity are further discussed on Chapter 6.  
Individuals with a diagnosis of dementia, which were confirmed with ICD-10 criteria 
using the DCR- 10, were recruited to the study together with their carer. In order to 
be eligible, participants had to have at least one behavioural & psychological 
symptom in one of the sub-scales (paragraph 1.2.3.1, pp50) of the Neuropsychiatric 
Inventory (NPI) (except hallucinations or delusions occurring in isolation); and score 
at least 2 for severity (‘causes distress’) and 2 for frequency (‘often- about once a 
week’) in the NPI rating sub-scale. There is no plausible mechanism by which the 
intervention (exercise) might affect psychotic symptoms (paragraph 1.4.2.6, pp80) 
therefore the domains of delusions and hallucinations were excluded from the 
inclusion criteria. Suitability for inclusion into the trial was assessed, based on 
availability of an identified carer and the ability of the patient-carer dyad to perform 
exercise regime safely.  
Community-dwelling individuals including those living in residential and care 
facilities were being recruited through the EVIDEM programme, Central and North 
West London NHS Foundation Trust, West London Mental Health NHS Trust, East 
London NHS Foundation Trust, Surrey and Borders Partnership NHS Foundation 
Trust and North Thames Dementias and Neurodegenerative Diseases Research 
Network (DeNDRoN). 
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Risk assessment was performed to assess the suitability of participant dyads for the 
intervention at baseline.  Assessment included measurement for risk of falls using 
the Falls Risk Assessment Tool (FRAT) (Nandy et al., 2004) and the Timed 
Unsupported Steady Standing (TUSS) scale (Studenski et al., 1994). These 
measures were chosen because they are validated and widely used in the 
population and they were not likely to be burdensome to participants.   
FRAT is a widely used tool validated for application in primary care and community 
populations. It includes recording history of any fall in the previous year, four or 
more prescribed medications, diagnosis of stroke or Parkinson's disease, reported 
problems with balance, inability to rise from a chair without using arms. Potential 
participants with three or more risk factors were not included in the study.   
TUSS is test of balance that is widely used by physiotherapists and occupational 
therapists when assessing falls’ risk in aging population living in the community. 
During the tests the participant is asked to stand without holding onto a support 
(e.g., a table or chair) with their hands by their sides for 60 seconds. Participants 
who could not stand unaided for 1 minute were not included in the study. 
After confirming eligibility and obtaining consent from carers and people with 
dementia that had the capacity to consent, and assent from the carers of 
participants that lacked such capacity, initial baseline assessments were carried out 
at participants’ homes. Eligible dyads were then randomized into one of two arms: 
the treatment arm which included receipt of the intervention in addition to treatment 
as usual (TAU) or the control arm which received TAU only. Both the treatment and 
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control arms were re-assessed for all outcomes at week 12 (primary end point). 
Interim re-assessment happened at 6 weeks after initiation of exercise. Further 
telephone contact occurred at 26 weeks to assess adverse events (including 
mortality) change in domiciliary status and adherence to the exercise regime. 
Treatment as usual (TAU) for BPSD could encompass any of the following: 
 Pharmacological Interventions 
 Antipsychotic drugs 
 Anti-anxiety drugs 
 Mood stabilizers 
 Antidepressants  
 Sedative hypnotics 
 Cholinesterase inhibitors  
 Psychological Therapies and Approaches 
 Behavior-oriented approaches 
 Cognition-oriented approaches (reality orientation, skills (or memory) 
training) 
 Emotion-oriented approaches (supportive psychotherapy, validation therapy, 
sensory integration) 
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 Stimulation-oriented approaches (activities and recreational therapies, art 
therapies) 
3.2.1 Stopping rules and discontinuation 
If there were a significant statistical difference (p<0.05) between the number of 
reported AE/SAE by the intervention and control groups the Trial Steering 
Committee (TSC) and Principal Investigator (PI) would consider discontinuation of 
the trial. The TSC had the authority to stop the trial.  
3.2.1.1 Safety variables and endpoints 
Safety variables included falls risk assessments and functional abilities. Safety 
endpoints were falls and significant adverse events (AEs) spontaneously reported 
during the study and discontinuations due to AEs. 
3.2.2 Intervention 
Physical exercise was delivered as an individually tailored regime of walking 
designed to become progressively intensive. This was facilitated by a qualified 
exercise therapist and delivered to participants in the treatment arm of the trial at 
their homes.  
3.2.3 Type of exercise 
The steering committee and study management team discussed different modes of 
exercising such as: strength, cardiovascular or flexibility regimes. Ultimately, a 
simple walking regime was decided upon, as it met the criteria for exercise yet 
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seemed more likely to be acceptable, applicable to a wider population and 
sustainable in a community setting (Piercy et al., 2008). Walking does not require 
specific training or use of equipment, can be done almost anywhere and at any time 
at no extra financial cost. Our literature review findings also favoured walking to 
other types of exercise. Regular walking can improve physical health (Eyler et al., 
2003) and several BPSD elements such as depression (Robertson et al., 2012), 
anxiety (Merom et al., 2008) and sleep (Shub et al., 2009), consequently it may 
have a positive effect on BPSD.  
3.2.4 Intensity and duration of exercise 
The exercise therapist facilitated physical exercise in the participant-carer dyad with 
the expectation that the participant-carer dyad performed the exercise regime 
regularly (5 days per week) and independently of the therapist. The Department of 
Health (2011, 2004) advises that older adults should carry out at least 30 minutes of 
moderate intensity walking on 5 days a week, in order to obtain health benefits. 
Eggermont & Scherder (2006) also suggest that exercise programmes should 
include walking of at least 30 minutes duration in order to benefit mood and 
agitation. Considering the frailty and complex physical conditions of our target 
population walking frequency was established as 20-30 minutes of walking, 5 days 
a week at a moderate intensity.  
In terms of intervention length, the decision for it to last for 3 months was taken 
pragmatically as a balance between attrition and duration. Subsequent research 
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has reported that 50% of people who start an exercise program will dropout within 6 
months (Linke et al., 2011). 
The intensity was measured through Rating of Perceived Exertion scale 
(RPE)(Heath, 1998), in which the dyads were trained by the exercise therapist. The 
RPE is a Likert type scale that is used to measure the intensity of exercising by 
assessing body's physical signs such as heart rate, breathing rate and 
perspiration/sweating. There are a number of RPE scales but the most commonly 
used by trainers is the 15 point scale, which runs from 6 (rest) to 20 (exhaustion). 
Participants were instructed and supported to gradually increase their exertion to 
moderate level i.e. score 12-13 in the Borg scale (Figure 3.1). 
 
Figure 3.1 Rating of Perceived Exertion (Heath, 1998) 
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3.2.5 Dyadic exercising 
It was decided to involve a dyad (person with dementia and their carer) in the 
intervention for several reasons. Pragmatically, we could have not been able to 
support every participant 5 days a week, 20-30 minutes a day, because of lack of 
resources. We did discuss group exercising as an optional intervention but this 
alternative would have affected the ability of the exercise therapist to tailor the 
intervention to each participant. The duration, intensity and frequency of the 
intervention were tailored to each dyad’s abilities and physical condition. Tailoring 
interventions to individuals’ needs and abilities maximises compliance with the 
intervention (Castro et al., 2002; Connell and Janevic, 2009). Another crucial reason 
was that we sought to withdraw the social support from the exercise therapist, which 
may be considered as a confounder, and explore the effect of just walking during 
weeks 6-12. The intervention was structured so that the therapist adopted a phased 
withdrawal approach utilising both face-to-face contacts and telephone support 
contacts (Figure 3.2).  Most importantly, according to the Reduced Stress-Threshold 
Model of BPSD: a person’s abilities need to match the environmental demands and 
a discordance between the two can result in BPSD. Therefore, our exercise 
therapist had to make sure that the level of exercise was appropriate and would not 
exceed individuals’ skills and abilities, otherwise we would have instigated 
deterioration rather than improvement of negative mood and challenging 
behaviours. 
It was decided to involve a dyad (person with dementia and their carer) in the 
intervention for several reasons. The essential principle of Kitwood's (1997) person-
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centred approach is to promote personhood and it is the carer’s responsibility to 
ensure this. Likewise, the Reduced Stress-Threshold model hypothesizes that 
stress levels can improve by providing support to compensate for impaired abilities, 
and carers are the best suited persons who can provide this kind of support. 
Walking with a carer could control for factors that could lead to increased stress 
levels such as fear of falling or getting lost and improve the perception of self-
efficacy.      
Pragmatically, we could have not been able to support every participant 5 days a 
week, 20-30 minutes a day, because of lack of resources and the costs attached. 
We did discuss group exercising as an optional intervention but this alternative 
would have affected the ability of the exercise therapist to tailor the intervention to 
each participant. Another crucial reason was that we sought to withdraw the social 
support from the exercise therapist, which may be considered as a confounder, and 
explore the effect of just walking during weeks 6-12. The intervention was structured 
so that the therapist adopted a phased withdrawal approach utilising both face-to-
face contacts and telephone support contacts (Figure 3.2).   
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Figure 3.2 Intervention schedule 
Particular consideration was given by the Steering Group and study management to 
the use of monitoring equipment by the participants to record their activities e.g. 
Global Positioning System receivers and pedometers. The following issues were 
identified: 
Week 1- visit 1 - Exercise therapist: 
 Explains Exercise regime 
 Explains Diary including the use of a visual analogue scale for Rating 
Perceived Exertion (RPE) (Borg) 
 Assess RPE and extend exercise to 60-70%, or 12-14 on 20 point scale 
 Joins Carer-Participant dyad on first walk of approximately 20-30 minutes 
(depending on ability) and notes time and distance 
 Supports completion of diary and facilitates participants’ completion of RPE 
Week 1- visits 2 and 3 - Exercise therapist 3 visits over 10 
days; visits at day 3-5 and day 8-10 
 Assesses RPE and re-explains exercise programme 
 Assesses and  re-explains diary 
 Joins carer-participant dyad on walk  
 
Week 2 and 4 – Exercise Therapist 
 Telephone contact to encourage compliance and adherence 
 Respond to participant-carer dyad on an ‘as needs basis’ for 
information about exercise programme only 
 
Week 6 and 12- visits 4 and 5 - Exercise therapist 
 Joins Carer-Participant dyad on  walk of approximately 20-30 
minutes (depending on ability) and notes time and distance 
 Supports completion of diary and facilitates participants’ 
completion of RPE 
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 Measurement accuracy and information bias (participants would be likely to 
forget wearing their equipment or they would continue to wear equipment during 
non−activity time)  (Cyarto et al., 2004) 
  Practicality and intrusion (wearing equipment for 12 weeks on daily basis can 
be intrusive and this could have affected participation in the study and could 
give rise to differential attrition) 
  Methodological problems (introducing a self-administered assessment of 
exercise within the control group could constitute an intervention in its own right 
(Cyarto et al., 2004). There is potential for this to promote increased levels of 
exercise within the control group and thus reduce the detectable effect size).  
Therefore, it was agreed to evaluate participants' level of exercise through 
measurements of the participants' self-reported Rate of Perceived Exertion 
(exercise group only). A proxy measure of fitness was also utilised to assess for 
compliance with intervention. Heart rate at rest was assessed at the beginning, 
middle and end of the trial for all participants. We expected that should participants 
adhere to the prescribed exercise regime, their fitness would improve and 
consequently so would their heart rate at rest.  However we recognised that 
detecting such changes in cardiovascular health were ambitious. 
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3.3 Trial protocol 
3.3.1 Sample 
Patients with a clinician’s diagnosis of dementia with at least one significant BSPD 
symptom defined by the Neuropsychiatric Inventory (NPI) (excluding the domains of 
delusions and hallucinations) were eligible for the trial. The diagnosis of dementia 
was confirmed in accordance with the ICD-10 Diagnostic Criteria for Research 
(DCR-10). All types of dementia subtypes were included in the trial as they are all 
characterized by overlapping BPSD symptoms.  
We recruited participants with dementia with an identified carer. The carer could be 
either a family member or a professional e.g. a care home worker. We ensured the 
carers’ level of physical health and their ability to support the participant with 
dementia in the trial by assessing risk of falls through FRAT and TUSS, and by 
writing to their GP (Appendix 1.2). 
3.3.2  Recruitment base 
This study was conducted in several inner city, urban and semi-rural locations in 
and around London. Participants were recruited either directly from a research 
register of people with dementia (managed by North Thames DeNDRoN) whom had 
expressed a general interest in research, or by self-referral; or indirectly via primary 
clinical services or specialist mental health services (e.g., memory assessment and 
community mental health).  
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Participant recruitment was both retrospective and prospective: individuals with 
dementia known to secondary care professionals were identified and suspected 
new cases were further investigated to confirm diagnosis. Regular reminders about 
the study were sent to participating secondary care teams within the network 
catchment area. A central register of all referrals was maintained.  
3.3.3 Recruitment process 
3.3.3.1 The Clinical Research Network: Dementias and Neurodegeneration  
The Clinical Research Network: Dementias and Neurodegeneration (DeNDRoN) is 
part of the National Institute for Health Research (NIHR) and supports the set up 
and delivery of clinical research in the NHS in dementias. The Clinical Research 
Network: Dementias and Neurodegeneration has established a research register 
called DemReg, of patients diagnosed with dementia and carers willing to take part 
in research studies. Its aim is to link patients and carers, who are interested in 
dementia research, to teams leading research studies (Iliffe et al., 2011). 
Recruitment from DemReg was initiated by an assigned field worker from North 
Thames DeNDRoN who inspected the registry for people that were eligible to 
participate in our study, and sent the following information to the person with 
dementia and the carer: 
-a covering letter signed by North Thames DeNDRoN clinical lead 
-a participant information sheet 
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-a response letter and a freepost envelope 
3.3.3.2 Memory Clinics, CMHTs and Admiral Nurses Teams 
Memory Clinics, Community Mental Health and Admiral Nurses Teams were asked 
to inspect their patient lists. Lists of people with dementia identified by clinics were 
checked by their lead clinician. Practitioners were then asked for their opinion about 
the capacity of the person with dementia to give informed consent, using the Mental 
Capacity Act (Department of Health, 2005) and the MRC ethics guide (MRC, 2007) 
as the framework for their judgement. When there were no doubts about capacity, 
the following information was posted to the person with dementia and the carer: 
-a covering letter signed by the lead clinician 
-a participant information sheet 
-a response letter and a freepost envelope 
For those judged as lacking capacity to consent, a consultee was identified and 
consulted about involvement in the trial. In the event when a consultee could not be 
identified, the person with dementia was excluded from participation in the trial. 
The content of the invitation letter included all study details, and informed the 
patients of their opportunity to be allocated to one of two groups (exercise 
intervention; usual care) once they were screened for eligibility and had given their 
consent to take part in the study. Participants were directed to return letters on a 
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self-addressed pre-paid envelope to the research team or contact the research 
team by phone or email. See Appendix 1 for the invitation letter.   
Once a response (letter, phone-call or email) was received an initial telephone 
screen was undertaken to confirm: their interest, the presence of carer, and the 
likelihood of at least one BPSD symptom. Then an initial interview was arranged at 
a time and venue convenient to the participants (participants’ homes). Potential 
participants received a written and verbal explanation of the trial. If the participant 
met inclusion and exclusion criteria we sought consent from both participant and 
carer, using the consent protocol (see Appendix 1.3, 1.4 and 1.6). Once consent 
was obtained in accordance with accepted guidelines (Brodaty et al., 1999), 
participants proceeded to the baseline interview/assessment and then  
randomisation (Figure 3.3). In the case of individuals who were not capable of 
giving informed consent, the assent of the participant with agreement of carer was 
attained (see Appendix 1.5).  
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Figure 3.3 Recruitment Process 
Risk falls assessed in both patient and 
carer using: 
• Falls Risk Assessment Tool (FRAT) 
• Timed Unsupported Steady Standing (TUSS) 
 
 
 
 
Exclude 
Participants 
Low Falls Risk 
Patient and carer give consent or assent to 
participate in the study 
RANDOMIZED TO TREATMENT OR CONTROL GROUP 
Baseline Data Collection Patient and carer give 
consent or assent to participate in the study. 
 
No 
 
 
Repeat assessments at week 6 and 12 
Carer asked - Does the patient or you have 
any cardio-respiratory conditions impairment 
of mobility, hearing or vision that would 
prevent them/you from taking part? 
 
Letter sent to GP requesting that they inform 
us if there are any conditions compromising 
patient’s or carer’s ability to participate in a 
programme of regular walking  
 
Yes 
Yes 
 
Yes 
No 
Is there presence of Dementia and BPSD (+1 BSPD symptom in NPI 
except delusions or hallucinations) and identified carer? 
No 
High 
Falls 
Risk  
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People with dementia and their carers were given two weeks to respond to the initial 
contact from DeNDRoN or their clinician. A second mail-out was posted to non-
responders once this time has elapsed. Non-response to the second mail-out was 
considered to be a refusal to participate.   
3.3.3.3 Inclusion criteria 
The inclusion criteria were as follows: 
 Diagnosis of :  
a.   Dementia in primary or secondary care OR 
b. Suspected dementia confirmed by the researcher to ensure the ICD-10 
criteria was met; 
 Presence of a carer (professional, friend or family member; 
 NPI score in any domain (except only hallucination or delusion) of more than or 
equal to two in severity and more than or equal to two in frequency; 
 Consent of participant, or in the case of an individual who was not capable of 
giving informed consent, the assent of the participant with agreement of carer; 
 Consent of carer. 
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3.3.3.4  Exclusion criteria 
Potential participants were excluded if they met any of the following criteria: 
 Cardio-respiratory condition, neurological or musculo-skeletal condition of a 
degree that prevented safe participation in the modified exercise regimen. This 
decision was taken by participant’s GP.  
 Three or more falls in the previous year (“frequent fallers”) assessed by FRAT 
and high falls risk defined by TUSS. 
 Uncontrolled medical problems, which the GP considered would exclude 
participants from undertaking the exercise programme. For example, 
pneumonia, poorly controlled angina, acute rheumatoid arthritis, unstable or 
acute heart failure. 
 Sensory impairment to an extent that it prevented facilitated exercise. 
 Patient or carer dissent to engage in the exercise programme. 
3.3.3.5 Informed consent 
The process for obtaining participant informed consent was in accordance with the 
Research Ethics Committee (REC) guidance and Good Clinical Practice (GCP).  
The decision regarding participation in the study was entirely voluntary. All 
participants that had the capacity to consent and their carers provided written 
informed consent before they underwent any interventions (including history taking) 
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related to the study. The consenting process for participants who did not have the 
capacity to consent are described in the following section (3.3.3.6).  
People with dementia and their carers were given a minimum of 24 hours to 
consider whether they liked to be involved in the trial. The participants were 
encouraged to ask any questions that could help them make a decision on their 
potential involvement in the trial. The research worker (the PhD candidate) 
emphasized that consent regarding study participation could be withdrawn at any 
time without penalty or affect to the quality or quantity of dyad’s future medical care, 
or loss of benefits to which they were otherwise entitled. 
The Informed Consent Forms were signed and dated by both the patient and carer 
before they entered the trial. One copy of the Informed Consent Form was kept by 
the participant, one was kept by the research worker (the candidate) (placed in the 
Trial Master File), and a third was retained in the participant’s general practice 
records. 
Where a participant who appeared to be eligible and signed a consent form was 
subsequently found not to be eligible (e.g. the GP considered they fulfilled one of 
the exclusion criteria) they were not considered to have entered the study. 
The research worker undertook to inform the dyads of any new relevant information 
about the effect of exercise on BPSD that became available during the course of the 
trial, and discussed with them whether they wished to continue with the trial.  
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3.3.3.6 Inclusion of participants unable to consent 
The majority of people with dementia are unable to give informed consent 
themselves (Warner J, McCarney R, Griffin M et al., 2008). In the past the 
experiences of people with dementia have not been explored and they have often 
been excluded from participating in research due to ethical concerns. Since 
involvement in research tends to improve outcomes and may provide access to 
novel more effective treatments earlier than the rest of the population, such 
exclusion can itself be considered unethical (McCarney et al., 2007). 
We anticipated that any participant who lacked capacity to consent, but who had an 
Advanced Directive concerning their involvement in research, would be involved 
according to the information outlined in their Advanced Directive. When clinicians 
were considering an individual's potential participation in the study they were asked 
whether the individual had an Advanced Directive and whether this contained any 
information about research participation. No participant had an Advanced Directive 
about research participation.  
The clinician who recruited the person with dementia to the trial was asked for their 
opinion about the capacity of the person with dementia to give consent, using the 
Mental Capacity Act (MCA: Department of Health, 2005) and the Medical Research 
Council ethics guide (MRC, 2007) as the framework for their judgement. The 
framework included ability to: understand and retain the information regarding study 
participation; to use or weigh that information as part of the process of making the 
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decision and to communicate his/her decision (not necessarily verbally). This 
process was guided by the five MCA principles:  
1. It should be assumed that everyone can make their own decisions unless it is 
proved otherwise.  
2. A person should have all the help and support possible to make and 
communicate their own decision before anyone concludes that they lack 
capacity to make their own decision.  
3. A person should not be treated as lacking capacity just because they make 
an unwise decision.  
4. Actions or decisions carried out on behalf of someone who lacks capacity 
must be in their best interests.  
5. Actions or decisions carried out on behalf of someone who lacks capacity 
should limit their rights and freedom of action as little as possible. 
Where capacity to consent was absent, a “best interest” decision was made based 
on advice from clinicians, carers and past behaviour of the person with dementia in 
accordance with the Mental Capacity Act 2005. In this instance the best interest 
decision was made by the carer, with the agreement of the participant’s GP, for the 
person with dementia to participate in the trial. Checking ‘best interests’ included the 
following MCA guidelines: 
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 •  Never make assumptions about the person lacking capacity based solely on 
their looks, age, appearance, behaviour or condition.  
•  Consider all the relevant circumstances, including looking at other options.  
•  Consider postponing the decision if the person may regain the capacity to 
make it.  
•  Make sure that the person retains as much control and involvement in the 
decision-making as possible.  
•    Think about what the person lacking capacity would have decided for 
themselves by taking into account what is known of their past and present 
wishes, feelings, beliefs and values, (particularly if they have been written 
down). For example, considering a person’s views about participating in 
research before they lost the capacity to consent. 
•  As far as possible consult with others, such as family, friends and any Deputy or 
Attorney, and take into account what they think would be in the person’s best 
interests.  
It is possible that capacity of participants could have fluctuated during the study. 
Therefore, the researcher monitored for verbal and non-verbal signs of potential 
distress in participants’ and kept in communication with their carer/consultee to 
review and reaffirm consent before every stage of data collection. Observation of 
behaviours, expressed feelings and interactions were also used to assess whether 
the person with dementia desired to participate in the research (McCormack, 2002).  
 133  
 
If informal or formal carers in frequent contact with the person with dementia 
believed that continued involvement in the trial was a source of distress, their view 
had precedence over the clinical or researcher perceptions. 
3.3.3.7 Compliance and diaries 
Compliance was defined as continuation with the exercise programme. This was 
recorded though diary entries. Participant carers on both study arms were asked to 
record daily if the dyad walked out as well as length of walks in minutes. Diaries are 
described in more detail in paragraph 3.5.1.  
3.3.3.8 Randomisation 
Patient/carer dyads were randomly allocated to receive treatment as usual (TAU) or 
exercise therapy in addition to treatment as usual (ET). The randomisation ratio for 
the two groups was 1:1 (ET:TAU). A computer algorithm was used to perform the 
randomisation centrally by an Independent Randomisation Officer after the initial 
interview, who then communicated the results to the participant and carer, and to 
the exercise therapist; but not the research worker or the other Independent 
Researcher (IR).  
3.3.3.9 Concealment and Blinding 
In order to maintain blinding, randomisation was performed independently of the 
research worker (RW) following baseline evaluation. The exercise programme was 
initiated and supervised by an ‘Exercise Therapist’ (ETh). Baseline and subsequent 
evaluations were undertaken by RW.  An independent researcher (IR) collected the 
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primary outcome data (NPI) at weeks 6 and 12 by telephone to minimise the risk of 
un-blinding. 
3.4 Outcome Assessment 
Participants were visited in their own homes, by the research worker (RW/the 
candidate) masked to arm allocation. See Appendix 1.13 for a detailed schedule of 
assessments. All possible measures were taken to ensure that blinding was not 
compromised. However, some dyads divulged information about the group they 
were allocated to. Therefore the efficacy of blinding was assessed at each time 
point by asking both the IR and RW to indicate which arm they believed each 
individual dyad was randomised to.  
3.4.1 Outcome measures 
The research team, the trial steering group and the broader EVIDEM programme 
board reviewed the available outcome measures and agreed on the following 
battery: 
The Neuropsychiatric Inventory (NPI) (Cummings et al., 1994) is a validated 
clinical instrument for evaluating BPSD in dementia and  is a structured interview 
that is administered with an informant who is familiar with the patient. This tool can 
also be used to derive a score which pertains to the carer’s distress caused by each 
behavioural domain. The NPI evaluates the following neuropsychiatric domains: 
delusions, hallucinations, dysphoria, anxiety, agitation/aggression, euphoria, dis-
inhibition, irritability/lability, apathy, aberrant motor activity, night-time behaviour 
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disturbances. For each domain a screening question is asked to determine if the 
behavioural change is present or absent. If the answer is positive the domain is 
explored at greater depth with the sub-questions. If the sub-questions confirm the 
screening question, the severity and frequency of the behaviour are determined 
according to the criteria provided for each domain. 
Frequency is scored 1 to 4, and severity is rated 1 to 3. The product (severity x 
frequency) is calculated for each behavioural change present during the previous 
month or since the last evaluation. NPI scores range from 0 (no disturbance) to 144 
(maximum disturbance).  
In carrying out the NPI assessment, the focus rested on eight of the ten domains. 
The difference between the treatment and control groups in composite scores of 
agitation/aggression, dysphoria, anxiety, euphoria, apathy, disinhibition, 
irritability/ability and aberrant motor behaviour was measured. An impact of physical 
exercise on hallucinations and delusions was not expected. In studies where NPI 
was measured in the placebo group a mean reduction of 2.2 was observed (Rolland 
et al., 2007). 
Researchers who carried out the NPI in the study, attended training sessions with 
the PI, who is an expert user of NPI, in order to enhance inter-rater reliability and 
increase scoring consistency between assessors. Blind scoring between assessors 
was compared and training was repeated in two occasions until individual raters 
were in agreement when scoring blindly on 95% of scores. 
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DEMQOL-Proxy (Smith et al., 2005)  is a 31 item interviewer-administered 
questionnaire answered by an informant. The measure has been developed by the 
Section of Mental Health Ageing in cooperation with the London School of Hygiene 
and Tropical Medicine, the London School of Economics and Nottingham 
University. The instrument has been validated in the UK and allows assessment of 
quality of life in moderate and severe dementia. Scores on the DEMQOL-Proxy 
range from 31 to 134, with higher scores indicating better patient health-related 
quality of life. DEMQOL-Proxy was chosen in preference to DEMQOL because the 
latter cannot be applied with participants with moderate and severe dementia 
allowing assessment in a wider range of population.  This instrument is reported to 
have good acceptability (missing data >5%), internal consistency (Cronbach’s alpha 
≥ 0.70) and test-retest reliability (Cohen’s Kappa = 0.82) (Smith et al., 2005).  
The General Health Questionnaire (GHQ-28) (Goldberg, 1972) is a measure of 
current mental health. The instrument was developed by Goldberg in the 1970s as a 
60-item instrument and shorter versions (GHQ-30, GHQ-28 and GHQ-12) were 
developed later. The GHQ-28 is the most used and popular version, which is 
divided into four subscales: 
o Somatic symptoms (items 1-7) 
o Anxiety/insomnia (items 8-14) 
o Social dysfunction (items 15-21) 
o Severe depression (items 22-28) 
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All items have a four point Likert scoring (0-1-2-3) that ranges from ‘better than 
usual’ to ‘much worse than usual’. Caseness in GHQ is identified as the total of the 
above sub-scales. Thus, the higher the score the more severe the condition. There 
are no thresholds for individual subscales.  
The GHQ-28 was chosen in favour to other measures because it is the most widely-
used measure of psychiatric ill health in the UK and has been validated for both 
clinical and general populations. Internal consistency has been reported in a range 
of studies using Cronbach’s alpha, with correlations ranging from 0.77 to -0.93. The 
predictive validity of the GHQ in comparison with other scaling tests of depression is 
good with specificity coefficients ranging  from 74-92 and sensitivity coefficients 
ranging  from 72-92 (Goldberg, 1985). Sensitivity relates to the test's ability to 
accurately identify a condition while as its specificity refers to the test's ability to 
exclude a condition correctly. 
The Zarit Burden Interview-short version (ZBI) (Bedard et al., 2001) is a 
commonly used measure that evaluates carers’ burden of caring for older adults 
with dementia. The original version was published in 1980 (Zarit et al., 1980) and 
comprised 29 items, later reduced to 22 items version. The short version 
encompasses 12 items, which are self-reported statements of how carers feel when 
taking care of someone. All items have a five point Likert scale (0-1-2-3-4), ranging 
from ‘never’ to ‘nearly always’. Severe burden is represented by high scores. Cut-
offs have been developed by arbitrarily dividing the total possible score into roughly 
equal parts. Bedard et al. (2001) suggest that high burden may be identified by 
using the top quartile as indicators with an overall score of 17.  
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The scale was chosen because it has high face validity (α= 0.83), is acceptable to 
carers and is widely used (Bedard et al., 2001). In a review of 53 articles on caring 
for someone with dementia published between 1980 and 1997, Bedard et al 
(2001) found that the ZBI, or a measure based on it, was used in 25 (47%) of the 
studies. The shorter version was used in favour of the longer one to reduce 
assessment time and carer overload, considering the extensive baseline 
assessment battery. Bedard et al. (2001) report that the short version of the ZBI 
produced comparable results to the full version (correlations ranging from 0.92-
0.97) and reducing the number of items did not affect the properties of the ZBI. 
The Client Service Receipt Inventory (CSRI) (Beecham and Knapp, 2001) has 
been developed in the Centre for the Economics of Mental Health and the Personal 
Social Services Research Unit. The CSRI is a questionnaire that gathers 
retrospective information about the interviewee’s use of health and social care 
services, accommodation and living situations, income, employment and benefits as 
well as socio-demographic information. It also records information about the main 
carer. The CSRI is a tool commonly used in service and economic evaluation 
studies. This data was collected retrospectively at baseline, covering the six months 
prior to the assessment, and at follow up 12 weeks into the trial. The resources 
used during the exercise intervention were recorded to estimate the costs of the 
intervention. This outcome will not be reported in this thesis as it is beyond its scope 
and I (the candidate) was not involved in its analysis. 
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Participants’ general level of fitness was assessed as heart rate at rest and 
blood pressure readings taken during each time point by the research worker using 
an Omron (BP562) wrist blood pressure monitor. 
3.5 Baseline assessment 
In addition to the outcomes outlined above MMSE, socio-demographic data, co-
morbidities and prescribed medicine were sought at recruitment (see Appendix 
1.13). Confirmation of clinical diagnosis of dementia was ascertained during 
screening using the ICD-10 criteria. 
Baseline demographic data that was collected for the dementia participants 
consisted of: age, gender, occupancy, ethnicity, marital status, level of education, 
dementia sub-type, length of diagnosis, medical problems and FRAT score. Carers’ 
demographic data included: age, gender, relationship to patient, GHQ, ZBI. The 
measures described above were collected at baseline, 6 and 12 weeks follow-up. 
Mini-mental State Examination was performed with all participants with dementia. 
This outcome was only measured at baseline.  
3.5.1 Diaries  
All participant-carer dyads were provided with diaries to record the level of their 
exercise and any difficulties they encountered when walking (See Appendix 1.11 
and 1.12). Diaries for the intervention group differed slightly from the control group. 
The dyads in the intervention group were also asked to complete a visual analogue 
scale called Rating of Perceived Exertion (RPE) (Heath, 1998). Both groups were 
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also asked to enter information in the diaries about what they enjoyed or did not 
enjoy regarding their walks, as well as reasons for not exercising.  
3.5.2 Follow-up assessments  
Table 3.2 depicts the assessment schedule for both the intervention and control 
groups.    
Table 3.2 Administration of outcome measures 
Day Administrator Assessment Schedule 
Exercise Dyad group Treatment as usual group 
Measure Subject Measure Subject 
0 Researcher Demographics 
ICD-10  
MMSE 
NPI 
DEMQOL  
GHQ 
ZBI 
CSRI 
Medication 
Vital Signs             
( BP&HR) 
Participant+Carer 
Participant  
Participant 
Carer 
Carer 
Participant+Carer 
Carer  
Participant+Carer 
Participant 
Participant+Carer 
 
Demographics
ICD-10  
MMSE 
NPI 
DEMQOL 
GHQ 
ZBI 
CSRI 
Medication 
Vital Signs 
(BP&HR) 
Participant+Carer 
Participant 
Participant  
Participant 
Carer 
Carer 
Participant+Carer 
Participant+Carer 
Participant 
Participant+Carer 
 
0 Independent 
Researcher 2 
RANDOMISATION and SEND DIARIES TO ALL 
1-2 Exercise 
therapist 
RPE  
Timed walk 
Diary 
 
Participant+Carer 
  
3-4 Exercise 
therapist 
RPE  
Timed walk 
Diary 
Participant+Carer 
Participant+Carer 
  
6-8 
 
Exercise 
therapist 
RPE  
Timed walk 
Diary 
 
Participant+Carer 
  
40-46 
Week 6 
Independent 
Researcher 1 
(telephone 
contact) 
NPI 
Remind 
Completion of 
Diaries 
 
Carer 
Participant+Carer 
 
NPI 
Remind 
Completion 
of Diaries 
 
Carer 
Participant+ Carer 
 
40-46 
Week 6 
Researcher DEMQOL  
GHQ 
ZBI 
Carer 
Participant+Carer 
Carer 
DEMQOL 
GHQ 
ZBI 
Carer 
Participant+Carer 
Carer 
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Day Administrator Assessment Schedule 
Exercise Dyad group Treatment as usual group 
Measure Subject Measure Subject 
Medication 
Adverse events 
Vital Signs 
(BP&HR) 
 
Participant 
Participant+Carer 
Participant+Carer 
Medication 
Adverse 
events 
Vital Signs 
(BP&HR) 
 
Participant 
Participant+Carer 
Participant+Carer 
40-46 Exercise 
therapist 
RPE  
Timed walk 
Diary 
 
Participant+Carer 
  
80-88 Independent 
Researcher 1 
(telephone 
contact) 
NPI 
Remind 
Completion of 
Diaries 
 
 
Participant 
Participant+Carer 
 
NPI 
Remind 
Completion 
of Diaries 
 
Carer 
 
Participant+Carer 
 
80-88 
Week 
12 
Researcher DEMQOL  
GHQ 
 ZBI 
CSRI 
Medication  
Adverse events 
Vital Signs 
(BP&HR) 
Carer 
Participant+Carer 
Carer 
Participant 
Participant 
Participant+Carer 
Participant+Carer 
 
DEMQOL  
GHQ 
 ZBI 
CSRI 
Medication 
Adverse 
events 
Vital Signs 
(BP&HR) 
Carer 
Participant+Carer 
Carer 
Participant 
Participant 
Participant+Carer 
 
Participant+Carer 
 
80-88 Exercise 
therapist 
RPE  
Timed walk 
Diary 
 
Participant+Carer 
 
  
90-98 Researcher Collection of 
Diaries 
Participant+Carer 
 
Collection of 
Diaries 
Participant+Carer 
 
182-
196 
Week 
26 
Researcher Telephone 
contact 
Change in 
domicile? 
Still exercising? 
Mortality 
assessment 
 
Carer 
 
Telephone 
contact 
Change in 
domicile? 
Still 
exercising? 
Mortality 
assessment 
Carer 
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3.6 Statistical Methods 
3.6.1  Sample size and power calculations 
Improvement of BPSD measured by the NPI was used as the main outcome 
measure for the purpose of the power calculations Assuming that 80% of patients in 
the control group were likely to have scored positively for BPSD  as measured by 
the NPI at the 12 week follow-up; and based on an anticipated between-group 
(control minus intervention) absolute risk difference of 30% in the proportion of 
people with BPSD, it was calculated that a sample size of n=116 would provide 
90% power to detect this difference with a 5% (2-sided) significance level. To allow 
for an anticipated attrition rate of 20%, the target sample was set at n=146 
(calculated by http://www.stat.ubc.ca/~rollin/stats/ssize/b2.html) 
Table 3.3 Power Calculation 
Intervention Difference N (including compensation for 
20% attrition) 
0.4 0.4 70 (88) 
0.5 0.3 116 (145) 
0.6 0.2 238 (298) 
 
3.6.2 Data entry 
To minimize the risk of errors of data entry, a double entry method was used. The 
Epidata program (Lauritsen, 2008) provided an opportunity for automated checks 
for consistency of data entry. Double entry of data provided in paper form was 
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undertaken using automated consistency and logical checks on Epidata Entry 
(Version 3.1). The results of each questionnaire for each time period, and the 
screening and demographic data was entered onto an Epidata master file. The 
content of the master file was checked for accuracy by double entry by a different 
individual. These files were then exported to SPSS (Version 21) (IBM Corp, 2012) 
data files and were combined to provide a comprehensive database of variables 
(Norusis, 2010). Table 3.4 describes the advantages and disadvantages of using 
different database systems to enter data.  
Table 3.4 Description of database systems 
Database 
Systems 
Easy to 
design 
Validation 
and 
checks 
Minimizes 
error/data 
corruption 
No 
privacy 
issues 
Suitable 
for large 
projects 
Spreadsheet 
(e.g. Excel) 
V X X V X 
Commercial 
database 
programs (e.g. 
Access) 
X X V V X 
Web-based data 
entry (e.g. 
Opinio5) 
V X X X X 
EpiData V V V V V 
                                            
5 Opinio is a web-based survey tool developed and supported by University College London 
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Data was stored encrypted and password-protected on local drive with weekly 
backup. The central database was maintained at CNWL NHS Foundation trust 
headquarters.  
3.6.3  Data protection 
The study was fully compliant with the provisions of the Data Protection Act (UK 
Parliament, 1998). All records were kept in a locked filing cabinet at the study 
centre. Confidentiality of electronic records was ensured by password protection.  
3.6.4 Data analysis 
Categorical data was analysed using Chi-squared tests. Means and standard 
deviations or proportions were calculated (by group) for age, sex, years of 
education, the presence of significant medical or psychiatric history, diagnosis, 
duration of dementia, and MMSE score at baseline. 
At 26 weeks mortality rate and domicile status were compared between groups 
using Chi-squared tests. 
Primary analysis was by intention-to-treat and based on available data without 
imputation of missing values. The primary outcome was the absolute number of 
participants below the threshold (reduction of three points or more in the NPI score) 
at endpoint.  
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1. ANCOVA was used to analyse the differences in mean NPI scores between the 
control and intervention groups at end point (12 weeks), adjusting for baseline NPI 
scores. 
2. Participants were categorised into two groups: Those who had a clinically 
significant reduction of three points or more in the NPI score, and those who had 
not. We analysed the difference in the proportions of those who had a clinically 
significant reduction in NPI score (by three points or more), between the control and 
intervention groups at end point (12 weeks). 
3. Per-protocol analysis was also conducted. Sensitivity analyses were conducted 
to determine the possible effects of withdrawals. Compliance with the intervention 
was explored and analysed. All analyses were completed by the candidate blind to 
allocation status using the statistics package SPSS, version 21 (IBM Corp, 2012). 
3.6.5 Adverse events and risk management 
3.6.5.1 Definitions 
An adverse event (AE) is any unfavourable and unintended sign, symptom, 
syndrome or illness that develops or worsens during the period of observation in the 
trial.  
An AE includes a / an: 
1. exacerbation of a pre-existing illness. 
2. increase in frequency or intensity of a pre-existing episodic event or condition. 
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3. condition detected or diagnosed after intervention even though it may have been 
present prior to the start of the trial. 
4. continuous persistent disease or symptoms present at baseline that worsen 
following the start of the trial. 
An AE does not include a / an: 
1. medical or surgical procedure (e.g., surgery, endoscopy, tooth extraction, 
transfusion); but the condition that lead to the procedure is an AE. 
2. pre-existing disease or conditions present or detected at the start of the trial that 
did not worsen. 
3. situations where an untoward medical occurrence has not occurred 
(e.g., hospitalisations for cosmetic elective surgery, social and/or convenience 
admissions). 
A Serious Adverse Event (SAE) is any adverse event occurring following study 
mandated procedures, having received exercise intervention or usual treatment that 
results in any of the following outcomes: 
1. Death 
2. A life-threatening adverse event 
3. Inpatient hospitalisation for non-elective procedures 
4. Sudden or rapidly progressive major disablement  
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5. An event that caused the participant to seek non-routine medical treatment. 
Important medical events that did not result in death, be life-threatening, or require 
hospitalisation could be considered a serious adverse event when, based upon 
appropriate medical judgment, they could jeopardize the patient or participant and 
could require medical or surgical intervention to prevent one of the outcomes listed 
in this definition. All adverse events were assessed for seriousness, expectedness 
and causality. 
A distinction was drawn between serious and severe AEs. Severity is a measure of 
intensity whereas seriousness is defined using the criteria above. Hence, a severe 
AE need not necessarily be serious.  
3.6.5.2  Reporting of adverse events 
All treatment related serious adverse events were recorded and reported to the Trial 
Steering Committee (TSC) and Research Ethics Committee (REC) as part of the 
annual reports. Unexpected serious adverse events were reported within the 
timeframes to the REC as stated below.  
During the trial conduct monitoring of adverse events was carried out. Participants 
were asked to contact the trial site immediately in the event of any serious adverse 
event. Adverse Events were brought to the attention of the study team by either: 
 Telephone call to the study team. Participants were encouraged to call the 
study team if they experienced any adverse effects during the study. 
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 Notification by GP. Participant’s doctors were encouraged to contact the study 
team of any AEs they were made aware of. 
 Notification by carer. The participant’s carer was encouraged to contact the 
study team, either by returning an AE postcard or by telephoning the study 
team, if they observed any AEs in the participant or themselves. 
On notification of an AE at the study centre, the Principal Investigator called the 
subject and carer for further information. The Principal Investigator determined 
seriousness and causality in conjunction with any treating medical practitioners. 
All adverse events were recorded and closely monitored until resolution, 
stabilisation, or it had been demonstrated that the study treatment was not the 
cause.  
3.6.5.3  Risk management  
To ensure the safety of the researchers the GP was asked if there was a history of 
violence with any participants to be interviewed. In case of participants recruited 
from residential or nursing homes, staff were approached and asked for their 
opinion of any relevant history of violence in the individual being approached for 
participation. Where participants were recruited from secondary care, similar 
information was obtained from the secondary care team or Community Mental 
Health Team (CMHT). Falls risk were minimised by assessment prior to 
randomisation. 
The risk issues identified by the project team were:  
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 Inadvertent disclosure of dementia 
 Carer suffering from undiagnosed dementia 
 Falls – (excluded high falls risk; exercise therapist monitored; adverse event  
reporting) 
 Cardiovascular events (excluded high risk, exercise therapist monitored; 
adverse event reporting) 
 Worsening of BPSD (exercise therapist monitored; adverse event reporting) 
 Accidents – exercise therapist assessed road sense and undertook location 
risk assessment for exercise location (e.g. traffic density, kerb height, risk of 
mugging/assault), ability of carer to manage the person with dementia safely 
in the streets.   
3.6.5.4 Trial intervention related SAEs 
Any serious adverse event that was deemed directly or possibly related to or 
suspected to be related to the trial intervention was reported to the TSC and ethics 
committee. The event was reported immediately of knowledge of its occurrence to 
the Principal Investigator. The Principal Investigator would: 
 Assess the event for seriousness, expectedness and relatedness to the trial 
treatment. 
 Take appropriate medical action, which could include halting the trial and 
inform the sponsor of such action. 
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 If the event was deemed related to the trial treatment,  inform the REC using 
the reporting form found on the NRES web page within 7 days of knowledge of 
the event. 
 Within a further 8 days send any follow-up information and reports to the REC. 
 Make any amendments as required to the trial protocol and inform the REC as 
required. 
3.6.5.5  Removal of participants from interventions, assessments or the 
trial 
Participants could withdraw from the trial at their own request or be withdrawn at the 
discretion of the Investigator. The participants were made aware that this would not 
affect their future care. Those who withdrew from the trial or follow-up were not 
replaced.  
Participants who could not be contacted were considered as lost to follow up. 
Participants were accepted as lost to follow-up when 2 phone calls, letters or visits 
to the participant and carer were fruitless.  
3.6.5.6 End of trial notifications 
After the trial a summary of the results was sent to all participants (Appendix 2.8). 
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3.7 Ethical and regulatory aspects  
This trial was granted ethical approval by the Outer North East London Research 
Ethics Committee, REC reference number: 09/H0701/67, and local Research and 
Development Offices. 
The participant’s GP had clinical responsibility for the participant throughout the 
trial. Study personnel informed the GP of any adverse events and any significant 
clinical problems that were brought to the investigators’ attention. 
All study records will be securely stored for 5 years after the completion of the 
study. 
Every effort was made to maintain confidentiality of data supplied by participants. 
Participants were free to withdraw from the study at any time and were reassured 
that doing so would not affect their medical care. 
3.7.1  Records 
3.7.1.1 Case report forms  
Each participant was assigned a unique Participant Trial Number, allocated at 
randomisation, for use on Case Report Forms (CRFs), other trial documents and 
the electronic database. CRFs were treated as confidential documents and were 
held securely in accordance with regulations. A separate Trial Recruitment Log 
(TRL) was set up to record confidential participant information including, name, date 
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of birth, address, and Participant Trial Number. This permitted identification of all 
participants enrolled in the trial, in case additional follow-up was required. 
All paper forms were filled in using pen. Errors were lined out but not obliterated by 
using correction fluid and the correction inserted, initialled and dated. 
3.7.1.2  Source documents  
Source documents were filed at the investigator’s site and included consent forms, 
questionnaires and diaries. Only trial staff as listed on the Delegation Log had 
access to trial documentation other than the regulatory requirements listed below. 
The Delegation Log included the names and signatures of all team members, their 
specific trial duties and dates of their involvement in the trial. The Delegation Log 
was updated throughout the trial period. 
3.7.1.3  Direct access to source data / documents 
The CRF and all source documents were available at all times for review by the 
Principal Investigator, and for inspection by the sponsor [Central and North West 
London NHS Foundation Trust] and relevant regulatory authorities, including R&D 
departments.  
 153  
 
3.7.2 Quality Assurance & Audit  
3.7.2.1 Research staff training 
The researcher conducting the recruitment and outcome interviews underwent 
training in administering the relevant questionnaires, in Good Clinical Practice 
(GCP) and in participant risk assessment.  
3.7.2.2  Indemnity arrangements 
This project was indemnified through Central North West London NHS Foundation 
Trust.  This covered participants in the event of negligent or non-negligent harm. 
Standard NHS indemnities applied.  
3.8 User and Public Involvement/ Trial steering committee 
User representatives on the TSC were recruited through the Alzheimer Society and 
Age UK and were involved in the development, implementation and interpretation of 
the study.  This involvement included: advice on trial and intervention design, advice 
on recruiting patients, invitation letters, the design of information leaflets and 
research instruments, piloting assessments, helping to assess progress, 
contributing to the evaluation of the project, the interpretation of findings and the 
dissemination of results. User representatives were invited to trial steering 
committee meetings and also to provide assistance to the study.  
The Trial Steering Committee (TSC) provided a critical overview of the trial, and met 
quarterly. The TSC also acted as the Data Monitoring Committee. The TSC 
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included the Principal Investigator, the project lead, researchers, independent 
representatives of relevant voluntary organisations, individuals with expertise in 
exercise promotion and falls prevention, a statistician, and nominees of the funding 
body. The TSC membership criteria were that non-study personnel could not 
exceed study-personnel. Because no medicinal products were being tested and the 
risks of the kind of exercise that was being promoted were low, a separate data 
management and ethics committee was not convened, but responsibility for 
overview of the risks of the trial rested with the TSC. 
3.9 Methods for Disseminating and Implementing Research  
The detailed study methodology was published on BMC Trials (Cerga-Pashoja et 
al., 2010). Appendix 1.15 shows the dissemination strategy. The support of the 
National Institute for Health Research (NIHR) has been credited in all publications 
that have arisen from this project in accordance with the acknowledgment and 
disclaimer agreed between NIHR and the EVIDEM Consortium. 
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4 RECRUITMENT CHALLENGES 
One of the focal points of the EVIDEM-E study design was to make participation 
accessible and to keep involvement burden at minimum by means of limiting 
exclusion criteria; ensuring intervention was easy and imposed low risk to 
participants; limiting input required from professionals and teams who would identify 
potential candidates; simplifying documentation and study procedures; and by 
tailoring the intervention to each participating dyad. The study was hosted by 
Central and North West London (CNWL) NHS Foundation Trust, which is one of the 
largest providers of healthcare in the UK and provides care for about 2,000 people 
with dementia. The study had received strong support from Memory Clinics, 
Community Mental Health and Admiral Nurses Teams during pre-recruitment 
phase. On these bases we had predicted to recruit 146 participants in 17 months 
[January 2010-May 2011] (Figure 4.1). 
  
 
 
 
 
 
Figure 4.1 Predicted and actual accrual rates 
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During the first 6 months of the study the research team actively contacted 20 
teams that provide care for people with dementia in CNWL. The research team 
spent 130 hours of direct contact with clinicians from these teams, where they were 
briefed about: study aims and objectives, inclusion/exclusion criteria, identification 
of potential candidates and referral procedures. Clinicians were given study leaflets, 
identification flowchart (Appendix 1.14) and information sheets. During the first 6 
months of recruitment the research team prepared and sent out 300 invitation packs 
to clinical teams. During the same period of time the clinical teams distributed only 
25 of those packs to their patients, and just 4 patients (with their carers) were 
recruited within the first 6 months as a result. This initial recruitment rate was at high 
contrast with the study’s predicted recruitment target, for the same period, of 30 
dyads. 
Recruitment to the trial improved when alternative mechanisms were tried, 
especially expanding recruitment/identification sites including recruitment from a 
registry of patients and carers (DemReg) held by the North Thames Dementias and 
Neurodegenerative Diseases Research Network’s (NT- DeNDRoN). The DemReg 
is a register for people with memory problems and their carers, who are willing to 
take part in research studies of dementia and have given prior consent to be 
contacted by researchers working on the field. Initially we invited potential 
participants from DemReg though a mail-out. We sent study information sheets and 
reply slips to 88 people with dementia or their carers. Just 3 participants were 
recruited to the trial as the result of the mail out (Figure 4.2). 
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Figure 4.2 Recruitment frequencies from DemReg mail out and direct contact 
Direct contact with potential participants, however, had a quick and positive effect 
on increasing recruitment accruals. DemReg members, who had already given their 
consent to be contacted by the researcher, were called on the phone and study 
objectives and participations information was explained. Consequently, half of the 
persons contacted directly, during a period of two weeks, were recruited into the 
study. 
Surprised by the incongruity between clinicians’ verbal support and their limited 
promotion of the study, we invited clinicians (team managers, nurses, occupational 
therapists, physiotherapists and psychologists) to a focus group on their perceptions 
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of research, impediments to their role as recruiters and potential solutions to the 
study’s recruitment difficulties.   
The group described how clinicians are increasingly challenged by patients 
‘informed about the latest research’. The group indicated they often had to provide 
counter evidence in response to ‘headline’, and sometimes “sensationalised” 
research conclusions. Together with patients’ limited understanding of varying 
quality in research and the importance of clinical judgment for each individual, this 
could have (in the group’s view) an adverse impact on the patient/clinician 
relationship.  When recruiting to research, the group felt responsible as the source 
of the research invitation, assuming a degree of accountability for the research 
project’s value and conduct (See Table 4.1, quotation1a). This responsibility was 
experienced as unreasonable, as they often had no part in the study’s design and 
administration, and so there was a risk that recruiting might be perceived as 
potentially unrewarding or worse, detrimental to patients. While the group perceived 
the value of research, they also identified several concerns about recruiting their 
patients to EVIDEM-E (See Table 4.1, quotes 1b-d). Understandably, recruitment 
was regarded as a low priority in consultations and all too easily ‘slipped off the 
radar’ (See Table 4.1, quote 1e). However, the group did suggest ways to enhance 
recruitment to EVIDEM-E (Table 4.1, quotes 1f-h). All three suggestions aimed to 
enhance the participants’ experience opposed to theirs as recruiters, and the first 
suggestion involved increasing clinician workload.   
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Table 4.1 Findings from the focus group on recruitment to the trial 
a. 
 
Clinician accountability for research 
“What if they agree due to your relationship with them, when you’ve said this 
thing is going to be great…?” 
b. 
 
Overburdening ‘vulnerable’ individuals with voluminous Participant 
Information Sheets/Invitation 
“I was just wondering if you could take it (information pack) out and talk them 
(participants) through, rather than this big pack arriving. I’d be thinking ‘waw’ I 
thought I was just going out on a walk…” 
c. 
Anxiety over the patients’ feelings after researcher withdrawal 
‘“From our perspective they have participated in research……but they got 
nothing to say: thank you very much. I think that kind of puts people off.” 
 
d. 
Concern that participants would be dissatisfied when allocated to a control 
group 
“I’m thinking about when putting someone forward, they’ve agreed to go 
forward with it, only for them not to be put in the category where they actually 
get the intervention. I think this maybe holds people [professionals] back from 
encouraging people [clients].  
 
“We have to tell the client what is it they get out of this. ………..what if they go 
on the control group and get nothing?  
e. 
Low priority in individual clinical context 
“A lot of people just want practical advice and support….if someone is, let’s 
say, incontinent. What can I do, what can I put in place? It’s the practical 
solution to a problem that they have. And even if we say that we bring 
experience, knowledge and information that doesn’t really matter because 
there is something that is going on at that time that needs to be sorted.”  
“I don’t see it as likely that patients that will be offered some sort of treatment 
will ask: ‘why are you saying this is the best treatment?’ and ask for a 
justification. Many of our patients would be grateful because what they are 
looking for is an outcome, they are not interested how we get there. They just 
want positive outcome.” 
f. 
Continuation of treatment – themselves to be trained to deliver the EVIDEM-E 
intervention 
“I think it would be really useful if we could do it (exercise intervention) 
ourselves and have a go. With proper training and under you observing it, I 
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don’t see a reason why we couldn’t.”  
 
“Would it be possible, not as part of the trial, simply a form of walking with 
somebody who has got some sort of behavioural problems, and we can try it 
out after being trained by your exercise therapist.” 
g. 
Feedback provided face to face to participants 
“You need to talk to people. The feedback is very important, whether it (the 
study) has success or not. At the end they (participants) should be given 
some feedback.” 
 
h. 
Provision of carer respite 
“There is a lot going on for carers at that particular time. And I think that whilst 
in their heart of hearts they might want to be involved and participate, but if 
the services are not going in to enable them to have a good night sleep, or 
maybe incontinence worry is a primary concern…..  A lot of times carers will 
actually say: I want a break. I want someone to physically do it (walking) for 
me. I’ve been up all night, they’ve been going to the toilet, they are restless, 
agitated, they ask repetitive questions. And it will be really nice that while the 
therapist takes them out the carer can put their feet up for 10, 15, 20 minutes. 
That’s the expectation of the carer, that someone will do that. That’ll be the 
motivation.”  
i. 
Tangible Rewards 
“what’s in it for us?” 
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5 RESULTS 
5.1 Introduction 
This section begins with a description of the flow of participants through each stage 
of the trial. The characteristics of the sample recruited are presented and compared 
for both the intervention and control group. Results and associated statistical 
analysis for primary and secondary outcomes are presented. Per-protocol analysis 
and compliance with the intervention have also been addressed and findings from 
the analysis are described.   
Finally, blinding efficacy for the researchers and qualitative data findings are 
presented towards the end of the chapter.   
5.2 Recruitment 
The results of this study are reported in accordance with the CONSORT statement 
on reporting randomized controlled trials (Schulz et al., 2010). The flow diagram 
below (Figure 5.1) gives an outline of the recruitment and attrition process during 
the trial. 
One hundred and thirty-one participant dyads were randomized to either receive the 
exercise regime in addition to treatment as usual (treatment), or to receive 
treatment as usual only (control). Eighty nine percent of dyads completed the trial, 
with seven and eight dyads lost from the control group and the intervention groups 
respectively.  
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Total population considered 
N= 465 
Randomised 
N=131 
Excluded n=82 
No BPSD (n=39) 
Falls Risk (n=29) 
No carer (n=8) 
GP excluded (n=4) 
No dementia (n=2) 
 
Declined n=252 
Included in Primary Analysis 
N=58 
Included in Primary Analysis 
N=56 
Week 12 
Withdrew  n=5 
Died   n=1 
Week 12 
Withdrew  n=1 
 
Week 6 
Lost to follow up n=2 
Withdrew  n=2 
Died   n=1 
Week 6 
Lost to follow up  n=1 
Withdrew      n=4 
Allocated to Intervention 
N=67 
Allocated to Treatment as Usual 
N=64  
 Figure 5.1 Flow diagram of recruitment and attrition 
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5.2.1 Exclusions 
Four-hundred and sixty-five dyads were approached during the study. Two-hundred 
and twenty-five individuals declined participation in the study. Eighty-two individuals 
were not recruited for the reasons outlined below.  
The most common reason for exclusion was because potential participants did not 
meet the criteria for BPSD. The rest were identified as being at risk of falls, had no 
carer that could support them during the trial, were excluded by their GP, and two 
individuals were not diagnosed with dementia. Comparison of excluded sample with 
recruited participants was not possible because of lack of baseline data for those 
excluded. 
Characteristics of participants that discontinued the trial are presented on Table 5.1. 
There were no statistically significant differences between participants that 
discontinued the trial and those that carried on (Table 5.5) for: gender (χ2=1.01, 
DF=1, p=0.386), age (t=3.19, DF=21.5, p=0.69), MMSE (t=-0.54, DF=21, p=0.59) 
and NPI (t=1, DF=22, p=0.31). 
 
 
 
 
                                            
6 Fisher’s exact test 
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Table 5.1 Description of participants that discontinued the trial 
Participants that 
discontinued the trial 
Control Intervention 
Gender           M    0 
F     6 (100%) 
M    4 (36%) 
F     7 (64%) 
Age  
(mean, sd, range) 
75.5, 6.7, 64-84 79.7, 6.7, 64-89 
MMSE 
(mean, sd, range) 
12.33, 10.9, 10-28 18.91, 5.3, 10-25 
NPI 
(mean, sd, range) 
26.67, 11.1, 11-36 26.73, 19.14, 7-68 
 
Main reasons for attrition were loss to follow up and deterioration of physical health. 
More details are presented in Table 5.2. 
Table 5.2 Reasons for attrition 
Reasons for trial 
discontinuation 
Control Intervention 
Died 0 2 
Lost to follow up 1 2 
Withdrawn by research 
team (at risk of falls)7 
0 1 
Physical health 
deterioration 
1 2 
Carer could not commit 2 1 
No reason given 2 3 
Total (frequencies and %)       6  9%         11 16 % 
 
Attrition was relatively low given the age of participants and the severity of the 
dementia (Forbes et al., 2015). The Chi-square statistic is 1,4377, the p-value is 
0.230, therefore this result is not significant at p<0.05.  
                                            
7 Participant contributed to data collection at all time points.  
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5.2.2 Declines 
Twenty-two percent of the persons approached did not respond (DNR). The main 
reasons for declining study participation were carer unavailability (46%) and person 
with dementia and/or carer being too unwell to take part (36%) (Figure 5.2).  
 
Figure 5.2 Reasons for declining participation in the trial 
5.3 Characteristics of study sample 
5.3.1 Demographic data of sample 
Descriptive statistics for the baseline demographic and the outcome data are 
presented for each group in Table 5.5, Table 5.6 and Table 5.7. 
Baseline characteristics of carers and patients in the two randomised groups were 
compared using summary statistics. Numbers and proportions are presented for 
binary and categorical variables while means and standard deviations are 
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presented for continuous variables. No statistical inference was used (i.e. there was 
no significance testing or use of confidence intervals) for baseline comparisons. 
5.3.2 Gender 
The overall sample (people with dementia and carers) was predominantly female 
(163: 99). This was as the result of a higher prevalence of female carers (89:42). 
The sample of the participants with dementia was more balanced with 57 males and 
74 females. The Alzheimer’s Society (2007) reports that the male to female gender 
ratio of dementia in UK population is 1.4 to 1, at age 65–69 years. This ratio falls to 
0.2 to 1 (five women for every man affected) for those aged 95 and over. Our 
sample’s male: female ratio was 0.77 to 1, which considering sample’s wide age 
spectrum (58-99 years old) was representative of the population. 
5.3.3 Age 
The age of participants with dementia ranged from 58 to 99 years old with a mean 
and mode of 78. Men and women did not differ and had a mean of 78 and 79 years 
old respectively.  
Participants with dementia were typically older than the carer participants 
(78.85±7.1 Vs. 63±16.2). Carers’ ages varied from 22 to 89 years old, with a mean 
age of 63.  
5.3.4 Education 
The majority of our sample of patients and carers was educated to secondary 
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school level (n=85, 65.9%). They were followed by those who attended University 
and post-graduate courses (n=25, 20.3%). Eleven participants (8.9%) had 
accomplished primary school education and two people had not attended any form 
of formal education. 
5.3.5 Living arrangements 
Most of the participants with dementia were living in the community (89%, 116/131) 
and were being cared for, most commonly, by partners or adult age children. The 
remainder (11%, 15/131) of participants with dementia were residents of care 
homes. A recent survey of the Alzheimer Society (Lakey et al., 2012) reports that 
69% of people with dementia live in the community and 31% live in a care or 
nursing home. Our sample is slightly under representative of the proportion of 
people in care or nursing homes. This may be explained by the dyadic character of 
the intervention and the time commitment, which rendered participation in care 
home settings very challenging.  
5.4 Description of Disease Characteristics of the Analysed Sample at 
Baseline 
5.4.1 Dementia subtype and severity 
Alzheimer’s disease was the most prevalent type of dementia (n=82, 62.6%), 
followed by unspecified dementia in 20 cases (15.3%), vascular dementia (n=10, 
7.6%), mixed dementia (n=7, 5.3%), Lewy-body (n=5, 3.8%), frontotemporal 
dementia (n=4, 3.1%) and one person was diagnosed with Parkinson’s.     
 168  
 
Our sample included a range of dementia severities assessed by baseline MMSE.  
MMSE was classified as mild for scores ranging from 21-24, moderate for scores 
10-20, and as severe for scores lower than 10 (Folstein et al., 1975). Thus, 52 
people (40.3%) presented with mild symptoms, 42 (32%) moderate symptoms and 
35 (27.1%) participants suffered from severe dementia.  
5.4.2 Time when diagnosed with dementia 
Most participants were diagnosed with dementia within the previous two years 
(n=73, 56%). Just above 33% (n=42) were diagnosed three to five years before 
study participation, and 10 participants (8%) were diagnosed more than 5 years 
prior to participation. 
5.4.3 BPSD 
Behavioural and psychological symptoms of dementia measured by the NPI (30.6, 
sd 17.7; range 4-80) were comparable to those reported in similar populations 
(Cummings et al., 1994; Lebert et al., 2004). 
The NPI total score indicates the summation of various behaviors, and can be 
regarded only as a rough guide to the extent of the BPSD. Gauthier et al. (2010) 
argue that the total NPI score may not reflect a change in BPSD symptoms despite 
a reduction in individual domain scores, as “the domain effect is not sufficient to 
impact significantly on the total NPI score”. NPI clusters, on the other hand are 
considered to provide information that is more clinically relevant (Gauthier et al., 
2010), and evaluating the effect of a treatment intervention on each cluster of NPI 
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symptoms may be more likely to give an accurate representation of its efficacy. The 
NPI items were grouped into four sub-syndromes (Aalten et al., 2007, 2008; Robert 
et al., 2005), Table 5.3). 
Table 5.3 Clustering of NPI categories 
Category Symptoms 
 
 
 
Hyperactivity 
Agitation/aggression 
Irritability 
Euphoria 
Disinhibition 
Aberrant motor behaviour 
  
 
Affective 
Dysphoria/Depressed mood 
Anxiety 
Night time behaviour 
Appetite 
  
 
Apathy 
Apathy 
Night time behaviour 
Appetite 
Aberrant motor behaviour 
  
 
Psychosis 
Delusions 
Hallucinations 
 
NPI cluster scores at baseline were comparable between the control and the 
intervention groups (Table 5.4, Figure 5.3, Figure 5.4, Figure 5.5, Figure 5.6). 
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Table 5.4 NPI cluster scores for the intervention and the control group 
NPI Clusters Group Allocation N Mean Std. Deviation 
Hyperactivity Control 64 10.81 7.932 
Intervention 67 11.88 10.756 
 
Affect Control 64 13.73 8.354 
Intervention 67 11.51 8.466 
 
Apathy Control 64 14.13 9.511 
Intervention 67 12.39 8.440 
 
Psychosis Control 64 5.05 4.858 
Intervention 67 6.36 6.333 
 
Figure 5.3 Hyperactivity cluster scores for the control and intervention arms.8  
                                            
8 The central band is the median score, the box represents the inter-quartile range 
and the lines represent the 2.5% and 97.5% percentiles. Outliers are shown as small 
circles outside the whiskers. 
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Figure 5.4 Affect cluster scores for the control and intervention arms 
 
 
 
Figure 5.5 Apathy cluster scores for the control and intervention arms 
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Figure 5.6 Psychosis cluster scores for the control and intervention arms 
5.4.4 Quality of life 
Quality of life for people with dementia at baseline as measured by the Demqol-
Proxy was relatively good (101.3 ± 13.9). The scores for Demqol-Proxy can range 
from 31 to 124, with higher score indicating better quality of life  (Banerjee et al., 
2006). Smith et al. (2005) reported findings and validation data for Demqol-Proxy on 
99 carers of people with mild to severe dementia. They reported a mean of 92.4 and 
range 55.8–118.83.   
5.4.5 Carers’ psychological wellbeing 
Thirty-six carers (27%) reached validated threshold for ‘caseness’ relating to 
psychological wellbeing (GHQ) (Goldberg et al., 1997). Range scores are 
presented in detail in Table 5.7. 
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5.4.6 Carer burden 
Twenty-five carers (19%) reached validated threshold for ‘caseness’ for carer 
burden (ZBI) (Schreiner et al., 2006). Range scores are presented in detail in 
Table 5.7. 
5.4.7 Physiological measures 
Heart rate and blood pressure readings were within the normal range in our sample 
(Table 5.6, Table 5.7) 
5.4.8 Psychotropics and antipsychotics intake 
Most of the patients with dementia (85/131 or 64.9% overall) were not prescribed 
any type of psychotropic drugs; 41/131 (31%) patients were taking one 
psychotropic medication; and just 5/131 (3.8%) people were taking two types of 
psychotropic drug ( 
Figure 5.7). Antipsychotics’ intake was also low with 12 patients (6 in each 
intervention arm), or 9% of the sample being prescribed antipsychotics. 
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Figure 5.7 Psychotropics’ intake for the intervention and control group participants 
5.4.9 Ethnicity 
Our sample was predominantly white but with representation from all major ethnic 
groups residing in London urban areas. Figure 5.8 depicts pie-charts of ethnicity 
groups’ data in London according to Census 2011 and ethnicity groups of EVIDEM-
E sample. Although the ethnic diversity of the study population did not match that of 
the local population we were able to recruit participants from different ethnic 
backgrounds.  
 
White, 60%
Mixed/Multiple 
Ethnic Groups, 5%
As ian/Asian British, 
18%
Black/African/Carib
bean/Black British, 
13%
Other Ethnic 
Groups, 3%
Ethnic Groups, London, Census 2011
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White, 81%
Mixed/Multiple 
Ethnic Groups, 1%
Asian/Asian 
Bri tish, 11%
Black/African/Cari
bbean/Black 
Bri tish, 6%
Other Ethnic 
Groups, 1%
Ethnic Groups, Evidem-E
 
Figure 5.8  Ethnic group data from Census 2011 and the EVIDEM-E sample 
5.4.10 Marital status 
The majority of our sample were married (89, 68.5%), 33 (25.4%) were widowed, 4 
(3.1%) single, 2 (1.5%) divorced and 2 co-habiting. 
5.4.11 Effectiveness of randomisation 
Socio-demographic characteristics, health parameters and carers’ descriptors were 
compared between the control and intervention groups (Table 5.5). There were no 
significant differences between groups in all parameters indicating effective 
randomisation.  
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Table 5.5 Demographic characteristics 
Control Group      N 64 Intervention Group    N 67 
Age (mean; sd; 
range)     
78; 7.4;  58-99 Age (mean; 
sd; range)     
79;  6.8;  64-97 
Gender M              25 (39.1%) 
F               39 (60.9%)  
Gender M            32 (47.8%)  
F            35 (52.2%)  
Ethnicity White        50 (78.1%)  
Asian          9 (14.1%)  
Black            3 (4.7%)  
Other            2 (3.1%) 
Ethnicity White      56 (83.6%)  
Asian          5 (7.5%)  
Black          5 (7.5%)  
Other          1 (1.5%)  
Marital Status Married     45 (71.4%)  
Widowed  15 (23.8%)  
Single          1 (1.6%)  
Divorced      2 (3.2%) 
Marital Status Married    46 (68.6%) 
 Widowed 18 (26.9%)  
Single         3 (4.5%)  
Divorced      0 
FRAT score 0               12 (18.8%)  
1                16 (25%)  
2                36 (56.3%) 
FRAT score 0            14 (20.9%) 
1           26 (38.8%)  
2           27 (40.3%)  
Accommodation Home        57 (89.1%) 
  
Care home 7 (10.9%) 
Accommodation Home     59 (88.1%)  
 
Care home 8 (1.9%)  
Years of 
Education 
(mean; sd; 
range) 
11.92; 5.9;  0-36 Years of 
Education 
(mean, sd, 
range) 
12.1; 4.1; 6-23 
 
 
 
 
 
 
 177  
 
Table 5.6 Characteristics of participants, by study arm 
Control Group      N 64 Intervention Group    N 67 
MMSE (mean, 
sd, range) 
14.9;  8.7; 0-29 MMSE 
(mean, sd, 
range) 
16.3; 7.4; 0-30 
 
Dementia  
Severity 
Mild                    26 (40.6%) 
Moderate           19 (27.7%) 
Marked              19 (27.7%) 
  
 
Dementia  
Severity 
Mild                        26 (40%) 
Moderate              23(35.4%) 
Marked                 16 (24.6%) 
Unknown9                2 (1.3%) 
 
 
 
Dementia  
Subtype 
Alzheimer’s       38 (64.4%)    
Unspecified          6 (10.2%)   
Vascular               6 (10.2%) 
Mixed                    3 (5.1%) 
Lewy body            3 (5.1%) 
Frontotemporal     1 (1.7%)  
Other                     2 (3.3%) 
Unknown               9 (3.2%) 
 
 
Dementia  
 
Subtype 
Alzheimer’s         44 (67.7%) 
Unspecified           7 (10.8%) 
Vascular                 4 (6.2%) 
Mixed                     4 (6.2%) 
Lewy body              2 (3.1%) 
Frontotemporal       3 (4.6%)  
Other                      1 (1.4%) 
Unknown                 2 (1.3%) 
 
Years since 
Diagnosis 
≤2 years           38 (62.3%) 
 3-5 years        18 (29.5%) 
6-9 years            5 (8.2%) 
Unknown            3 (1.9%) 
 
Years since 
Diagnosis 
≤2 years              35 (54.7%) 
 3-5 years            24 (37.5%) 
 6-9 years                5 (7.8%) 
Unknown                 3 (2%) 
 
 
Physical  
 
Conditions 
None                 22 (34.9%) 
One                   23 (36.5%) 
Two                     9 (14.3%)  
Three                   7 (11.1%)  
Four                     1 (1.6%)  
Five                      1 (1.6%) 
Unknown              1 (1.6%) 
 
 
Physical  
 
Conditions 
None                   28 (41.8%) 
One                     26 (38.8%) 
Two                         6 (9%) 
Three                       5 (7.5%)  
Four                         2 (3%)  
Five                          0  
Antipsyc. 
intake 
6 (9.4%) Antipsyc. 
intake 
6 (9%) 
 
NPI   
(mean, sd, 
range) 
 
30.6;  16.8; 4-80 
NPI  
(mean, sd, 
range) 
 
30.6;  16.8; 4-80 
Demqol-Proxy  
(mean, sd, 
range) 
 
97.3; 14.1; 59-117 
Demqol-
Proxy  
(mean, sd, 
range) 
 
99.8; 13.1; 58-122 
 
Heart Rate 68 Heart Rate 66 
Blood 
Pressure 
127/70 Blood 
Pressure 
129/70 
 
                                            
9 This information was not available from the informants. 
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Table 5.7 Carers’ characteristics by study arm 
Control Group      N 64 Intervention Group    N 67 
Age  
mean, sd, 
range                     
60. 9;17; 22-88 Age  
mean, sd, 
range                     
65.4; 14.9; 27-89 
Gender M            25 (39.1%) 
 
F            39 (60.9%)   
Gender M               17 (25.4%) 
 
F                50 (74.6%)   
FRAT 
score10 
0             46 (71.9%) 
 
1             13 (20.3%) 
 
2                5 (7.8%) 
FRAT score 0               40 (59.7%) 
 
1              21 (31.3%) 
 
2                 6 (9%) 
Relationship partner   35 (54.7%)  
                                      
child        21(32.8%) 
                                      
relative      5 (7.8%)  
                                       
paid           3 (4.7%)  
                                     
friend        0  
Relationship partner     42 (62.7%) 
 
child          17(25.4%) 
                                  
relative            2 (3%) 
                                 
 paid             5 (7.5%) 
                                
 friend           1(1.5%)  
GHQ cases         17 (27%) 
 
non-cases 46 (73%) 
GHQ cases    19 (28.4%) 
 
non-cases 48(71.6%) 
ZBI cases       10 (16.1%) 
 
non-cases 52 (83.9%) 
ZBI cases        15 (23.1%) 
 
non-cases 50 (76.9%) 
NPI  
(mean,sd, 
range) 
 
11.9; 8.1; 0-39 
NPI  
(mean, sd, 
range) 
 
11.8; 8.9; 0-38 
Heart Rate 70 Heart Rate 69 
Blood 
Pressure 
127/73 Blood 
Pressure 
122/71 
 
                                            
10 Falls risk assessment was carried out for both people with dementia and their 
carers as part of the risk assessment.  
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5.4.12 Missing data 
Missing data was examined for all main study variables by randomised group 
through logistic regression. Data was missing at random from both the intervention 
and control groups without being affected by group allocation and gender of 
participants (β=1.57, p=0.42); gender of carers (β=1.7, p=0.35); age of participants 
(β=1.6, p=0.40); age of carers (β=0.88, p=0.85); dementia subtype (β=1.69, 
p=0.36), dementia severity (β=1.49, p=0.47); education (β=1.94, p=0.30); ethnicity 
(β=1.39, p=0.56), marital status (β=1.37, p=0.57); relationship to carer (β=1.65, 
p=0.38) or co-morbidity (β=1.29, p=0.65). 
5.4.13 Tests of Normality 
Normality of data is a prerequisite for utilising parametric statistical tests.  
Distribution of the primary outcome data, the NPI, was assessed through the 
Kolmogorov-Smirnov test. The p-value was 0.004 therefore we rejected the 
alternative hypothesis and concluded that the data came from a non-normal 
distribution (Table 5.8, Figure 5.9). 
Table 5.8 Test of normality for NPI scores at week 12 
 
Kolmogorov-Smirnova Shapiro-Wilk 
 
Statistic df Sig. Statistic df Sig. 
Week12NPI .104 116 .004 .908 116 .000 
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The Q-Q plot (Figure 5.9) provides a visual comparison of the quantiles from our 
data sample to the theoretical quantiles. The points in the Q-Q plot depart from the 
straight line and form a bow shape that indicates right-skewed data, which could 
not have come from a normal distribution. 
  
 
 
 
 
 
Figure 5.9 Normal Q-Q Plot of NPI values at week 12 
NPI data was log transformed using natural logs (all values were added 0.5 initially 
because 0-vales cannot be logged). The log transformation, however, did not 
normalise the data (p=0.003) (Table 5.9, Figure 5.10), thus, non-parametric 
analysis was used to analyse NPI at week 12.  
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Table 5.9 Test of Normality for the NPI log transformed data 
 Kolmogorov-Smirnova Shapiro-Wilk 
Statistic df Sig. Statistic df Sig. 
NPILOG 
(12 
weeks) 
.107 113 .003 .966 113 .006 
 
Figure 5.10 Normal Q-Q Plot of NPI log transformed values at week 12 
 
The points in the Q-Q plot (Figure 5.10) represent quantiles of the log-transformed 
data compared to theoretical quantiles. The inverted bell shape indicates left-
skewed data that is not normally distributed. 
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5.5 Analysis of Primary Outcomes-Intention to treat analysis 
Intention-to-treat (ITT) analysis provides unbiased comparisons among the 
treatment and control groups because it avoids biases introduced by non-random 
attrition (Detry and Lewis, 2014). ITT analysis requires that all participants are 
analysed as members of the treatment group to which they were randomized 
regardless of their compliance with, or whether they received, the intervention.  
5.5.1  ANOVA analysis  
Participants were categorised into two groups: Those who had a clinically 
significant reduction in BPSD (NPI score) of three points or more, and those who 
had not. Binary logistic regression was used to analyse the difference in the 
proportions of those who had a clinically significant reduction in NPI score between 
the control and intervention groups at 12 weeks. There was no significant 
difference in the proportions of participants reaching a clinically significant 
reduction of three or more points in NPI score at week 12 compared to baseline, 
between the control and intervention groups (OR=1.41, p=0.36, 95% CI [0.67, 
3.01], Table 5.10). 
Table 5.10 BPSD improvement at week 12 
NPI Control Intervention Odds Ratio 
(OR) 
95% CIs P-value 
Change   
(≥3) 
33/57 
(57.9%) 
39/59 (66.1%) 1.41 0.67-3.01 0.36 
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5.5.2 Mann-Whitney U test 
In addition, change in NPI total score (8 domains) between groups at 12 weeks 
was tested by Mann-Whitney U test, which indicated no significant difference 
between intervention groups (Z=-1.077, p= 0.28) [Figure 5.11, Table 5.11]. 
 
Figure 5.11 NPI scores at week 12: means, medians and interquantile range 
 
Table 5.11 Descriptive for NPI values at week 12 
Group 
Allocation Mean 
Median Range 
Control 25.65 
22 0-72 
Intervention 23.93 
17 0-106 
 
5.5.3 ANCOVA analysis 
In order to test week 12 NPI score adjusted by baseline score (ANCOVA), 
residuals were inspected to check the assumption of normality. A residual plot 
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allows visual assessment of the distance of each observation from the fitted line. 
The relationship between residuals and predictive values in Figure 5.12 and Figure 
5.13 look reasonable enough to carry out a linear regression.  
 
Figure 5.12 Normal P-P plot of regression standardized residuals of NPI values at week 
12 
 
 
 
 
 
 
 
 
Figure 5.13 Scatterplot of regression standardized residuals of NPI values at week 12 
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There was no significant difference in NPI score at 12 weeks (β=-0.41, p=0.6, 95% 
CI [-7.37, 4.32]), where β represents the difference in mean NPI scores 
(intervention minus control groups at week 12) adjusted for baseline NPI scores.  
5.5.4 6-week follow up analysis 
NPI was also examined at 6 weeks to measure interim changes. There were no 
significant differences in BPSD symptoms at 6 weeks between the intervention and 
control groups in: 
 Clinical reduction of BPSD (reduction of NPI score of 3 or more points) (β=-0.81, 
p=0.76, 95% CI [-6.08, 4.45]) Table 5.14 (ANOVA). 
 Differences in NPI scores tested by Mann-Whitney U test (Z=-0.59, p= 0.56). 
 Differences in NPI scores adjusted by baseline score (ANCOVA), (β=-0.81, 
p=0.76, CI [-6.08, 4.4.45]).   
5.5.5  NPI cluster analysis 
There were no significant differences at weeks 6 and 12, between groups, for all 
cluster categories (Table 5.12, Table 5.13). 
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Table 5.12 Between-group analysis for NPI clusters at week 1211 
Cluster 
Categories 
Allocation Mean±sd  
12 weeks 
Adjusted 
difference 
in means  
95% CIs p-value 
Hyperactivity Intervention 10.86 ±1.03 -0.82 -4.03,1.15 0.27 
Control 9.68 ±1.27 
Affective Intervention 9.86 ±1.08 -0.03 -3.38, 
2.42 
0.74 
Control 8.63 ±1.13 
Apathy Intervention 11.6 ±1.13 -0.03 -3.38, 
2.45 
0.75 
Control 10.2 ±1.23 
Psychosis Intervention 4.51 ±0.68 -0.05 -2.32, 
1.26 
0.56 
Control 4.58 ±0.83 
 
Table 5.13 Between-group analysis for NPI clusters at week 612 
Cluster 
Categories 
Allocation Mean±sd  
6 weeks 
Adjuste
d 
differenc
e in 
means  
95% CIs p-
value 
Hyperactivity Intervention 10.1±9.2 -1.59 -4.7, 0.5 0.11 
Control 11.8±8.9 
Affective Intervention 9.9±8.9 -0.19 -2.5, 3.03 0.85 
Control 11.8±8.3 
Apathy Intervention 9.9±8.8 -0.88 -3.8, 1.5 0.38 
Control 11.8±8.3 
Psychosis Intervention 5.9±6.9 0.9 -0.9, 2.6 0.37 
Control 4.5±5.2 
                                            
11 Adjusted for baseline corresponding measures.  
12 Adjusted for baseline corresponding measures. 
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5.6 Analysis of Secondary Outcomes 
Carer’s burden as measured by the Zarit Burden Inventory (ZBI) doubled by week 
12 for the control group participants, but decreased from 23% to 17% for those in 
the intervention group; (OR=0.18, p=0.01, CI [0.05, 0.69], Figure 5.14). 
 
Figure 5.14 ZBI cases 
There were no statistically significant differences between the groups at week 12 
on: Carers’ mental health (GHQ), carers’ distress (NPI) and quality of life of 
participants with dementia (Demqol-proxy) (Table 5.14). 
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Table 5.14 Secondary outcome analysis – Categorical data 
 
 
                                            
13 Odds Ratio of an improvement (reduction) of composite NPI score of 3 or more points 
between baseline and weeks 6 and 12 
14 Scoring at or above the validated threshold for ‘caseness’ at weeks 6 and 12 
 
Outcome Week Control 
Frequency 
(%) 
Intervention 
Frequency 
(%) 
OR 95% CI p-
value 
NPI13  
 
6 
 
32/56 (57.1%) 
 
39/62 (62.9%) 
 
 
1.27  
 
 
0.61 : 2.66 
 
 
0.52 
 
12 33/57(57.9%) 39/59 (66.1%) 1.41 0.67 : 3.01 0.36 
GHQ14 
baseline 
 
6 
46/63 (73%) 
 
24/57 (42.1%) 
48/67(71.6%) 
 
16/62 (25.8%) 
 
 
0.42  
 
 
0.18 : 1.00 
 
 
0.05 
 
12 24/56 (43%) 17/55 (31%) 0.59  0.24 : 1.43 0.19 
     
ZBI14 
baseline 
 
6 
52/62 (83.9%) 
 
14/55 (25.5%) 
50/65 (76.9%) 
 
14/59 (23.7%) 
 
 
0.48  
 
 
0.14 : 1.67 
 
 
0.25 
 
12 18/56 (32%) 10/57 (17.5%) 0.18  0.05 : 0.69 0.01 
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Table 5.15 Secondary outcome analysis – Continuous data 
 
 
5.6.1 Standardized effect size 
Cohen’s effect size value (d = .091) suggests a very small effect size. It means 
there is a large overlap between the NPI means (week 12) for the control and 
intervention groups. We only have a 9% chance of finding an effect if one exists.  
                                            
1 The denominator of week 6 and week 12 data varies as result of participant availability. 
2 Analysis of Covariance (ANCOVA) of the adjusted difference in means (Intervention - 
Control) at weeks 6 and 12 
Outcome Week Control1 
Mean ± SD 
Intervention 
Mean ± SD 
β 95% CI p 
NPI2  6 26.6 ± 17.5 25.7 ± 20.5 -0.81 -6.08 : 4.45 0.76 
 12 25.6 ± 16.6 23.9 ± 20.6 -1.53 -7.37 : 4.32 0.60 
Demqol  6 101.1 ± 14.9 103.6 ± 11.9 1.27 -2.33 : 4.86 0.49 
 12 101 ± 13.5 104 ± 10 2.62 -0.78 : 6.02 0.09 
NPI 
Carer 
distress 
6 11.07 ± 7.2 11.5 ± 8.5 -0.06 -2.25 : 2.14 0.96 
12 9.98 ± 5.9 10.9 ± 9.3 1.14 -1.31 : 3.58 0.76 
ZBI 6 18.58±8.76 17.71±9.1 -1.19 -3.05 : 0.65 0.20 
 12 19.45±8.51 17.07±9.82 -2.81 -4.89 : -0.73 0.009 
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5.7 Compliance with the intervention  
Diaries were returned by 90 (69%) participant dyads; 52 (77.6%) from the 
intervention group and 38 (59.4%) from the control group. Overall, there were no 
significant differences between dyads who returned diaries and those who did not 
for all demographic, disease and carer characteristics.  
Within the control group there were some statistically significant differences 
between dyads which returned diaries and those that did not. Dyads which 
returned diaries had predominantly partner-carers 26/38 (68.4%); (OR=4.09, 
p=0.009, CI [1.42, 11.79], carers’ age was younger than the carers of those that did 
not return the diaries and their (patients) MMSE score was higher (Table 5.16).   
Table 5.16 Characteristics of groups that returned and did not return diaries   in the control 
group 
Outcome Returned 
diaries 
Mean ± sd 
Did not return 
diaries 
Mean ± sd 
OR 95% CI p-
value 
Carers’ 
Age 
 
 
53.88±17.3 
 
 
65.63±15.44 0.34 
 
3.14, 20.4 
 
 
0.008 
 
MMSE 17.55±8.31 11.04±7.89       0.37     2.37,10.6    0.003 
 
Walking compliance was achieved when each dyad walked five times or more a 
week. Walking compliance was slightly higher for the intervention group, with 19/38 
(50% of the sample that returned diaries) dyads from the control group and 27/52 
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(51.9% of the sample that returned diaries) dyads from the intervention group 
reaching the threshold (Table 5.16, Table 5.17). The difference between the two 
groups regarding walking frequency was not significant (OR=0.93, p=0.86, CI 
[0.40, 2.14]).  
Table 5.17 Frequencies of walking compliance on the control arm (diary respondents only) 
 
There were statistically significant differences at the end of week one in the self-
reported walking time (minutes) between the control ( =27, SD=47.2) and 
intervention ( =10.4, SD=13.7) groups (t=2.1, p=0.04, CI [0.68, 32.5]). This 
differences remained statistically significant during week 6 for the control ( =29.3, 
SD39.4) and intervention ( =16.2, SD=16.9) groups (t=2.2, p=0.05, CI [-0.51, 
26.8], but were not statistically significant at week 12 (t=1.03, p=0.31, CI [-5.58, 
17.51]. 
Walking Frequency Compliant Non-Compliant 
Control 19/38 (50%) 19/38 (50%) 
Intervention 27/52 (51.9%) 25/52 (48.1%) 
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Figure 5.15 Mean walking times for the intervention and control groups 
Self-reported walking time (diary) appeared to differ between the groups. The 
control group increased walking by just over two minutes at week 6 in comparison 
to week 1, but by week 12 their reported walking time had decreased by almost 
eight minutes in comparison to week 6. Participants in receipt of the intervention 
reported increasing their walking time by six minutes at week 6 and retained this 
change at week 12 (Figure 5.16). 
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Figure 5.16 Change in walking times 
RPE was reported just in the intervention group as it was part of the intervention. 
Out of the 52 returned diaries on the intervention group only 38 participants 
reported their RPE, half of which achieved the threshold for compliance (Table 
5.18). There were no significant differences between participants that were RPE 
compliant and those that were not on all demographic, disease and carer 
characteristics.  
Overall compliance with the intervention was considered achieved when 
participants walked at least 5 times a week and achieved an RPE of 12 or above. 
This information was obtained by self-reported measures from diary entries. Just 
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19% (13/67) dyads on the intervention arm were fully compliant with the 
intervention (Table 5.18, Figure 5.17). 
Table 5.18 Frequencies of intervention compliance on the Intervention arm 
 Compliant Non-Compliant 
Walking Frequency 27 (51.9%) 25 (48.1%) 
RPE 19 (50 %) 19 (50%) 
Overall compliance   13 (19.4%) 39 (80.6%) 
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Control 64 Intervention 67
RPE Compliant 
14 
Overall Compliance
13
Not- walking 
19
Walking
19
Returned 
Diaries
38
Returned 
Diaries
52
Walking
27
Not- walking 
25
RPE Non-
Compliant 
12 
RPE Compliant 
5 
RPE Non-
Compliant 
7 
 
Figure 5.17 Flow diagram of compliance with the intervention 
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5.8 Per-protocol analysis 
Considering the high rate of non-compliance with the intervention, per-protocol 
analysis was carried out.  This analysis was restricted to participants that were 
compliant with the trial. Compliance was established when participants walked 5 
times a week and reached an RPE rate of 12 or above. These elements were 
analysed individually as well as combined in order to build a better picture of the 
intervention effectiveness. 
5.8.1 Walking Compliance and NPI 
The NPI mean score at week 12 was lower for participants in the intervention arm 
that walked at least five times a week compared to those that did not. The opposite 
happened with participants in the control arm (Figure 5.18). However, none of 
these differences were statistically significant.  
 
Figure 5.18 NPI mean scores for walking compliant and non-compliant participants 
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5.8.1.1 ANOVA analysis 
Binary logistic regression was used to analyse the difference in the proportions of 
those who had a clinically significant reduction in NPI score between walking 
compliant participants in the control and intervention groups at 12 weeks (Table 
5.19). A clinically significant reduction in NPI score occurred for 47.1% of 
participants that were walking compliant in the intervention arm, and for 57.7% of 
walking-compliant particiapant in the control arm.  
Table 5.19 Proportions of walking-compliant participants who reached a significant 
reduction in NPI at week 12 
Group Allocation 
Control Intervention 
NPI not reduced NPI reduced NPI not reduced NPI reduced 
Count % Count % Count % Count % 
9 52.9% 8 47.1% 11 42.3% 15 57.7% 
 
 
There was no statistically significant difference in the proportions of participants 
reaching a clinically significant reduction of three or more points in NPI score at 
week 12 compared to baseline, between the control and intervention groups 
(OR=0.65, p=0.49, 95% CI [0.19, 2.43]. 
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5.8.1.2 Mann-Whitney U test 
There was no difference in NPI scores at week 12 between participants that were 
walking compliant in the intervention and control group (Z=-1.48, p= 0.14)  (Figure 
5.19).  
 
Figure 5.19 Boxplots of NPI scores (week 12) for participants that were walking compliant.  
 
5.8.2 RPE Compliance and NPI – Intervention Group 
RPE measurement was part of the intervention and consequently this data is not 
available for the control group. Between-groups comparisons regarding RPE 
compliance were therefore impossible.  
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The NPI score at endpoint was significantly higher for participants on the 
intervention arm that were RPE compliant compared to participants on the same 
arm but who did not comply with the RPE β=0.35, p=0.038, 95% CI [0.77, 25.8] 
(Figure 5.20 & Figure 5.21). This difference was not significant at baseline (β=0.2, 
p=0.23, 95% CI [-4.49, 18.4]) or at 6-week follow-up (β=0.25, p=0.14, 95% CI [-
3.37, 23.6]).  
 
Figure 5.20 NPI mean scores for RPE-compliant and non-compliant participants 
(intervention arm only) 
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Figure 5.21 Boxplots of NPI scores (week 12) for participants that were RPE compliant 
and not-compliant (intervention arm only) 
There was no statistically significant difference in the proportions of participants 
reaching a clinically significant reduction of three or more points in NPI score at 
week 12 compared to baseline, between the RPE-compliant and non-compliant 
participants OR=1.2 p=0.79, 95% CI [0.31, 4.59] (Figure 5.21). 
5.8.3 Effect of compliance within the intervention group 
There was no difference in NPI scores at week 12 for participants that were 
compliant overall and those that were not (β=0.128, p=0.181, 95% CI [-3.62, 
18.99]) (Figure 5.22).    
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Figure 5.22 Boxplots of NPI scores (week 12) for participants that were compliant and not-
compliant with the intervention (RPE + walks) (intervention arm only) 
However, The NPI score at 6-weeks was significantly higher for participants on the 
intervention arm who were compliant compared to participants on the same arm 
who did not comply overall β=0.27, p=0.032, 95% CI [1.28, 26.88] ( 
Figure 5.23).  
 
 
Figure 5.23 NPI mean scores for compliant and non-compliant intervention group 
participants (RPE + walks) (intervention arm only) 
There was no statistically significant difference in the proportions of participants 
reaching a clinically significant reduction of three or more points in NPI score at 
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week 12 compared to baseline, between the intervention compliant and non-
compliant participants OR=1.75 p=0.36, 95% CI [0.53, 5.83]. 
5.8.4 Blinding 
Table 5.20 indicates de-blinding occasions for researchers that collected study 
data. Researcher 1 (the candidate) had face to face contact with participants and 
researcher 2 contacted participants on the phone. Face to face contact led to more 
de-blinding occurrences compared to telephone contact, and intervention arm 
participants were more prone to divulging such information compared to 
participants in the control arm of the trial.  
Value of Kappa=1 indicates full agreement between scores. In our analysis Value 
of Kappa=1 means that the researcher is de-blinded on every occasion. The 
further the value from 1 the lower the level of de-blinding.  The level of agreement 
is higher for the researcher who had face to face contact with participants than the 
researcher who contacted participants on the phone (week-6: K=0.46 Vs K=0.002 
and week-12: K=0.69 Vs K=-0.25) [Table 5.20]. 
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Table 5.20 De-blinding for researchers 
 De- blinded 
Control Intervention Measure of 
agreement 
(Kappa) 
P value 
     
Week 6  
Researcher 1 
5/57 
(8.8%) 
9/62 (14.5%) 0.46 0.03 
Week 6 
Researcher 2 
0/54 6/60 (10%) 0.002 0.89 
Week 12  
Researcher 1 
4/56 
(7.8%) 
10/57 (17.5%) 0.59 0.13 
Week 12  
Researcher 2 
0/47 3/50 (16%) -0.25 0.58 
 
5.8.5 Adverse events 
Two serious adverse events and six adverse events were reported during the study 
(Table 5.21). All events were followed up by the research team and were 
consequently classified as unrelated to the trial. Both serious adverse events were 
reported as deaths from natural causes and both participants were on the 
intervention arm.  
The adverse events were all falls, which did not happen during trial activity and 
were not trial related. Overall, two adverse event happened to participants on the 
control arm of the trial and four to those on the intervention arm. Only one of the 
adverse events resulted in injury but not hospitalisation. The participant that was 
injured was in the control arm of the trial.  
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Table 5.21 Rates of adverse events 
Type of adverse event Control Intervention Total 
Adverse Events Falls without injury 4 1 5 
Falls with injury 0 1 1 
Serious Adverse Events 0 2 2 
 
5.8.6 Follow-up at week 26 
No major changes were reported at 26-week follow up. Four individuals had moved 
from their family homes to care homes. Three of those individuals were in the 
control group and one in the intervention group (OR=0.38, p=0.42, CI [0.04, 3.85]).  
Further three deaths were reported at week 26, two from the control group and one 
from the intervention group. This difference was not significant (OR=1.76, p=0.55, 
CI [0.28, 11.07]) 
No significant difference was reported in medication intake.   
Walking adherence was difficult to directly assess because the candidate was 
blinded to arm allocation. Therefore, carers were asked if the person with dementia 
was walking more, less or the same compared to the beginning of the trial. Results 
are presented in Figure 5.24. 
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Figure 5.24 Self-reported walking activity at week 26 
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6 DISCUSSION 
6.1 Overview of results 
6.1.1 Primary Outcome 
It has been reported that exercise can potentially improve a range of factors, which 
psychological theories of BPSD (Paragraph 1.3.3) consider critical for symptom 
development and maintenance, including:  
 Physical health: through reduction of pain, improvement of constipation, 
enhancement of balance (Allan et al., 2009; Plooij et al., 2012). 
 Mental health: improved depression and anxiety symptoms through possible 
increase of brain neurotransmitters; increased release of β-endorphins; 
reduction in muscular tension; by providing positive reinforcement and 
improving self-efficacy (Conn, 2010; Craft and Perna, 2004; Craft, 2005; Dunn, 
2010; Gogulla et al., 2012). 
 Cognitive decline: by improving brain neuroplasticity and cognitive networks 
(Ahlskog et al., 2011; Erickson et al., 2011). 
 Sleep problems: through increased light exposure, suppression of melatonin 
secretion during the day, to help regulate circadian rhythms (Loprinzi and 
Cardinal, 2011; McCurry et al., 2005). 
 Environmental factors: as a result of increased social interactions and sensory 
stimulation (Hersch and Falzgraf, 2007).  
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Based on the above (discussed in paragraph 1.4.2, pp 74), we hypothesized that 
an array of BPSD symptoms would improve as a consequence of these changes. 
Although the process of EVIDEM-E study design focused on intervention 
effectiveness rather than theoretical frameworks our hypothesis was underpinned 
by several theoretical models of BPSD such as: 
- Kitwoods’s Theory of Personhood: embraces a person-centred, non-
pharmacological approach to individuals with dementia (Paragraph 1.1.2) 
(Kitwood, 1997). Our tailored, programme of walking took into account 
individual needs and skills, environmental factors, physical and mental 
health in line with this theory.  
- The Environmental Vulnerability model: argues that considering the 
decreased level of competence of people with dementia their likelihood of 
being disturbed by the environment increases (Cohen-Mansfield, 2000). In 
accordance with this approach we tried to increase the level of 
competence of participants and lower environmental stressors by: 
conducting the intervention with individuals rather than groups; including 
carers who could provide unique support; involving an exercise therapist 
who devised individualised programmes; selecting walking as an activity 
that is easy to carry out and sustain.  
- The Unmet Needs model: Figure 6.1 depicts the way the Unmet Needs 
model may apply to our exercise intervention for BPSD (Cohen-Mansfield, 
2000) (Paragraph 1.3.3, pp 58).  
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Figure 6.1  Unmet needs model and exercise (based upon Cohen-Mansfield, 2000) 
 
This study shows that the intervention of walking, tailored to participant-carer 
dyads, designed to become progressively intensive and lasting between 20-30 
minutes per day, 5 days a week, does not appear effective in treating behavioural 
and psychological symptoms of dementia as measured by NPI score after 12 
weeks. The intervention group was 41% more likely than the treatment as usual 
group to experience a clinically important reduction of Neuropsychiatric Inventory 
score (3 points or more), but this was not a statistically significant difference. 
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All the aforementioned models of BPSD are very complex and include a range of 
factors that we could not control for such as: lifelong habits and personality; coping 
styles and help seeking attitude; quality of relationship with carer; socioeconomic 
factors. The inability to influence these components obviously limits the effect of 
what at first sight we considered to be a simple intervention of walking. Perhaps 
exercise alone is insufficient to have a significant effect on BPSD, in a population 
(both people with dementia and carers) where unmet needs are substantial (Carers 
UK, 2008; Lakey et al., 2012).  
The possibility remains that the exercise regime we prescribed was not appropriate 
or of sufficient intensity or duration to impact upon BPSD. It would have been 
unethical for the therapist to have encouraged more intense exercise within this 
frail population who are prone to falls. Furthermore, prevailing NICE guidelines 
were taken into account in the study design, which recommend that older people 
should exercise 30 minutes a day on 5 or more days a week (NICE, 2008).  
A large proportion of the treatment as usual group experienced an improvement in 
BPSD over the course of the study, which may be a Hawthorne effect (participants 
improving aspects of their behaviour in response to their awareness of being 
observed) attributable to the engagement of research staff with participants 
(McCarney et al., 2007), or a consequence of the natural fluctuation of BPSD 
(Devanand et al., 1997).  An alternative explanation is that bias was introduced due 
to changes in exercise behaviour in the control group. Participants in the control 
group, who were expected to carry on with their normal level of physical activity, 
increased their walking. The main analysis compared the intervention and control 
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groups under the assumption that the only significant difference between them was 
the amount and intensity of physical activity, with the intervention group being more 
active than the control group.  
According to the Health Belief Model (Strecher and Rosenstock, 1997) and the 
Theory of Planned Behaviour (Ajzen, 1991) (described in paragraph 1.3.3, pp58), 
participants in the control group who believed they could benefit from regular 
exercise might have increased their exercise during the study period, which in turn 
may have reduced any detectable effect due to the intervention. The Trans-
theoretical model of change may suggest that participants who joined the trial, 
unlike those who refused participation, were at least at a preparatory (ready to 
exercise) stage (Prochaska and Velicer, 1997). Additionally, they were given 
detailed information about the study hypothesis and the rationale for the 
intervention design through patient and carer information sheets. Therefore, 
participants on both arms, at the beginning of the trial, may have had a degree of 
confidence that the walking intervention could be effective for BPSD, and 
considered it feasible to be carried out. Of course, this could have changed as the 
participants progressed into the trial, and some individuals probably regressed in 
regards to their stages of change. Also, time spent in exercise does not necessarily 
mean both groups exercised in the same way, but unfortunately we have no means 
of directly comparing the objective exercise intensity of each group. However, 
improving and sustaining exercise intensity is notoriously difficult; and those in the 
intervention group - with the support of a therapist - will have been better placed to 
achieve this. 
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On the other hand, our between group comparison could have also been affected 
by non-compliance in the intervention group. Just 19% of the intervention 
participants were compliant with the intervention. According to theories of 
behaviour change, intentions to engage in particular activities are determined by 
the person’s attitude towards the behaviour including the perception of feasibility 
and benefits after pros and cons are weighed (Ajzen, 1991; Strecher and 
Rosenstock, 1997). Participants in EVIDEM-E were informed that this was a 
pragmatic trial and that there was no established evidence that dyadic walking 
could affect BPSD. Therefore, the benefits for complying with the intervention could 
have been perceived as not very high by some participants in the intervention arm. 
Moreover, the barriers of complying with the intervention for this particular 
population are numerous, such as poor physical health and being prone to falls; 
worsening of BPSD symptoms; and limited time availability for stressed and busy 
carers. Compared to health promotion interventions where benefits are established 
and participants can be influenced to change their behaviour through various 
strategies, clinical trials are clearly at a disadvantage. It would be considered 
unethical to unduly influence long term behaviour change in pragmatic clinical trials 
in case the intervention turns out to be non-beneficial or even unsafe for the 
participants.  
According to the Theory of Planned Behaviour (paragraph 1.5) intentions are 
determined by the person’s beliefs regarding important others’ support of the 
behaviour and perceived self-efficacy (Ajzen, 1991). The fact that the exercise 
therapist withdrew their support mid-intervention (6 weeks into the trial) may have 
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been not just premature but also may have had a negative impact on the dyad’s 
perception of self-efficacy and consequently their intervention compliance. The 
Environmental Vulnerability/Reduced Stress Threshold models (Cohen-Mansfield, 
2000) would also suggest that the support from the exercise therapist would have 
increased the level of perceived self-competency and coping abilities of the person 
with dementia and their carer and thereby lowered their possibility of being 
distressed by the environment. Withdrawal of the therapist may have unbalanced 
the ‘press-competence’ stability established at the beginning of the trial and 
consequently may have contributed to the level of non-compliance. Withdrawal of 
support by the exercise therapist may have, therefore, contributed to a reduction of 
the effect of exercise on BPSD.  
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Figure 6.2 Press-competence balance during and after engagement of the exercise 
therapist 
 
NPI categories were clustered into four groups: hyperactivity, affective, apathy and 
psychosis. Analysis of these clusters did not reveal any statistically significant 
differences between arms. This analysis was however carried out post-hoc and the 
study may have not been sufficiently powered to detect any significant differences 
for clustered syndromes. Each NPI category was also individually analysed but 
none of the individual between-group differences reached statistical significance.  
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6.1.2 Secondary Outcomes 
6.1.2.1 Carer’s burden 
Caregiver’s burden as measured by the Zarit Caregiver Burden Inventory 
decreased significantly in the intervention arm but increased in the control arm. 
Carers in the intervention group were 82% less likely to become significantly 
burdened at week 12. This finding might seem surprising considering that BPSD 
symptoms did not improve, however, subsequent studies have reported similar 
findings (Yu and Swartwood, 2012; Yu et al., 2013), indicating that there may not 
be a causal relationship between patients’ BPSD symptoms and carers’ burden. Yu 
et al. (2013) who evaluated the impact of aerobic exercise on Alzheimer’s 
symptoms of a community based sample (n=26) reported that although NPI scores 
remained unchanged over a 6-month period the carers’ distress decreased by 
40%. However, these studies provided exercise interventions to patients with 
dementia only, offering 8-10 hours per week respite to carers during intervention 
periods. Thereby, carers’ burden in these studies may have been reduced as a 
result of respite provisions (Conlin et al., 1992; Flint, 1995). Carers in the 
intervention arm of EVIDEM-E, did not experience respite. On the contrary their 
responsibilities towards the person with dementia increased with their engagement 
with the study, therefore, respite provision cannot explain our findings.  
One of the drawbacks of single-blind, behavioural trials can be participants’ pre-
existing preferences about group allocation (McCambridge, Kypri, et al., 2014). 
According to theories of behaviour change it can be hypothesized that carers who 
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agreed to participate in the trial were more motivated and/or ready to exercise in 
order to improve the BPSD of the person they cared for, than carers who refused 
participation. Furthermore, they probably found our intervention attractive and 
feasible and agreed to make a significant commitment in time and energy. 
Therefore, being assigned to the control arm may have been disappointing for 
some carers (Skingley et al., 2014). In fact a few carers allocated to the control arm 
asked if they could withdraw and re-enter the trial, and be re-assigned to the 
intervention arm. We can hypothesize that carers’ disappointment about being 
allocated in the control arm may have either affected (biased) their ZBI responses 
or actually caused an increase in carers burden. This, however, remains an 
hypothesis that can be explored on future research.     
Improvement in carers’ burden for participants in the intervention arm may have 
occurred as a consequence of the beneficial effects of exercise on the carer, rather 
than due to any change in the person with dementia (King et al., 2002; Orgeta and 
Miranda-Castillo, 2014). In fact, exercise interventions are reported to be quite 
effective in improving the quality of life for carers of people with dementia and in 
reducing their burden (Castro et al., 2002; Connell and Janevic, 2009; Hirano et al., 
2011; King and Brassington, 1997). It has been reported that carers of people with 
dementia have less time and opportunities to engage in preventive health activities 
such as exercise (Pinquart and Sörensen, 2007). Carers in the intervention arm of 
EVIDEM-E were given the opportunity to engage in such activity and this can be 
considered as an intervention on its own. Caring for someone with dementia is 
considered a chronic stressor given that the length of caring may range between 8 
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to 10 years (Moore et al., 2001), and regular exercise has been associated with 
reduction of negative physiological reactions to chronic stress (Netz et al., 2005; 
Vitaliano et al., 2003). Engaging in exercise has also been reported to improve 
sleep (McCurry et al., 2007) and increase stamina (King and Brassington, 1997), 
which are essential factors that affect daily caregiving activities.  
Increased social interaction among intervention arm participants with the exercise 
therapist may also be a factor that could have affected carer’s burden differentially. 
However, carer’s burden was very similar in both arms during the peak of social 
interaction (week 6) for the intervention arm, and significant changes were only 
reported at week 12 when this interaction was at its minimum. Possible latent 
effects of social interaction may also have played a role in the findings. However, 
no examples of latent effects could be found in the literature. In addition, this was a 
complex intervention in which the social contact between the person with dementia 
and their carer formed an important component. Dyadic walking may have 
intensified habitual support from the carer, and this may partly explain the changes 
we observed for caregiver burden. 
The input from the exercise therapist consisted of support for the participant’s goal-
setting and training participants to self-monitor and become self-efficacious. These 
activities are behavioural strategies and though not the direct focus of our 
intervention could have had an impact on carers’ burden.  
The ZBI is a self-reported measure and consequently carries the risk of being 
affected by response bias. Considering participants were not blinded to the 
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intervention, a tendency amongst carers in the intervention arm of the trial to give 
socially desirable answers may have had an impact in our findings. However, if 
such tendency existed it would be expected to have been present in other self-
reported measures such as NPI, DEMQOL, GHQ etc which did not appear 
affected.  
6.1.2.2 Carers’ mental health 
Carers on the intervention arm had a 58% decrease in odds of suffering from 
mental health problems (measured with the GHQ) than their control counterparts. 
This difference was statistically significant at week 6 only. At week 12, although 
this difference was no longer significant, there was still a 41% reduction in odds of 
experiencing mental health problems for carers in the intervention arm compared 
to carers in the control group.  
6.1.2.3 Quality of life for people with dementia 
People with dementia in the intervention arm were reported to have slightly better 
quality of life than those in the control arm. The median DEMQOL-Proxy score for 
the intervention group at week 12 was 2.62 points higher than in the control group, 
but this difference did not reach statistical significance.  
Although DEMQOL-Proxy is considered to be one of the best available proxy 
measures for people with mild to moderate dementia, this instrument’s validity has 
been criticised for several reasons (Smith et al., 2005). Firstly, DEMQOL-Proxy is 
based on health-related quality of life only and it lacks reference to social 
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consequences, environment and unmet needs, which according to psychological 
theories of BPSD are essential factors of its development and maintenance 
(Bowling et al., 2015). Secondly, five out of 31 items are reversed in order to 
minimise response bias, however considering the length of the questionnaire this 
approach may not be very effective (van Sonderen et al., 2013). Thirdly, quality of 
life is a subjective concept and as such its’ scoring is influenced by the informant’s 
characteristics, personality and relationship with person with dementia (Bowling et 
al., 2015).  
Quality of life assessment should be an ideal approach to explore if an intervention 
has made a meaningful difference to participant’s life, which is characterised by 
various domains. DEMQOL-Proxy does not asses many of these domains, 
especially ‘unmet needs’. Instruments that assess ‘unmet needs’ as well as all 
domains of quality of life would be useful in similar research in the future. 
6.1.2.4 Compliance with the intervention and BPSD 
Adherence to the intervention was assessed through diarised entries that were 
completed by carer participants (Appendix 1.11 & 1.12). Diaries were returned by 
69% of participant dyads (Figure 5.17). The reported reasons for unreturned 
diaries were that they were lost by the participants or lost in the post. The main 
predictors for returning diaries were carers’ younger age and patients’ milder 
dementia symptoms (Table 5.16). Assessment of adherence with the intervention 
is therefore potentially biased as a result of missing information from more than a 
quarter of the sample. The intuitive deduction is that those who did not return the 
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diaries may not have exercised. If this deduction is taken one step further it might 
mean that those who tried to adhere to trial requirements were supported by 
younger carers and had milder cognitive symptoms compared with those who did 
not abide by trial requirements. This assumption is consistent with behaviour 
change theories and the Unmet Needs model, according to which carer’s support 
and perceptions of self-efficacy are central to engaging in exercise. Younger carers 
are likely to have less physical health problems, a lower risk of falls and be more 
physically active than older carers (Schutzer and Graves, 2004). People with 
milder cognitive symptoms of dementia, on the other hand, are also probably 
younger than those with more severe dementia and consequently overall have 
better physical and mental health status (including BPSD symptoms). As a result, 
these specific dyads may feel more autonomous, self-efficient and supportive of 
each other, and consequently may perceive themselves as at a lower risk of pain 
or injury when engaging in regular exercise. However, this remains a hypothesis 
that may be explored in future studies.  
Another challenge to achieving intervention compliance may have rested with the 
involvement of dyads (as opposed to individuals) which may have held conflicting 
views about exercising. Thus, even when one person was willing to exercise and 
believed that it would be advantageous, the other person perhaps did not (or was 
perceived as such).    
Adherence consisted of two elements: frequency - walking at least 5 times a week 
for 20-25 minutes each time; and intensity - reaching an RPE of 12 or above. Only 
19% of the intervention participants were fully compliant. Compliance was higher 
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for frequency (40% walking compliant) than intensity (28% RPE compliant). 
Significant non-adherence with intensity suggests that participants either found the 
exercise physically challenging to achieve or they did not fully comprehend how to 
accomplish it. Nevertheless, literature indicates that frequency of exercise 
interventions rather than intensity is most strongly associated with mental health 
benefits (King et al., 1993). 
Interestingly, Figure 5.20 shows a significant increase of BPSD symptoms at week 
12 for RPE compliant participants in the intervention arm compared to RPE non-
compliant participants in the same arm. RPE compliance and BPSD symptoms at 
week 12 were positively correlated (r=+0.35, p=0.03), which means that as RPE 
compliance increased so did BPSD symptoms or vice-versa. However, this 
correlation was weak and the direction of the relationship could not be confirmed 
because correlation does not imply causation (Judea, 2009). When baseline BPSD 
scores were controlled for in the multivariate analysis this difference became 
insignificant (r=+0.29, p=0.09). It can be assumed that the association between 
RPE compliance and BPSD symptoms at 12 weeks was partially due to differences 
in BPSD symptoms at baseline. However, the sample analysed was very small, 
which increases the probability of Type II error (not determining an effect when one 
exists).  
Thirty percent of participants in the control arm of the trial walked 5 times a week or 
more. Surprisingly, there were no significant differences in walking frequency 
between the intervention and control groups, which may indicate two possibilities: 
the control group independently increased their walking or the intervention group 
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was non-compliant. The data suggests both these explanations may apply (Figure 
3.14). Although the control group did not receive the prescribed intervention they 
were introduced to information regarding possible benefits of walking through 
information sheets and were asked to record their daily activity in diaries. Diaries 
on their own right are considered as significant motivational factors in 
enhancement of exercise (Bravata et al., 2007; Kang et al., 2009) and could have 
consequently affected the walking behaviour of the control group.  
Although control participants initially increased their walking, by week 12 their 
walking times decreased by almost 8 minutes. Intervention participants, on the 
other hand retained their increased walking times (by 8 minutes) throughout the 
course of the trial. This may reflect the input and support from the exercise 
therapist designed to maintain increased levels of physical activity.  
 
Figure 5.23 depicts an interesting tendency: intervention participants who adhered 
to walking 5 times a week reported fewer BPSD symptoms (4.63 points lower) at 
week 12 than those within the same intervention arm who did not walk. This 
pattern was reversed for control participants (7.73 points higher).  This may 
indicate that walking can have a beneficial effect on BPSD only if it is supported by 
a trained therapist. Another explanation may be that carers in the control arm who 
looked after people with more BPSD symptoms may have been more motivated to 
alleviate BPSD, and walked more than their counterparts within the same arm with 
less BPSD symptoms to manage. Another explanation, in accordance with The 
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Theory of Reasoned Action, may be that carers in the control arm who looked after 
people with more or more severe BPSD symptoms may have been more motivated 
to alleviate BPSD, and walked more than their counterparts within the same arm 
with less BPSD symptoms. Campbell et al. (2001) reported that compliance with 
exercise was higher when the condition was perceived as more severe. They also 
state that a precondition for continued compliance is the perception that the 
intervention is effective in improving unpleasant symptoms.  
6.2 Internal and external study validity 
Internal validity of a study refers to the extent to which its findings are a result of 
the intervention being tested.  External validity, on the other hand, relates to the 
degree those findings can be extrapolated from the study sample to other 
populations of interest. RCTs, compared to other study designs, have good internal 
validity because confounders and bias are limited through specific trial design, 
conduct, analysis and interpretation. The external validity of RCTs, however, is 
criticised especially in explanatory trials (Fahey, 1998; Rothwell, 2005).  
In EVIDEM-E we attempted to maximise the precision and validity of the findings, 
and establish a good balance between internal and external validity.  Both 
strengths and limitations of the trial that impinge on its internal and external validity 
are discussed below.  
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6.2.1 Population/sample 
One of the main strengths of this study in terms of internal validity was the 
relatively large sample and low attrition rates, which provide sufficient power to 
detect an effect of clinically significant magnitude. However, the power calculation 
assumed a higher level of fidelity to the intervention than was actually achieved. 
EVIDEM-E employed limited exclusion criteria, consequently increasing its external 
validity. The recruitment of a clinically relevant sample in terms of age, ethnicity, 
diagnosis, severity of disease and mobility (Paragraph 5.3, pp. 165-97) allows 
greater generalisability to people with dementia and BPSD in the UK. Both 
prevalent and incident cases were recruited to the trial. Participant identification 
was carried out from a widespread geographic area in secondary and tertiary care 
provisions and from DemReg (Paragraph 3.3.2, pp 122). Patients in primary care 
services were not approached as previous research indicated that a very small 
number of GP patients with dementia were not in contact with secondary care 
services (Iliffe et al., 2011). Non-inclusion of primary care services in participant 
identification could have led to a sampling bias. Patients with dementia seen in 
primary care may be different from those reviewed in secondary and tertiary care 
(Sackett et al., 1991), therefore our sample is not representative of primary care 
patients.   
More than half of our study participants (52%) were recruited from DemReg, e 
registry for people with dementia and their carers who have expressed an interest 
to participate in research (Iliffe et al., 2011). According to Heiman (2002), research 
volunteers tend to have a higher social status and intelligence, exhibit an increased 
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need for approval, and have a tendency to be less authoritarian and conforming 
than others that do not volunteer. People who volunteer to participate in research 
may also have outcomes and exposures (e.g. healthier status) that differ from 
those of non-volunteers (Rosnow and Rosenthal, 1997). Volunteering bias is one 
of the limitations of EVIDEM-E in terms of its external validity, because of the high 
prevalence of volunteering by DemReg participants. We do not expect volunteering 
bias to have affected study’s internal validity as randomisation should have 
balanced both study arms.   
6.2.2 Measurement 
EVIDEM-E used well validated and clinically relevant outcome measures (see 
paragraph 3.4.1). Most measures were collected blindly by the researchers 
involved in the trial, thereby minimising information bias in the trial and 
strengthening its internal validity. The primary outcome (NPI) was collected by the 
author at baseline and by a different blinded researcher at 6 and 12 weeks. Inter-
rater reliability was maximised through continuous training between both 
researchers and the PI. Although, individual differences could have affected 
scoring this would have happened equally for both intervention arms. Therefore it 
is not considered as a threat to study’s internal validity.  The NPI is a self-reported 
measure and as such is prone to response bias. However, since no other 
outcomes indicated being influenced by social desirable responses or their 
opposite, we do not think it is likely that possible biases would affect the two 
randomly allocated groups differently. 
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The choice of measurement methods was a trade-off between the available 
resources and feasibility. One of the trial’s design weaknesses was using self-
report in measuring exercise. Assessing exercise with minimum intrusion to study 
participants is challenging and we relied on participants’ self-reports through daily 
diaries. Self-report is prone to information bias, especially when participants are 
not blinded to their group allocation (Bauhoff, 2011). We gave considerable thought 
to the issue of measuring physical activity. It was decided not to use such objective 
measurement instruments to avoid excessive intrusion and facilitate recruitment.  
This approach was thought to prevent use of such instruments affecting exercise 
behaviour in their own right (see paragraph 6.2.3). 
Self-reports of exercise are criticized for over-estimating actual activity levels 
(Dyrstad et al., 2014).  However, self-reported measures seem to correctly predict 
both self-reported and measured functional ability 3-5 years later (Young et al., 
1995) and mortality in middle aged men 21 year later (Eaton et al., 1995). 
Another limitation of the study design is failing to assess individual levels of activity 
prior to entering the trial. We assumed that everyone started exercising (planned, 
structured, and repetitive action for the purpose of improving health) at baseline. 
However, some participants were already physically active even though 
conceivably their activities may have not been strictly ‘planned, structured, or 
repetitive actions for the purpose of improving health’, while many others led 
sedentary lives. Although, we do not think that individual differences would have 
affected study arms differentially, it would have been useful to know if participants 
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in each group increased, maintained or decreased their physical activity after they 
joined the trial. 
6.2.3 Intervention 
We attempted to develop an individually tailored, pragmatic exercise regimen 
which did not require intense specialist training or equipment and was home rather 
than gym based (Cress et al., 2004; King et al., 1998).  
A walking regime was decided upon, as it seemed more likely to be acceptable, 
applicable to a wider population and sustainable by our target population (Piercy et 
al., 2008). Walking does not require specific use of equipment, can be done almost 
anywhere and at any time at no extra financial cost. All these factors are crucial 
according to the Reduced Stress Threshold model of BPSD (Cohen-Mansfield, 
2000) as they lower the environmental demands people with dementia face.  By 
applying an intervention that is feasible, acceptable, sustainable, enjoyable and low 
cost we strived to lower the burden of engaging in exercise which, according to 
theories of behaviour change and current knowledge, is the main barrier to 
exercising (Schutzer and Graves, 2004).    
The intervention was designed to be delivered in individuals’ homes in order to 
maximise safety and to ensure that individuals exercised within familiar and 
comfortable surroundings. The home environment can enhance adherence to 
exercise interventions as it also reduces the time and financial commitment that 
participants would incur were they required to travel to an exercise facility (Chao et 
al., 2000). Furthermore, the home environment was considered as advantageous 
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in regards to exercise sustainability after the withdrawal of support from the 
exercise therapist. This decision is supported by the Environmental Vulnerability 
model (Cohen-Mansfield, 2000), which asserts that increasing the level of 
competence of people with dementia reduces their likelihood of being disturbed by 
the environment.  
We endeavoured to control for the impact of therapist contact. Phasing out the 
effect of psychosocial contact (from the exercise therapist) from the exercise 
intervention appeared to allow a relatively successful control for contact between 
participants and the exercise therapist. Results were consistent across both time 
periods. However, withdrawing the exercise therapist six weeks after the 
intervention started may have been premature and may have had a negative effect 
on participants’ compliance with the intervention and/or the trial. All theories of 
behaviour change and psychological theories of BPSD emphasise the importance 
of support and perceptions of self-efficacy when engaging in new behaviours, such 
as exercise, which are particularly difficult to maintain without ongoing support and 
encouragement (van der Bij, 2002). Perhaps separating social support from 
exercising interventions is not prudent and by endeavouring to do so we affected 
compliance with the intervention. As a result, the statistical power to detect a true 
difference in BPSD scores may have been reduced.     
6.2.4 Fidelity to the intervention 
Tailoring the intervention to the individual(s) is vital to maximising compliance, 
however, measuring the fidelity of tailored interventions is a major challenge. 
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Fidelity means that the intervention is carried out as planned and delivered 
comparably to all study participants (Horner et al., 2006). However this process 
becomes very complex when the intervention is not standard but tailored to 
individuals or in our case, dyads. Although the facilitation of the intervention by a 
single exercise therapist increases internal validity the fact that the intervention 
itself was tailored to each participating dyad makes it difficult to compare between 
participants. The fidelity of the EVIDEM-E intervention was affected because 
interventions consisted of multiple sessions, were delivered to heterogeneous 
groups (Kerns and Prinz, 2002), and the location of the intervention delivery varied 
(Soldano and Markell, 1997). While the exercise therapist had guidance on the 
components that could be modified in tailoring and the extent of those 
modifications, guidelines on when and how to record such modifications was 
lacking. Standard operating procedures for intervention delivery would have helped 
to set controls and tolerance levels. They could also have aided monitoring and 
limitation of intervention variability (Horner et al., 2006).  
6.2.5 Blinding 
The single-blind design of EVIDEM-E had the inherent and unavoidable risk of 
affecting control participants exercise behaviour and self-reporting of all 
participants. Additionally, there was also a risk that participants would divulge 
information about the group allocation to the researcher. We attempted to reduce 
this risk through the inclusion of a second, independent, researcher who blindly 
collected primary outcome data (NPI) at 6 and 12 weeks.  
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6.2.6 Analysis 
Analysis was carried out blindly strengthening the study’s internal validity. An 
analysis plan was devised with the assistance of a statistician prior to the analysis 
to avoid biases and ‘data phishing’. Intention to treat analysis provides unbiased 
comparisons among intervention groups and avoids the effects of non-random 
attrition.   
6.3 Future directions of research 
The Evidem-E trial found that our intervention of walking did not have an effect on 
BPSD symptoms. This contradicts the meta-analysis reported by Heyn et al. 
(2004). Our finding may be related to the poor adherence to the full exercise 
regimen, premature withdrawal of the exercise therapist and/or the duration of the 
programme. Heyn et al. (2004) reported that the mean duration of exercise 
interventions that reached a large effect size was 14.5 weeks and a medium effect 
size was 23.4 weeks. Longer follow up periods and methods for increasing 
adherence might result in a significant effect, and this warrants further 
investigation. 
Given that less than half the intervention group achieved the prescribed exercise 
frequency and intensity targets, further studies attempting to increase uptake are 
warranted, as are longer studies to measure the effects of reduced carer burden.    
It may seem counter-intuitive that declining carer burden was attenuated in the 
treatment group given the absence of effect for BPSD. However, considering that 
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carers co-participated in exercise activity, we may hypothesize that their burden 
was improved as a direct consequence of their engagement in exercise (Orgeta 
and Miranda-Castillo, 2014). Feelings of mastery (or lack of in the control group), 
because of an anticipated positive effect of the intervention is another possible 
explanation; this could have methodological implications for the design of future 
research and should be explored along with other potential mechanisms and long-
term effects. This will also be important for optimising this intervention and the 
development of other interventions. This finding is potentially important because 
improved physical and emotional conditions of carers contribute to patients’ 
wellbeing and quality of life (Neil and Bowie, 2008). Carer burden mediates 
decisions to relocate the person with dementia to a care home (Dunkin and 
Anderson-Hanley, 1998), and is associated with greater use of services (Miller et 
al., 2010); consequently, it may provide a useful proxy measure of both a longer-
term outcome and future service use. Furthermore, carers’ effective coping styles 
can increase survival for people with dementia (McClendon et al., 2004), whereas, 
carers’ burden is reported to be an independent risk factor for carers’ mortality 
(Schulz and Beach, 1999). 
Participants’ exercise behaviour was measured through feedback from self-
reported diaries. It was not possible for the research team to control the quality and 
quantity of data entry. Future studies measuring exercise should, if feasible, 
employ objective measurement(s) of participants’ exercise behaviour such as 
pedometers, GPS watches, accelerometers, calorimetry.  
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In conclusion if I were to carry out the same study again I would consider the 
following: 
 Conduct a larger, multicentre trial to increase the study power and its 
generalizability.  
 Apply longer intervention and follow up periods (12-24 months). 
 Consider employing narrower inclusion/exclusion criteria by excluding 
participants who are not likely to comply (e.g. participants with severe 
dementia and older carers), to minimise attrition and maximise compliance.  
 Assess the stage of behaviour change for all participants in accordance with 
the trans-theoretical model using validated measures e.g. ‘Exercise: Stages of 
Change’ (Marcus et al., 1992).  
 Record pre-trial activity level and lifelong activity habits (CHAMPS Physical 
Activity Questionnaire for Older Adults may be an option). 
 Assess participants’ preferences about arm allocation, which may potentially 
bias the findings (McCambridge, Sorhaindo, et al., 2014). 
 Use objective measures of physical activity such as pedometers, actigraphs 
etc., as well as standardised questionnaires such as CHAMPS Physical 
Activity Questionnaire for Older Adults (Stewart et al., 2001), which is  a widely 
used reliable and validated measure for older adults and is grounded on social 
cognitive theories, principles of self-efficacy and readiness to change, as well 
as motivational techniques (Harada et al., 2001). 
 Include several exercise therapists to the trial to increase external validity. 
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 Withdraw the exercise therapist at a later period, after dyads had become 
confident enough to sustain intervention independently (as measured by 
specific outcomes).   
 Establish fidelity monitoring for the exercise therapists. Train therapists in 
treatment delivery and also in the process of tailoring the intervention. Design 
clear Standard Operating Procedures identifying the extent to which 
modifications can be made and when and how to record such modifications.  
 Tailoring should take into account the particular stage of behaviour change 
(readiness to change) of each dyad (Treasure, 2004).    
 Exercise therapists to carry out the exercise programme alongside the dyad to 
increase compliance and to improve reliability in physical activity reporting.   
 Measure the level of unmet needs through reliable and validated 
questionnaires such as Camberwell Assessment of Need for the Elderly 
(CANE) (Reynolds, 2000). 
 Carry out qualitative interviews with participants and exercise therapists to 
explore feasibility, benefits, disadvantages, barriers and compliance issues.  
 Consider offering the intervention to control arm participants at the end of the 
trial to improve recruitment rate, increase compliance and minimise response 
bias that may arise as consequence of being allocated into the control arm 
(Skingley et al., 2014). This approach would however bring about added costs 
and resources considering the extended engagement of the exercise 
therapists.  
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7 CONCLUSIONS 
Previous studies have reported that exercise is beneficial in reducing some 
behavioural and psychological symptoms of dementia (BPSD), especially 
depressed mood and agitation and may also improve sleep and reduce 
‘wandering’. However, research evaluating the efficacy of exercise as a therapeutic 
tool for other important symptoms such as anxiety, apathy and repetitive 
behaviours is limited (Thuné-Boyle et al., 2012).  
The EVIDEM-E trial evaluated the effectiveness of a walking intervention as 
treatment for BPSD. Although overall BPSD were lower at week 12 in the group 
that received the exercise in comparison to the TAU group, this difference was not 
statistically significant. There are several possible explanations for this: first, our 
exercise intervention is not a clinically effective therapeutic intervention for BPSD; 
second, the intervention has not had sufficient intensity and/or duration to have an 
impact on BPSD symptoms; third, the findings were biased by non-compliance in 
the intervention group and increased physical activity in the control group; fourth, 
the effect size was smaller than anticipated. 
Our seemingly simple intervention of dyadic walking involves complex mechanisms 
and intricate consequences, which seem to support the main multifaceted 
psychological theories of BPSD such as The Environmental Vulnerability model 
and the Unmet Needs model.  
Regular simple dyadic walking does not appear to be effective for reducing 
behavioural and psychological symptoms of dementia, although, it does appear to 
 234  
 
help reduce carer burden. Given the absence of impact on behavioural and 
psychological symptoms, it is unclear why carers from the control group reported 
having a significant worsening of burden in comparison to those in receipt of the 
intervention. The increase may have been due to worsening burden because of 
BPSD, differential physical burden between the two groups (there was a slightly 
higher, statistically not significant, number of physical conditions in the control 
group at baseline) or unhappiness amongst carers about not being randomised to 
the intervention. Conversely participation in exercise in the intervention group may 
have attenuated the perception of burden directly or by enhancing carers’ physical 
health or self-efficacy.  
This study has shown that an acceptable exercise intervention for people with 
dementia can be developed and tested. However, future interventions need to 
make sure the intervention(s) can be sustainable and objectively measured. 
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1Study Design and Ethics  
 
 
Re. ‘EVIDEM-E: A randomised controlled evaluation of exercise therapy and 
its impact on behaviour, sleep and quality of life’ 
 
Dear Sir/Madam 
 
Please take time to read the following information carefully. 
 
What is the purpose of the study? 
Dementia can cause many problems including difficulties with memory and 
thinking, and more commonly occurs in older people. Dementia can also cause 
changes in personality, mood and behavior and these are called Behavioural and 
Psychological Symptoms of Dementia (BPSD).  This last group of symptoms 
can be very distressing for those who experience them as well as their families and 
carers. We recognize that managing these symptoms can have a very important 
role to play in everyday life.  
 
Behavioural and Psychological Symptoms of Dementia can be treated with 
drugs in the short term, but in the longer term it is important to make use of other 
treatment and management strategies.  One possible way, might be regular 
exercise and some previous research has shown that this might be a useful way of 
treating BPSD.  In particular, exercise has been shown to help reduce symptoms of 
depression and aggression.  These studies have often involved complicated 
exercise routines and have not looked at the impact on some important aspects of 
everyday life.  Therefore, we have proposed a study that will test whether going 
for regular walks can improve sleep, behaviour and your life in general. We will 
also be looking at the impact on medication use and quality of life for both the 
individuals with dementia and their carers.  
1.1 Participant and Carer Information 
Sheet 
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Why have I been chosen? 
You have been identified as a person with dementia or a carer of someone with 
dementia, who might like to take part in the study. We hope to speak to about 146 
people in a similar situation to you.  
 
Do I have to take part? 
No, it is entirely up to you whether you decide to take part or not. If you do decide 
to take part you will be given this information sheet to keep. If you would prefer not 
to take part, the way you access services will not be affected in any way. Once you 
have agreed to participate, you will still be able to withdraw at any time you like and 
you do not have to give a reason. If you decide to withdraw we will not gather any 
more information from you, but will make use of the confidential information you 
have given us up to the time of your withdrawal.  
 
What will happen to me if I take part? 
If you agree, we would put you into one of two groups. You would have an equal 
chance of being in either group and the research team can not choose who will be 
put into which group.  One group will carry on as normal with no change of 
treatment. The second group will get tailored exercise therapy which will involve an 
exercise therapist visiting you at home.  
 
If you are selected for visits by the exercise therapist, they will help you establish a 
programme of walking outside for you and your carer.  This will be at a pace and 
distance to suit both of you. The exercise therapist will visit you on five occasions:  
 
 three times during the first week;  
 once, six weeks into the study;  
 One final visit, 12 weeks into the study.  
 
For this therapy to work, we believe that you will need to go out for a walk at least 5 
times per week. Therefore, other than the five occasions that the exercise therapist 
 279  
 
visits, you will need to go out for walks as a pair.  During this time, you and your 
carer will be provided with a diary to record your exercise activities.   
 
In order to find out if the exercise therapy has made any difference; a member of 
our team will need to take you through a series of questions designed to be used in 
studies like this.  We will do this in person at your home, at a time convenient to 
you, no more than four times over one year from the start of the study; and by 
telephone no more than 3 times over one year from the start of the study.  Each 
visit should last no more than two hours and each call no longer than twenty 
minutes.  It is important that we ask you these questions whether the exercise 
therapist visits you or not.  Also, your participation on the trial is expected to last 
for 12-18 weeks.  
A few participants and their carers will be allocated to one further follow-up, where 
they will be asked questions about their experiences of the trial. This interview will 
be audio-recorded. If you agree to participate in this you will be given a separate 
information sheet and asked to sign a new consent form.  
 
If at any time during the study you cannot continue with the exercise or the 
interviews, we can agree what will be best for you at that time. This could include 
taking a break, returning to the interview at a later date or withdrawing from the 
study. 
 
What are the possible disadvantages and risks of taking part?  
We are aware that some people might be at risk of falling and/or have other 
physical health problems. Therefore, a research worker will meet with you and your 
carer to assess possible risks before including you in the study. If we or your GP 
believe that you might be at risk of falling, you will not be able to be involved in the 
study.  
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The exercise therapist will assess your road sense and undertake location risk 
assessment (e.g. traffic density, kerb height, excessive noise), as well as the ability 
of your carer to support you.   
 
What are the possible benefits of taking part? 
Your participation in this study will help furthering our understanding of non-
medical treatments for behavioral and psychological symptoms of dementia. Your 
support will help us improve the care people with dementia receive. You and you 
carer may benefit from walking exercises if drawn in the intervention group of this 
trial.  Your help will be appreciated. 
 
Will what I say in this study be kept confidential?  
All information collected about you and your carer will be kept strictly confidential. 
Any information about our visits and your answers will be anonymous and a code 
will be used rather than your name. This information will be stored securely on a 
computer at Central and North West London NHS Foundation Trust and only 
members of the EVIDEM-E research team will have access to this. However, if we 
feel your health may be in danger, we may have to report your results to your GP.  
 
What will happen to the results of the research study? 
The trial will be published in a peer-reviewed medical journal. Abstracts will be 
submitted to relevant conferences to inform other researchers of the work. We’d be 
happy to provide you with a copy of the published research, should you wish to 
have one.  
 
Who is organising and funding the research? 
EVIDEM-E is part of a broader programme of research called ‘Evidenced Based 
Interventions for Dementia’ which is funded by The National Institute for Health 
Research’s Programme: grant for applied research scheme.  The grant code is RP-
PG-0606-1005.  
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Contact for Further Information 
If you would like further information, please do not hesitate to contact: 
 
 
Arlinda Cerga-Pashoja    Dr David Lowery 
Research Worker     Project Manager 
Tel: 020 3214 5886               Tel: 020 3214 5889 
acerga-pashoja@nhs.net               d.lowery@ucl.ac.uk 
 
Address: CNWL NHS Foundation Trust, Greater London House, Hampstead Rd, 
London, NW1 7QY. 
 
You can also visit our website: www.evidem.org.uk  
 
Thank you for taking time to read this information sheet! 
 
Yours sincerely 
 
 
Dr James Warner 
Consultant Old Age Psychiatrist 
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 [Date]  
Dear Dr [name] 
Re: [Patient Name Surname] 
 
Following our letter dated [date], regarding your patient’s possible involvement in our 
study, we are writing to confirm that [patient’s name] is eligible to participate in the study 
and has consented to become involved. We are forwarding you a copy of the signed 
consent sheet for your record.  
As we have previously informed you, your patient will be involved in the study for a 
maximum of 26 weeks. He/she will be allocated into one of two groups: treatment as usual 
or exercise therapy. If [patient’s name]  is allocated into the intervention group he/she 
and his/her carer (he/she and the person he/she cares for) will meet with an exercise 
therapist on five occasions and go out on planned daily walks for 12 weeks. 
 We’d appreciate it if you could inform us of any changes in [patient’s 
name]’s health, medication or treatment that may affect his/her 
participation in the study.  
 We’d also kindly ask you to inform us of any Adverse Events 
(AE) or Serious Adverse Events (SAE) that may happen to 
[patient’s name]  that we might not be aware of.  
An adverse event is any unfavourable and unintended sign, symptom, 
syndrome or illness that develops or worsens during the period of 
observation in the trial.  
 An AE does include a / an: 
 Exacerbation of a pre-existing illness. 
 Increase in frequency or intensity of a pre-existing episodic event or 
condition. 
 
 
  
  
  
  
  
  
  
  
  
EVIDEM-
E 
Evidem-E Study Team 
Central and North West London NHS Foundation Trust 
Stephenson House, 75 Hampstead Road, London NW1 
2PL 
Tel: +44 (020) 3214 5886 email: acerga-pashoja@nhs.net 
 
1.2 GP Letter 
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  Condition detected or diagnosed after intervention even though it 
may have been present prior to the start of the trial. 
 Continuous persistent disease or symptoms present at baseline that 
worsen following the start of the trial. 
 An AE does not include a / an: 
 Medical or surgical procedure (e.g., surgery, endoscopy, tooth 
extraction, transfusion); but the condition that lead to the procedure is 
an AE. 
  Pre-existing disease or conditions present or detected at the start of 
the trial that did not worsen. 
 Situations where an untoward medical occurrence has not occurred 
(e.g., hospitalisations for cosmetic elective surgery, social and / or 
convenience admissions). 
A Serious Adverse Event (SAE) is any adverse event occurring following 
study mandated procedures, having received exercise intervention or usual 
treatment that results in any of the following outcomes: 
1. Death 
2. A life-threatening adverse event 
3. Inpatient hospitalisation for non elective procedures 
4. Sudden or rapidly progressive major disablement  
5. An event that caused the participant to seek non-routine medical treatment. 
I am attaching an Incident Reporting Form to report any AEs and a Serious Adverse Event 
Reporting Form to report any SAEs. Should an AE or SAE occur, could you please 
return the corresponding form in an envelope marked AE or SAE to: 
Dr David Lowery 
Project Manager 
Tel: 020 3214 5889 
d.lowery@ucl.ac.uk 
Address: Medical Directorate, CNWL NHS Foundation Trust, Greater London House, Hampstead 
Rd, London, NW1 7QY. 
Yours sincerely 
 
Dr James Warner 
Consultant Old Age Psychiatrist 
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Participant Identification Number:      
Version: 1.1 April 2009 
Title of Project: Randomized control evaluation of exercise on individuals    with 
dementia and their carers 
Principal Investigator: Dr James Warner, CNWL NHS Foundation Trust 
______________________________________________________________ 
 Please initial box to indicate agreement 
 
1. I confirm that I have read and understand the information sheet dated 
March 2009 for the above study.  I have had the opportunity to 
consider the information, ask questions and have these answered 
satisfactorily. 
 
2. I understand that my participation is voluntary and that I am free to 
withdraw at any time, without giving any reason, without my medical 
care or legal rights being affected. 
3. I understand that my participation in the above study will not affect the 
    standard of care I receive. 
4. I agree to my GP being informed of my participation in the above study. 
 
5. I agree to take part in the above study. 
 
6. I agree to be approached at a later date to take part in a tape-recorded 
 interview about participation in this trial. 
 
__________________         _____________    _______________________ 
Name of Participant          Date     Signature 
      
Researcher    Date   Signature 
 
 Participants’ Copy 
 Researchers’ Copy 
 GP’s Copy 
1.3 Participant Consent Form 
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Participant Identification Number:        
Version:1.1  April 2009 
Title of Project: Randomized control evaluation of exercise on individuals    with 
dementia and their carers. 
Principal Investigator: Dr James Warner, CNWL NHS Foundation Trust 
__________________________________________________________________ 
Please initial box to indicate agreement 
 
1. I confirm that I have read and understand the information sheet 
dated March 2009 for the above study and have had the 
opportunity to ask questions. 
2.  I understand that my participation is voluntary and that I am free 
to withdraw at any time, without giving any reason, without my 
medical care or legal rights being affected. 
 
3. I understand that my participation in the above study will not 
affect the standard of care I receive. 
 
4. I agree to my GP being informed of my participation in the 
above study. 
 
5. I agree to take part in the above study. 
 
6. I agree to be approached at a later date to take part in a  
tape-recorded interview about participation in this trial. 
 
      
Name of participant   Date   Signature  
      
Researcher    Date   Signature 
 Participant’s Copy   Researcher’s Copy   
1.4 Participant-Carer Consent Form 
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Participant Identification Number:        
Version: 1.1  April 2009 
Title of Project: Randomized control evaluation of exercise on individuals with 
dementia and their carers 
Principal Investigator: Dr James Warner, CNWL NHS Foundation Trust 
__________________________________________________________ 
My carer knows about EVIDEM-E study and wants me to be in the study if I want 
to.  I do want to be in the study, but I know that I can stop being in the study any 
time I want to.  I know that the research worker can talk about the study with my 
carer, but will not talk about it with anyone else who is not working on the study 
unless I and my carer say it is OK.  I can call the research worker any time I have 
any questions. 
 
I was present when _____________________________________ read this form 
and gave his/her verbal assent. 
 
Please initial box to indicate agreement 
  I have solicited the assent of the participant. 
____________________      ____________________ ____________________ 
Name of Researcher   Date    Signature  
 
Consent of Carer: 
__________________________________________________________________ 
Please initial box to indicate agreement 
  I agree with the manner in which assent was solicited and given by the 
participant.  
  Although the participant could not give his/her consent, I agree to have 
him/her participate in the study.  
 
  I will be given a signed copy of this Assent Form. 
____________________       ___________________ ____________________ 
Name of Consultee   Date    Signature  
 
Relationship to Participant  ________________________ 
 
 Participant’s Copy       Researcher’s Copy      GP’s Copy 
 
1.5 Assent Form 
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It is important to establish whether the potential participant and their carer have 
the capacity to provide informed consent at each interview. It is vital that the carer 
can provide informed consent. If the potential participant does not have the 
capacity to provide informed consent, they must still provide their assent (agree to 
participate) alongside the informed consent of their carer. 
Assessment of capacity is based on Current case law applicable in England. To 
determine whether the individual is capable of providing informed consent, it is 
important to test whether pertinent information about the trial and the alternative 
(i.e. no trial) can be understood; if it can be retained for a sufficient amount of 
time to weigh in the balance and reach a decision about participation; and that 
the person can communicate their decision to participate free from coercion. The 
process for doing this is as follows: 
 
1. Understanding the trial. As well as providing written information 
sheets, the main points of the trial and the alternative (i.e. no trial) 
should be provided (and discussed) verbally in a way the potential 
participant can understand. These points are: 
a. Dementia causes problems with memory and thinking as well as 
changes in mood and behaviour. 
b. Problems with mood and behaviour are usually treated with 
drugs, which can sometimes have a negative impact on the 
person taking them. 
c. There is some evidence that exercising may be a safe, 
alternative treatment to behavioural and psychological 
symptoms of dementia. 
d. Walking is a safe way of exercising.  
e. Participants will be randomly allocated into two groups: to 
receive either Exercise Therapy or care as usual for 12 weeks. 
There is an equal chance (50:50) of receiving either of these 
1.6 Consenting Protocol-Standard Operating Procedures 
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two allocations. This is because we do not know for sure 
whether Exercise works. 
f. A few participants and their carers will be allocated to one 
further follow-up, where they will be asked questions about 
their experiences of the trial. This interview will be audio-
recorded. 
g. A final telephone contact will occur at week 26, where all 
participants from the Exercise-Therapy group will be asked a 
few questions about their current activity levels.    
h. Participation is for 12-26 weeks but participants can withdraw 
at any time without having to give a reason. 
i. Participants at risk of falling or who have other physical health 
problems that may unable them to carry out a walking 
programme will not be included in the study. 
j. An exercise therapist will visit participants at home and 
establish a programme of walking outside for the participant-
carer dyad.  
k. The walking programme will be at a pace and distance to suit 
both the participant and his/her carer.  
l. The exercise therapist will visit participants on five occasions. 
Each visit will last approximately 1-2 hours and will take place 
in the home of either the participant or their carer. 
m. A research worker will visit participants on three or four 
occasions.  At each visit, we will complete various 
questionnaires. 
n. All information held about them will be strictly confidential and 
it will not be possible to identify them from published project 
data.  
o. They do not have to take part and if they don’t, the medical 
care they receive will in no way be altered. They can withdraw 
at any time. 
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2. Retain and weigh in the balance of the information. The length of 
time they need to retain this information for depends on the 
individual. If they are happy to give a decision immediately, then they 
only need to retain the information for that amount of time. Similarly if 
they ask to think about it and say that they will decide the next day, 
then they need to retain the information until the next day. The best 
way to test belief and retention of information is to ask the participant 
to repeat back the relevant information. 
 
3. Communicate a decision free from coercion. The individual needs 
to communicate their decision on participation without any pressure 
from the carer (if applicable) or the researcher attempting to obtain 
informed consent. 
 
Once this procedure is followed, the researcher can then assess whether they feel 
that the individual has the capacity to give informed consent. If it is decided that 
they are not so capable, then the potential participant may be able to participate 
but still needs to give their assent to the study (confirmation that they are happy to 
participate in the absence of full capacity). Therefore, an Assent Form will be 
completed. Three copies of the assent form are then made: one to go to the 
participant’s GP; one to go to the carer; one to be kept at the study centre. 
 
Participants with established capacity to consent will complete Participant’s 
Consent Form. One copy of the form will go to the participant’s GP; one to the 
participant and one to be kept at the study centre. 
 
The carer will complete a Participant-Carer Consent Form, at all occasions. One 
copy will be kept by the carer and one will be kept at the study centre. 
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Classification of event 
All adverse events will be classified by the Principal Investigator as either: 
 Adverse Event (AE): any unfavourable and unintended sign, 
symptom or disease temporarily associated with the use of an 
investigational product, whether or not considered related to the 
investigational product. 
 Serious Adverse Event (SAE): an AE that results in death; or is life 
threatening; or required in-participant hospitalisation; or results in 
persistent or significant disability or incapacity;  
 
Classification of intensity 
Regardless of the classification of adverse events as serious/non-serious, the 
maximal intensity of the event is to be evaluated by the responsible clinician, after 
consultation with the participant, carer and participant’s GP: 
mild: no impairment of normal daily activities; 
moderate: impairment of normal daily activities; 
severe: unable to perform normal daily activities. 
 
Classification of causal relationship 
Each adverse event (AE) must be classified on the basis of the available data with 
regard to the presumed causal relationship to one of the following categories:  
 
1 = probable 
Rational relationship to the time of intake of the investigational medication 
AE is already known to be a side effect of the investigational medication or may be 
expected 
Regression or disappearance of the AE after discontinuation of investigational 
medication or dose reduction 
Reappearance of the AE after repeated exposure 
1.7 Standard Operating Procedure for Monitoring of Adverse Events 
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AE cannot be explained in a reasonable manner by the clinical state of the 
participant 
 
2 =  possible 
Rational relationship to the time of intake of the investigational medication 
AE is already known as a side effect of the investigational medication or may be 
expected  
AE could be explained by numerous other factors 
 
3 =  improbable 
Rational relationship to the time of intake of the investigational medication 
AE has not been reported so far as a side effect of the investigational medication 
or cannot be expected 
AE persists after discontinuation of the investigational medication or dose reduction 
Repeated exposure does not lead to reappearance of the AE 
AE could be explained by numerous other factors. 
 
4 = no relationship 
No rational relationship to the time of intake of the investigational medication 
AE is evidently caused by other factors, e.g. symptom of a concomitant disease. 
 
5 = unable to evaluate 
Amount and content of data do not permit a judgement of the relationship to the 
 investigational medication. 
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Name : 
 
 
Date of Incident : 
 
Member of Staff Incident reported 
to : 
Details of the Incident 
 
 
Action Taken 
 
 
Witness Name and Role in Trial 
 
 
 
Outcome 
 
 
 
 Name of Member of Staff 
…………………………. 
 
Witness Signature 
……………………………….. 
 
Signed 
……………………………………………... 
 
Dated 
………………………………………
……… 
1.8 Adverse Event Reporting Form 
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Patient ID: _ _ _    Patient Initials: _ _ _ 
 
Patient Date of Birth: _ _/_ _/_ _  Allocation Group: 
Intervention/Control 
Date form completed: _ _/_ _/_ _ 
 
Death (any cause):        Yes  No 
Description: ___________________________________________________ 
Date of occurrence _ _/_ _/_ _      
 
Hospital Admission:       Yes  No  
Description: ____________________________________________________
  
 ____________________________________________________  
Was the admission as a result of a fall?    Yes  No 
 
Injurious fall without Admission:     Yes  No  
Description: ____________________________________________________
    Fall During the exercise sessions: 
Did a fall or medical event occur during an actual exercise session, requiring 
medical attention?        Yes  No 
 
Form completed by: 
______________ (Print name)  Date_ _/_ _/_     _____________ (Signature) 
Form reviewed by 
______________ (Print name) Date_ _/_ _/_ _   _____________ (Signature) 
 
For Principal Investigator 
Is this event an SAE relating to patient safety in the trial? 
  Yes – inform TSC, convene meeting to discuss trial safety  
  No – no further action required 
Signed by Chair of TSC      Date 
1.9 Serious Adverse Event Reporting Form 
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1.10 Risk Management Pathway  
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Research participant, 
carer or GP reports 
falls or other adverse 
events to Research 
Team. 
Research participant or 
carer experiences falls 
or other adverse event 
during exercise 
therapist visit.  
Exercise therapist 
takes immediate 
remedial action 
Inform GP Complete incident or falls report 
form, pass to Trial Manager / or PI  
Trial Manager /or PI reviews and 
classifies event, taking medical 
advice if needed 
Serious Adverse Event 
(Injurious fall, hospital 
admission, disablement, 
death etc) 
 
Adverse 
Event 
Complete SAE report, and 
decide if linked to trial 
Update risk log 
Review participant’s status & make decision with him/her 
about continued participation 
Inform TSC 
for review  
Yes 
No 
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9.1 1.11 Intervention Diary 
Monday 
Date 
Did you go out for a walk today? 
Yes/No 
 
How many times? 
 
How long was each of your walks? (in minutes)              
  [e.g. walk1=10mins; walk2=20mins, etc] 
What RPE did you achieve? Rating of Perceived Exertion  (Please circle below) 
___6___7___8___9___10___11___12___13___14___15___16___17___18___19_______20___ 
                                         no exertion        very light     light    somewhat hard     hard      very hard    extremely hard   maximal exertion 
What did you enjoy about your walk/s? What did you NOT enjoy about walk/s? Did you complete the course set by the exercise therapist? 
Yes/No 
 
If you did NOT go out, why not? Please circle below  
Didn’t feel like it / Something stopped me (i.e. pain, agitation, weather conditions)/ Carer unavailable/ Other (please describe below) 
 
Tuesday 
Date 
Did you go out for a walk today? 
Yes/No 
 
How many times? 
 
How long was each of your walks? (in minutes)             
   [e.g. walk1=10mins; walk2=20mins, etc] 
What RPE did you achieve? Rating of Perceived Exertion  (Please circle below) 
___6___7___8___9___10___11___12___13___14___15___16___17___18___19_______20___ 
                                      no exertion        very light         light    somewhat hard    hard      very hard    extremely hard   maximal exertion 
What did you enjoy about your walk/s? What did you NOT enjoy about walk/s? Did you complete the course set by the 
exercise therapist? Yes/No 
If you did NOT go out, why not? Please circle below 
 Didn’t feel like it / Something stopped me (i.e. pain, agitation, weather conditions)/ Carer unavailable/ Other (please describe below) 
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Week 1                                                                                                                                   
 
Monday 
Date 
Did you go out for a walk today? 
Yes/No 
 
How many times? 
 
How long was each of your walks? (in minutes)              
  [e.g. walk1=10mins; walk2=20mins, etc] 
What did you enjoy about your walk/s? What did you NOT enjoy about walk/s? 
If you did NOT go out, why not? Please circle below  
Didn’t feel like it / Something stopped me (i.e. pain, agitation, weather conditions)/ Carer unavailable/ Other (please describe below) 
 
Tuesday 
Date 
Did you go out for a walk today? 
Yes/No 
 
How many times? 
 
How long was each of your walks? (in minutes)             
   [e.g. walk1=10mins; walk2=20mins, etc] 
What did you enjoy about your walk/s? What did you NOT enjoy about walk/s? 
If you did NOT go out, why not? Please circle below  
Didn’t feel like it / Something stopped me (i.e. pain, agitation, weather conditions)/ Carer unavailable/ Other (please describe below) 
 
1.12 Control Diary 
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 Exercise 
Therapist (ET) 
Research 
Worker (RW) 
Independent 
Researcher 1 
(IR1) 
Independent 
Researcher 2 (IR2) 
 Exercise group 
only 
All participants All participants All participants 
 
 
Baseline T -1 
 Screens for eligibility; 
Obtains consent; 
Outcomes assessed; 
Demographics and 
medication 
BP & HR at rest assessed 
  
   Randomisation  & 
mails diaries and 
phone contact to 
provide instruction 
about diary 
completion 
 
Week 1 
RPE, walk, 
support to 
complete diary 
   
RPE, walk, 
support to 
complete diary 
   
RPE, walk, 
support to 
complete diary 
   
Week 2 Telephone 
contact 
   
Week 4 Telephone 
contact 
   
Week 6 RPE, walk, 
support to 
complete diary 
Visits: Outcomes; 
Medication 
BP & HR at rest assessed 
Telephone to 
complete NPI, 
remind diary 
completion 
 
Week 12 RPE, walk, 
support to 
complete diary 
Visits: Outcomes; 
Medication 
BP & HR at rest assessed 
Telephone to 
complete NPI, 
remind diary 
completion 
 
Week 13  Collects sealed diaries   
Week 26  Telephone contact 
Change in domicile? 
Still exercising? 
Mortality assessment 
  
 
1.13 Assessment Schedule of Delineation of Responsibility 
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1.14 Recruitment diagram 
 
Clinical team administrator generates a list of ALL 
patients with dementia (insert code) 
Clinical team (care co-ordinator) check list against 
inclusion/exclusion criteria 
 
This process must be documented using the 
search record form 
Patient expresses an interest 
Notify study team that search is complete 
& 
 Attach completed Search Record Form  
A member of the study team will then compile 
Participant Information Packs containing: 
 Cover letter 
 patient information sheets 
 follow-up request forms  
 Stamped Addressed Envelopes (for patient 
follow-up requests). 
Inclusion criteria: People with a diagnosis or 
suspected diagnosis of dementia 
Exclusion criteria: People who do not speak 
English for whom an interpreter cannot be 
located. 
IMPORTANT: THE RESEARCH TEAM WILL ASSESS FOR 
ALL OTHER INCLUSION/EXCLUSION CRITERIA 
Study team will keep clinical team 
informed of their patient’s responses 
and participation in the trial 
1. The patient should receive the letter if they have 
capacity to give consent and if it will not cause 
confusion or distress 
2. Where the patient does not have capacity to 
give consent or the letter may cause confusion 
or distress please send the letter to the known 
carer (family member or friend). 
3. Where the patient lacks capacity and there is no 
known carer, can you identify any individual who 
is capable of giving consent on behalf of the 
patient? 
Study team screen:  
o Behavioural & psychological symptoms (NPI) 
o Presence of carer 
o Risk of falls 
If eligible, GP’s opinion sought 
Clinical team administrator consolidates into a final 
list of people to invite and includes the following 
information: 
o Name of patient,  
o address, 
o telephone number,  
o name of carer.(address & tel. no if different) 
acerga-pashoja@nhs.net  
or 
CNWL NHS Foundation Trust, 
Greater London House, 
Hampstead Rd, London, 
NW1 7QY. 
Clinical team (care co-ordinator) makes judgement 
on mental capacity 
Cover letters are signed by a member of the clinical 
team 
One of the following: 
o Clinical care co-ordinator 
o Consultant 
o Dr Rahul Bhattacharya on behalf of 
clinical care co-ordinator  
A member of the study team will post out the packs 
After 2 weeks, study team calls all 
non responders and invites them  
Enrolled in trial 
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JW James Warner; DL David Lowery; ITB Ingela Thune-Boyle; ACP Arlinda Cerga-Pashoja; JL James Lee; SI Steve Iliffe; RB Rahul Bhattacharya 
Pub Publication; Pre Presentation; Pos Poster; Pro Promotional materials; Sym Symposium; OR providing advice for others; Med Media; Ed Produced for educational 
assessment 
 
Theme/Purpose Audience Title/Description Lead Type Target When  
BPSD, consequences & 
Management 
Mixed: 
practitioners, 
public 
The Use of Anti-Psychotic Medications in People with Dementia JW Pre EVIDEM Summer 
School 
2008 
Methodology Researchers EVIDEM-E: A randomized controlled evaluation of a tailored exercise 
package for individuals with dementia and their carers. The impact on 
sleep, behaviour and quality of life   
DL Pos DeNDRoN Ann’ 
Conference, 
Newcastle  
2008 
BPSD, consequences & 
Management 
Commissioners  Behavioural and Psychological Symptoms of Dementia (BPSD): the 
personal and practical costs of dementia 
DL Pub Journal of Integrated 
Care Vol 17(2) 
2009 
Raising Awareness  Public Exercising your mind JW Pre Enfield over 50's 
Group 
2009 
Methodology Mixed: providers, 
public 
Symposium on Activities and Therapeutic Interventions. EVIDEM-E: A 
randomised controlled evaluation of a tailored exercise package for 
individuals with dementia and their carers. The impact on sleep, 
DL Pre The DSDC 3rd 
International 
Conference, York 
2009 
1.15 Output Strategy 
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behaviour and quality of life 
BPSD, consequences & 
Management 
Mixed: 
practitioners, 
public 
The motion: People in the terminal stages of dementia are wasting their 
families’ lives and the resources of the NHS, as opposer 
JW Pre Dementia Congress, 
Harrogate,  
2009 
BPSD, consequences & 
Management 
Clinicians CNWL 
patch 
Behavioural & Psychological Symptoms of dementia and their 
management 
JW Pre EVIDEM Summer 
School 
2009 
BPSD, consequences & 
Management 
Mixed: 
researchers, 
practitioners 
Challenging Behaviour: Meaning and (Care) Management  DL Pre Making research 
Count, National 
Dementia Strategy 
Practice 
Perspectives: One 
year on – King’s 
College London 
Mar 
2010 
Methodology researchers Evaluation of Exercise on Individuals with Dementia and their Carers: A 
Randomized Controlled Trial 
ACP Pre PRIMENT Clinical 
Trials Unit Seminar 
2010 
Methodology researchers EVIDEM-E: A randomised controlled evaluation of exercise as a therapy 
for behavioural and psychological symptoms of dementia 
ACP Pub BMC Trials Volume 
11 (53) 
May 
2010 
Raising Awareness  Public Evidence based interventions in dementia: Opportunities to take part 
and change practice in dementia care in the community  
DL Pre Hillingdon Admiral 
Nurse Service Carers 
Jul 
2010 
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Information Day, 
Hillingdon Civic 
Centre 
Raising Awareness  Public The importance of Behavioural & Psychological Symptoms of Dementia 
&  a possible therapy: An invitation to participate in EVIDEM-E  
ACP Pre As Above Jul 
2010 
Raising Awareness Mixed: 
practitioners, 
participants 
Newsletter – Raise awareness and provide update on project progress ACP Pro Clinicians and 
participants – mailing 
list 
Biannu
al’  
Raising Awareness  Public Exercise & Dementia DL Pub Alzheimer’s Society 
Newsletter: Living 
with Dementia 
July 
2010 
Raising Awareness  Public Scientists assess whether exercise helps combat dementia DL Med BBC One Breakfast 
News + Radio 4 today 
programme 
April 
2011 
Methodology/ Capacity researchers WHELD NIHR Programme – Developing and testing a multi-component 
intervention for people with dementia in care homes. Expert Therapy 
Development Group 
DL OR Oxfordshire & 
Bunkinghamshire 
Mental Health NHS 
Foundation Trust and 
King’s College 
Oct 
2010 
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London 
Summarizing the 
literature 
Researchers & 
practitioners 
The effect of exercise on behavioral and psychological symptoms in 
dementia: Towards a research agenda 
ITB Pub International 
Psychogeriatrics 
2011 
Summarizing the 
literature 
practitioners Physical Activity: a tool for improving outcomes for people with 
dementia  
DL Pre Chartered Society of 
Physiotherapy 
Annual Congress 
2011 
Methodology Research 
network 
commissioners 
Developing a Dementia Registry: a descriptive case study from North 
Thames DeNDRoN and the EVIDEM Programme  
SI Pub BMC Medical 
Research 
Methodology 
2011 
Methodology Researchers Evaluation of Exercise on Individuals with Dementia and their Carers: A 
Randomized Controlled Trial – Presentation for Conversion to PhD 
ACP Ed Department of 
Primary Care & 
Population Sciences 
Feb 
2011 
Methodology Researchers, 
practitioners  
Clinicians as recruiters to dementia trials: lessons from the EVIDEM-E 
project 
DL Pub Letter to 
International Journal 
of Geriatric 
Psychiatry 
Apr 
2011 
Methodology researchers Methodological challenges of conducting research in the NHS ACP Pre Society for Academic 
Primary Care 
Regional 
Feb 
2011 
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Raising Awareness  Public ‘Taking a stroll beyond memory lane: can walking help with symptoms 
of dementia?’  
DL Pre Memory lane café – 
Alzheimer’s Society 
June 
2011 
Implementation Practitioners Managing Behavioural & psychological symptoms of dementia: training 
our colleagues to identify causes and consequences 
JW Pre EVIDEM/CNWL 
Training event 
2011 
Implementation Public, 
practitioners 
Providing People with Dementia and their Carers with Tools to improve 
their levels of Physical Activity 
DL/ 
JL 
Pre Dementia Care 
Congress -  
2011 
Implementation Public Invited to review and make recommendations for the Alzheimer’s 
Society UK factsheet on exercise and dementia 
ACP OR Alzheimer’s Society 
UK Website 
2011 
Methodology Researchers, 
practitioners 
Factors Affecting Clinician Engagement in Recruitment for Dementia 
Trials 
DL Sym Gerentological 
Society of America 
Annual Scientific 
Meeting, Boston 
Nov 
2011 
Raising Awareness  Public ‘Your say, your day’ RB/A
CP 
Pre Service Users forum 
in east London 
Nov 
2011 
Methodology/ Capacity Basic science 
undergraduate 
students 
The Role of Applied Health Research: experiences of implementing an 
intervention within a trial of exercise as a therapy for symptoms of 
dementia 
JL Ed University of 
Brighton  
2011 
Methodology/ 
Capacity 
Policy makers DeNDRoN helps shape government dementia research strategy – 
feature article in network magazine 
DL Pro National Institute for 
Health Research 
2011 
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Recruitment/ 
Methodology 
Researchers/ 
Practitioners 
The Acceptability of exercise as an intervention across ethnicities/ 
cultures 
RB  Cultural Psychiatry 
conference 
2011 
Raising Awareness Practitioners/ 
Participants/ 
Reasecrhers 
Evidem-E Newsletter  ACP/
DL 
 Evidem-E Dec 
2011 
Recruitment/ 
Methodology 
Providers/ 
Researchers 
News from the network  DL Pub NIHR Jan 
2012 
Outcome Researchers/ 
Practitioners 
Cross-cultural efficacy of exercise as an intervention for BPSD  RB   2012 
Methodology/ 
Research Capacity 
Academic  [insert Arlinda thesis title] Submission for examination for Doctorate of 
Philosophy 
ACP Ed University College 
London 
2012/1
3 
Outcome Researchers & 
practitioners 
EVIDEM-E: Exercise as a therapy for behavioural and psychological 
symptoms of dementia: a randomized control trial of clinical and cost 
effectiveness   
DL/ 
JW 
Pub International Journal 
of Geriatric 
Psychiatry 
2012 
Implementation practitioners Physical Activity: effects for people with dementia and their carers  DL Pre Chartered Society of 
Physiotherapy 
Annual Congress 
2013 
 
 305  
 
9.2 2.1 Evaluation of exercise on individuals with dementia and their carers: a 
randomised controlled trial 
 
2 Publication and Dissemination  
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9.3 2.2 Clinicians as recruiters to dementia trials: lessons from the 
EVIDEM-E project  
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9.4 2.4 Presentations 
Title Location and Date 
Evaluation of Exercise on Individuals and their carers: 
A randomised controlled trial. 
PRIMENT Clinical Trials Unit, 2010, UCL, 
UK. 
Evaluation of exercise on individuals with dementia 
and their carers: A randomised controlled trial. 
Presentation for conversion to PhD. 
Department of Primary Care and 
Population Health, 2011, UCL. UK. 
 
Methodological Challenges of conducting research in 
the NHS.  
Society for Academic Primary Care 
Regional Meeting, 2011. Cambridge. UK 
The importance of Behavioural & Psychological 
Symptoms of Dementia and a possible therapy: an 
invitation to participate in EVIDEM-E.  
Hillingdon Admiral Nurse Service Carers 
Information Day. Hillingdon Civic 
Centre, 2010, UK 
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9.7 2.7 Newsletter 3 
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3 Minutes of the Meetings  
9.9 3.1 Project Management Meetings 
 
3.1.1   27 March ‘09 
Attendees: A Cerga-Pashoja, R Bhattacharya, D Lowery, J Warner 
 
Aims, Scope & Membership of this Group 
 
The project management meeting will meet monthly to discuss and review:  
 Protocol 
 Recruitment process 
 Adverse events 
 Troubleshooting 
 Analysis 
 Audit (regular audit of data entry and security) 
 
It was agreed that longer time will be set aside during analysis stage for number 
crunching. Contingency meetings will be arranged every three months. 
 
Mark Griffin (statistician) and the exercise therapist will also be invited to attend 
project management meetings.  
 
Gantt Chart 
 
DL presented the Gantt Chart indicating the project has been progressing within 
arranged timeframes. Action: DL to update.  
 
Protocol – Final Thoughts Before Peer Review 
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Diaries were reviewed and suggestions from RB, DL and JW were incorporated. 
Each dyad will complete one common diary collaboratively instead of separate 
ones. Action: AP to finalize the diaries and send them to the steering group 
for review and piloting.   
 
Use of Pedometers was discussed and JW suggested both groups wear 
pedometers as a way of comparing between and within groups level of physical 
activity.   
 
Qualitative methods were discussed and it was agreed that qualitative interviews 
are deemed more appropriate than focus groups for this trial.  
Action: AP to finalize the protocol and send to JW for review.  
 
Ethical Application 
 
It was agreed that before submitting the Ethical application the protocol will be sent 
for peer review. JW suggested a few people that may conduct the peer review i.e. 
Craig Ritchie, Rob Howard and Roger Bullock.  
 
Action: DL to register EVIDEM-E with the Register of Clinical Trials.  
 
Dissemination, Outputs & Building Awareness 
a. DSDC abstract 
b. Expressions of Interest Flyer 
AOB & Dates of future meetings 
Recruitment of exercise therapist and funding for this purpose was discussed. 
Action: DL to follow up.  
 Project management meetings will happen on the first Tuesday of each month. 
Next meeting: 4th May 2009 at 9.30am at Fitzroy in Totenham Court Road.  
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3.1.2  04 May ‘09 
Attendees: A Cerga-Pashoja, R Bhattacharya, D Lowery, J Warner 
Minutes, progress and updates from last meeting (DL) 
 
 AP has finalized the diaries and sent them to the Steering Group for 
review and piloting.  
 
 The Demographic Questionnaire was reviewed in the meeting and it 
was agreed that version 1 will be used.  
 
 It was decided that pedometers will not be used but heart rate at rest 
will be measured instead.  
 
 DL has registered EVIDEM-E with the Register of Clinical Trials.  
 
Sponsoring 
 
Action: DL to obtain a letter from John Green stating that CNWL is 
sponsoring Evidem-E.  
 
Consent forms and access to medical records (AP) 
 
It was agreed that access to medical records will not be sought. Consent and 
assent forms were reviewed and updated.  
 
Economic Evaluation 
 
Economic evaluation and Client Service Receipt Inventory (CSRI) were discussed.  
 
Action: JW to contact Martin Knapp and clarify utilization of CSRI and 
economic evaluation.    
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Recruitment SOPs (AP) 
 
Recruitment SOP’s were discussed: it was agreed that recruitment will be made 
through: 
 DeNDRoN 
 Evidem Consortium (GPs) 
 Memory Clinics and CMHTs 
 
Action: AP to contact Tracy White (Information manager) and obtain mapping 
for older-people services in CNWL.  
 
Action: DL to contact Tania Burke from DeNDRoN and ascertain what help 
will DeNDRoN offer us regarding recruitment.  
 
Training and inter-rater reliability (DL) 
 
Action: AP to arrange TUSS training. NPI inter-rater reliability to be arranged.  
 
Kath Lowery has agreed to help us with piloting the study measures.    
 
Randomization Generation 
 
Randomization was discussed and in particular who will carry out the procedure. It 
was agreed that: a researcher independent of the study team will carry out a 
computerized random-number generation. Action: DL to discuss with Gira Patel.  
 
Ethics Application (AP) 
 
Action: DL to send the final protocol to Maria Tsappsis from the R&D office 
and ask for an external review.  
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Action: AP to finalize the IRAS application, send it to JW and DL for review 
then send it for ethical approval.  
 
Gantt Chart 
 
DL presented the Gantt Chart indicating the project has been progressing within 
arranged timeframes. Action: DL to update.  
 
Exercise Therapist 
 
Recruitment of exercise therapist and funding for this purpose was discussed. 
Action: JW to send a contract sample to DL and DL to follow up.  
 
 
Next meeting: 7th July 2009, 9.30am, at Fitzroy in Totenham Court Road.  
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3.1.3  02 June ‘09 
Attendees: A Cerga-Pashoja, R Bhattacharya, D Lowery, J Warner, M Griffin 
Minutes, progress and updates from last meeting (DL) 
 
 AP has piloted the measures with a volunteer from GLH. The 
screening might take longer than two hours to be administered. 
Should we break the first contact in two sessions? 
 
 The Ethical Application was submitted to IRAS. The review meeting 
is set for 9th June 2009. JW to attend. DL and AP may attend as well. 
 
Sponsoring 
 
Action: Letter from John Green stating that CNWL is sponsoring Evidem-E 
has been obtained.  
 
Economic Evaluation 
Economic evaluation and Client Service Receipt Inventory (CSRI) were discussed.  
 
Action: JW to contact Martin Knapp and clarify utilization of CSRI and 
economic evaluation.    
 
Recruitment SOPs (AP) 
 
Action: AP contacted Tracy White (Information manager) and obtained 
mapping for older-people services in CNWL.  
 
Action: DL met with DeNDRoN representatives and discussed what help will 
DeNDRoN offer us regarding recruitment.  
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Data Analysis 
 
MG went over the data analysis section and confirmed that it is accurate and no 
changes are needed. Data encryption was discussed and was taken further 
through CNWL IT department. MG stated that as long as the databases are 
integrated it doesn’t matter which statistical package is used for data entering from 
AP.  
 
Training and inter-rater reliability (DL) 
 
Action: AP met with Jacqui Morris (Physiotherapist) and practiced TUSS 
procedures.  NPI inter-rater reliability to be arranged.  
 
Kath Lowery has agreed to help us with piloting the study measures. AP is meeting 
with Kath’s team to pilot the measures on 16/07/09.   
 
Randomization Generation 
 
Randomization was discussed and in particular who will carry out the procedure. It 
was agreed that: a researcher independent of the study team will carry out a 
computerized random-number generation. Action: DL to discuss with Gira Patel.  
 
Ethics Application (AP) 
Action: DL sent the final protocol to Maria Tsappsis from the R&D office and 
asked for an external review.  
 
Gantt Chart 
 
DL presented the Gantt Chart indicating the project has been progressing within 
arranged timeframes. Action: DL to update.  
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Exercise Therapist 
Recruitment of exercise therapist and funding for this purpose was discussed. 
Action: JW to send a contract sample to DL and DL to follow up.  
 
 
Next meeting: 4th August 2009, 9.30am, at Fitzroy in Totenham Court Road. 
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3.1.4   01 September ‘09 
Attendees: A Cerga-Pashoja, D Lowery, J Warner, J Lee (exercise therapist) 
 
 Progress and updates from last meeting  
 AP has piloted the measures with the IMPS Westminster Team. The 
length of the screening and baseline interviews seem problematic. 
The interview schedules were discussed and some of the possible 
solutions are: 
1. Drop the ZBI from the schedule. 
2. Carry out the NPI on the phone with the carer. 
3. Leave the GHQ (and CSRI?) with the carer for completion. 
Remind the carer to post them back (reminders: on the day 
and through telephone follow-ups).  
4. AP to observe JW when administering the NPI and MMSE with 
clients.  
5. JW to clarify with Martin Knapp the utilization of the CSRI 
(does it need to be competed at baseline or just at week 6; if 
so can it be left to be completed by the carer independently) 
 
 IRAS application and R&G 
 
 On 9th June 2009 JW, DL and AP attended the Ethical Application 
review meeting. A favourable decision was received on 14 August 
2009, after making some minor amendments to the protocol.   
 We are still waiting to hear from the Research Governance about the 
ethical clearance. We still have not had any feedback from the peer 
review, which was sent out in May. (Action: DL to follow up) 
 
 Recruitment 
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 AP has obtained the organizational charts for Westminster and K&C. 
 JW is attending a meeting with consultants in the trust where he will 
give a 10 minute talk about Evidem-E. JW recommended we make 
contact with consultants regarding recruitment. Action: JW to give 
contact details of trust Consultants to DL. 
 
 Recruitment of study personnel 
 James Lee, the exercise therapist, was welcomed to the team.  
Intervention phase was discussed. JL has CRB clearance and DL will 
add this to his contract. DL to finalise JL’s contract. JL to keep a 
written log, which will be countersigned by DL or JW. Action: DL to 
identify the independent researchers: IR1 and IR2.  
 
 Economic Evaluation 
 Action: JW to contact Martin Knapp and clarify utilization of CSRI and 
economic evaluation.    
 
 DSDC Conference and BMC paper 
 DL has prepared slides for the DSDC conference. DL and AP to 
attend the conference 14-16 September 2009.  
 DL and JW have made comments to the first draft of the BMC paper. 
Action: AP to make suggested amendments. 
 
 BPSD management strategies/Literature Review 
 
 Erkida Mehmetaj has volunteered to carry out the lit review. She is a 
psychology graduate who is currently carrying out an MSc in Health 
Psychology. Action: DL to follow up.  
 
Next meeting: 13 October 2009, 1.00pm, at Greater London House.  
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3.1.5  13 October ‘09 
Attendees: A Cerga-Pashoja, D Lowery, J Warner  
 
 Progress and updates from last meeting  
 
1. The ZBI will not be dropped from the schedule. 
2. AP to carry out the NPI (baseline) on the phone with the carer. 
3. AP to leave the CSRI with the carer for completion. Remind 
the carer to post them back (reminders: on the day and 
through telephone follow-ups).  
4. AP has observed JW when administering MMSE with a client. 
AP to arrange observing JW administering the NPI. 
5. JW has clarified with Martin Knapp the utilization of the CSRI. 
It needs to be competed at baseline and week 12.  
6. JW has attended a meeting with consultants in the trust (who 
will help us recruit for the trial), where he gave a 10 minute talk 
about Evidem-E.  
7. DL and AP attended the DSDC conference in York, 14-16 
September 2009. DL’s presentation on EVIDEM-E was very 
well received.  
8. DL and AP attended the CNWL’s Older Adults Conference and 
displayed Evidem banner, leaflets and newsletter.   
 
 IRAS application and R&G 
 
 DL was informed that we need to complete a couple of other forms 
for R&G approval. SSI and R&D Supplementary Registration Form to 
be completed and sent as soon as possible to the R&D department  
(Action: DL and AP to follow up) 
 
 Recruitment of study personnel 
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 Two researchers will be joining the Evidem-E team. Alex Bailey who 
is a trust teaching fellow at St Charls and Ingela Thune-Boyle, a 
research associate with UCL.  
 
 AP to update the signature log for the trial.  
 
 Study Manual 
 AP has compiled the master file for the trial and a draft study manual. JW to 
go over the master file and make any further suggestions. 
 
 JW to check with Rob what database was used in the Digger trial.   
 
 The team discussed on the pros and cons of collecting the data 
electronically and in paper form. It was agreed that the data will be collected 
in paper form then transferred in the electronic databases.  
 
Next meeting: 17 November 2009, 12.00pm, at Greater London House.  
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3.1.6   09 February ‘10 
Attendees: A Cerga-Pashoja, D Lowery, J Warner  
Apologies : Jose Trevino (DeNDrON) 
Recruitment 
We have recruited one person into the study. AP shared a table indicating the 
number of invitation packs sent to teams and to patients. There is a big 
discrepancy i.e. teams not sending packs to patients. JW suggested we follow up 
actively with teams and attend their meetings. 
 
 DL suggested we recruit through the PCRN. Action: DL to contact 
Lennis Lewis and enquire about obtaining R&D approvals from 
PCTs. 
 Recruitment to be discussed in the Steering Group meeting 
 JW suggested we write an article for ‘Living with Dementia’ 
magazine. Action: AP to contact Rachel Doeg enquiring if we can 
publish an article in Alzheimer’s Society journal Living with 
Dementia. 
Databases  
 
We have currently set up the databases in Microsoft Access. The forms in Access 
give the opportunity to record the data in a way that is similar to the hard copies, 
thereby reducing entry errors. Action: AP to meet with Mark Griffin to discuss 
databases.  
 
Files and documentation 
 
JW asked if the management team can gain access of a shared drive where all 
study documentation can be filed. Action:  AP to enquire with David 
Gulbrandsen about establishing a shared drive for Evidem-E management 
team. 
  346  
 
3.1.7   12 January ‘11 
 
EVIDEM-E
Exercise as a Therapy for Behavioural & Psychological 
Symptoms of Dementia
James Warner, Arlinda Cerga-Pashoja & David Lowery


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




EVIDEM
www.evidem.org.uk
NIHR: Programme Grant for Applied Research
Hosted by Central and North West London NHS Foundation Trust
Collaboration with University College London, King’s College London, St. George’s, University of London, Kingston University,
London School of Economic and Political Sciences and The University of Hertfordshire
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Original Target
Revised Target
Actual
Projected
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 WLMHT CNWL BEH 
(demreg) 
Self 
referrals 
Demreg 
Total 
Total 
Invited 324 
(178D/146C) 
303 24  202 651 
Recruited 33 
(31 D/2C) 
25 4 2 34 64 
Ineligible 10 
(6D/4C) 
18 2 2 8 32 
Declined 68 
(39D/14C) 
46 12 3 51 131 
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9.10 3.2 Steering Group Meetings 
3.2.1   23 February ‘09 
Central & North West London NHS Foundation Trust, Greater London 
House, Boardroom 
 
Attendees: Steve Iliffe (SI), James Lee (JL), Clare Leonard (CL), David 
Lowery (DL), Sue Ricketts (SR), Lyn Strother (LS), Fiona Waters (FW), Jane 
Wilcock (JW). 
Apologies: Rahul Bhattacharya (RB), Sandra Brookes (SB), Mark Griffin 
(MG), Craig Ritchie (CR), James Warner (JR). 
 Welcome & Introductions 
 DL welcomedand thanked attendees – Apologised for not 
sending out the agenda and re-iterated the purpose of the 
meeting 
 DL invited the group to introduce themselves 
 
 Previous Minutes 
 DL took the group through the minutes of the previous meeting 
point by point. – The group agreed that they were an accurate 
reflection of the discussion at the November meeting. 
 At point 2 DL reminded the group that we had all agreed that 
the SG would benefit from the inclusion of a person with 
dementia. – LS nominated a potential representative, described 
his background to the group and agreed he was to be invited. 
 
Action: LS to approach potential new member on behalf of SG 
  
Chair & Membership 
DL thanked the group for the input at the previous meeting and advised 
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that as a result the protocol had undergone significant development 
DL informed the group that a sub-group of the EVIDEM management 
team had held a one of meeting to discuss the protocol and provide 
some critical advice. Two key points had been raised in reference to the 
SG: 1) The Chair of the group should be independent and 2) The 
membership for the group should hold a majority that do not have a 
direct interest in the outcome of EVIDEM 
SI elaborated that the SG should have a responsibility for reporting if 
anything goes wrong and so it will be important that the Chair and the 
membership have an independent majority. SI further emphasised that it 
would be important that the chair have experience of leading formal 
meetings 
DL nominated CR as Chair and CL as Vice Chair – The group agreed 
that these were good nominations – CL agreed so long as adequate 
guidance of the role would be provided 
A count of the membership revealed that the ratio of independent 
member/non-independent members is 6/7 – JW offered to alter her role 
to non-participant observer, and DL reminded the group that should 
candidate identified by LS agree to join, the ratio would alter to 7/6. – 
The group agreed that this was satisfactory 
During this discussion SR also expressed that she had felt the outcome 
of the previous meeting had been negative as the group had provided a 
significant amount of criticism – DL reminded the group that this had 
been overwhelmingly constructive and as a consequence had led to 
some positive advancements in the protocol.  DL further emphasised 
that by opening the project to criticism at an early phase, the 
researchers would have an opportunity to tailor the design of the project 
to help avoid such criticisms at its conclusion. 
 
Action: DL to approach CR to ascertain his willingness to fulfil this 
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role 
 
Infrastructure – Appointments & Adoption 
DL informed the group that we have applied for adoption by the 
North Thames Dementia and Neurodegenerative Diseases 
Research Network and that this network would likely be able to 
support the project with recruitment of participants. 
DL informed the group that the trust had successfully appointed a 
research worker specifically for the project and gave the group details of 
the post and the successful candidate. 
 
Methodology - Revised Design & Protocol 
DL provided the group with a handout that included several figures and 
tables that summarize the proposed design. DL worked through the 
document asking for questions and comments 
CL advised that the FRAT is good but instructions for TUG are 
sometimes too complex even for those with mild cognitive impairment –  
Described the ‘180 turn’ as an alternative: 5-6 steps ok; 9 and above is 
indicative of someone who is at high risk of falling. CL can provide 
evidence 
Another alternative – ‘time steady stand test’ - Can the participant stand 
unaided for 1 minute? CL  
JL suggests that it will be important to know whether the participant will 
be able to perform the intervention or not – JL Described the 3 min ‘step 
test’ 
CL – Most of population recruiting from are on multiple meds, have 
cardio vascular problems and so would be ruled out by the FRAT 
FW – The home step test might be beyond the capabilities of potential 
participants on grounds of co-ordination 
SR – Everyone will have different ability, so should measures be 
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individualized- yes 
DL – reminded the group that at this point we were trying to determine 
whether to exclude someone as a person who is of high risk of falls – 
Should we:  
Exclude on basis of either FRAT & 180 turn; or just the ‘time-steady 
stand’? 
CL - 180 turn may be adequate on own – if fail 1 minute standing they 
should be excluded – no matter what scores are on other assessments. 
To be completed without aids. There is a greater success rate if the 
participant is unaware of what they are being assessed for and are 
distracted 
SI – The FRAT is nationally used and would allow description of the 
population 
DL – Exclusion on the basis of one minute standing test and FRAT 
collected for completeness - agreed 
DL – The participants’ GP would be asked if they considered the 
participant unsuitable for the intervention on the basis of any existing 
cardio-vascular/pulmonary complaints 
DL – Do the group want to assess for vital signs? – yes 
JL asked if we were to include any operational assessment and criteria 
for exclusion based on sensory impairment – The group decided that 
the carer would be asked an over-arching question on whether they felt 
the person could participate in the intervention 
DL – Highlighted that the protocol development group had advised that 
the risk assessments should also be undertaken for the carers as they 
would be performing the intervention also. 
The group decided that utilizing the step test might be beyond some of 
the participants and so offered alternatives of attaching a heart rate 
monitor, or a pedometer.  
The use of a pedometer was further discussed. JL – the more 
  351  
 
expensive they are the more sensitive they are – this will be important 
within the population we’re recruiting from with limited mobility; 
Pedometer also good for motivation to persevere with the intervention. 
Suggested the therapist might test out the accuracy of the pedometer 
with participant on 1st visit- DL advised that this would be difficult.  
JL described the RPE and the group agreed that the target rate should 
be amended to 65%-70%, and that the participants should be 
encouraged to maintain this rate throughout the trial while extending the 
distance they cover. 
SI - need to measure the dose and increase if you can. 
Environment and terrain will have an impact, but the important point will 
be the RPE. 
DL asked the group if the therapist should suggest a minimum 
time/distance – The group agreed that it would be important to record 
these but not set a minimum 
There followed some discussion on the diaries, their purpose and who 
would complete them – the group were of the opinion that the diary 
should be structured in order to facilitate completion including the RPE – 
further, there should be separate diaries for carer and PWD to be 
completed individually where possible 
DL described the assessment schedule – and drew the group’s 
attention to the potential for accidental ‘unblinding’ the trial.  DL 
informed the group that they had devised two strategies to minimize this 
risk 1) The use of a separate researcher who administers the 
assessment via a telephone and 2) the completion of a scale by 
research workers to assess for knowledge of participant groupings – 
The group agreed these were good strategies and that there would be 
little other way in which to minimize this risk 
 
Action: 1. JL to investigate accuracy of pedometers and report 
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back to the group. 
2. DL to amend protocol to reflect today’s discussion and 
distribute to the group 
 
Time line 
The group worked through the projected timeline and the following 
additions were suggested: 1) the SG should see the final worked 
protocol by no later than May 2009 and this will be done electronically.  
2) Ethical and governance applications should be made by no later than 
June 2009 – If this is not the case, an emergency steering group should 
be convened. 3) Otherwise the steering group should next meet in 
September 2009. The primary topic for that meeting will be recruitment. 
 
Action: DL to distribute final worked protocol ASAP 
 
 AOB  and date of next meeting 
 NO AOB and date of next meeting is as above 
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3.2.2   13 October ‘09 
UCLH, Room 5 
 
Attendees: Craig Ritchie (CR)(Chair), Arlinda Cerga-Pashoja (ACP), Mark Griffin 
(MG), Clare Leonard (CL), David Lowery (DL), Lyn Strother (LS), Jane Wilcock 
(JWk) James Warner (JWr), 
Apologies: Rahul Bhattacharya (RB), Sandra Brookes (SB), Steve Iliffe (SI), James 
Lee (JL), Sue Ricketts (SR), Fiona Waters (FW), 
 
 Welcome & Introductions 
 CR welcomed and thanked attendees  
 CR introduced himself to the group 
 
 Previous Minutes 
 CR took the group through the minutes of the previous meeting point by 
point.  
 – LS informed the group that she was no longer comfortable with 
inviting her suggested person to the group due to circumstances 
surrounding that person’s experience of dementia. The group agreed that 
LS had made a wise decision. CR agreed to take this forward with his 
contacts. 
 - CR asked and DL confirmed that the project is DeNDRoN adopted. 
CR suggested contact with Tania Burke to support the project recruitment 
 - DL explained the decision not to use the pedometer: invasiveness, 
lack of sensitivity within our target population; and that we decided to use 
a proxy measure of heart rate at rest 
 - DL informed the group that the project had received ethical approval in 
July and that we were working with the relative trust to gain final 
governance approval. This involves completing two forms, after which the 
approval should take only a matter of days. 
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 - There followed some discussion of Site Specific Information forms and 
recruitment in Primary Care Trusts. CR advised the team to contact Jo 
Burns at Greater London Primary Care Research Network. 
 - There was some discussion on reporting accruals to the 
Comprehensive Local Research Network, JWk advised on processes 
and justification including recuperating service support costs for NHS 
Trusts; and CR described current policy on division of monies where 
complex research governance arrangements were in place 
 - CR offers open assistance to facilitate approvals for the study 
 - JWr informs the group that the project has also been registered with 
www.clinicaltrials.gov and describes the purpose of this  
 
Action: DL to discuss possible network support with Tania Burke 
(DeNDRoN) and Jo Burns (PCRN). 
 CR to seek a for person with dementia representative for the SG 
  
 Infrastructure 
 DL updated the group on study personnel 
 DL welcomed Arlinda Cerga-Pashoja (ACP) as research worker 
dedicated to the EVIDEM E project. JWr informed the group that ACP 
has registered to read for a PhD as part of this work with UCL.  
 DL informed the group of the appointment of a research worker, 
Ingela Thune-Boyle, who is to work across two EVIDEM projects with 
20% of her time specifically devoted to EVIDEM-E.  Ingela is likely to 
collect Neuro-Psychiatric Inventory data by telephone. 
 Also the management team decided to commission James Lee to 
provide the intervention part of the project on a consultancy basis.  DL 
explained that JL would not be employed by CNWL, but rather would 
provide the service according to a detailed payment structure  
 
  355  
 
 Methodology 
 DL tabled the scripts that form part of the trial master file. 
 The group agreed that the documents appeared to be fairly 
comprehensive, but the following issues were raised: 
 - LS The understanding and use of terms need to be checked 
 - JWk The use of the term dementia – JWk referred to the 
EVIDEM agreement to use ‘memory problems and difficulty with 
thinking’ 
 - CR Does the SG need to sign this off? 
Action: ACP to Pilot the Scripts and the Project Management Group is 
to sign them off when happy they are fit for purpose 
 
 Outputs – Dissemination Plan 
DL informed the group that the project had produced several outputs to date 
including a poster at DeNDRoN conference in 2008, a paper in the Journal of 
Integrated Care in early 2009 and a presentation to the Dementia Services 
Development Centre’s 2009 International conference.  DL highlighted that there 
had been some important aspects of our experiences during the design and 
development process that were worthy or reporting. DL informed the group that 
ACP is drafting a manuscript for submission to BioMed Central Trials.  DL also 
stated that it was his opinion that the SG membership should be included as 
authors given their contribution to the study design. JWk and JWr agreed with 
this position 
There followed some discussion on authorship policy, the role of the steering 
group with regard to outputs and the appropriateness of appearing as authors. 
CR clarified the SG role as 1) monitor, to ensure the adequate reporting of 
results; 2) Arbitrator, where disputes arise in authorship and acknowledgement. 
CR/LS/CL all stated that they did not expect authorship, and would leave this 
decision to the Project Management Group. 
Action: DL to draft and table an authorship policy at the next SG 
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Recruitment 
DL reminds the group of the three recruitment routes: 1. CNWL clinical teams; 
GP practices recruited to the EVIDEM programme; and North Thames DemReg. 
CR gave a description of NT DemReg its purpose, and current status.  CR also 
suggested discussion with Tania Burke, and that Ali Featherman would be in an 
ideal position to support recruitment. DL explained EVIDEM’s existing link with 
NT DemReg, through the operation of the pilot recruitment to the registry via 
GPs. 
LS asked if the recruitment was to be conducted of people using day centres  
 JWr informed the group that although participants wouldn’t be 
excluded on the basis of living within care homes, these wouldn’t 
be targeted as a specific source of recruitment 
 DL/CR raised the issued of methodological issue of recruitment 
strategy. MG highlighted that it would be impossible to obtain a 
‘representative’ population for any Randomized Control Trial 
 
 Time Line 
 JWr described a sigmoidal accrual profile the management group 
has approved for the recruitment targets – CR requested that this be 
provided to the SG for the next meeting to help them monitor the 
recruitment progress 
 CR inquired about data quality – MG described the double entry 
process – CR suggested the management group talk to CTU 
 
 AOB and date of next meeting 
 NO AOB and date of next meeting is as above 
 
3.2.3    25 May ‘10 
10:00 – 12:00   
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UCLH, 250 Euston Road 
 
EVIDEM- E: Randomized Control Trial looking in the Impact of Exercise on 
Individuals with Dementia and their Carers. 
 
Attendees: Craig Ritchie (CR)(Chair), James Warner (JWr), Natalie Fox (NF), 
Kalpa Kharicha (KK), Arlinda Cerga-Pashoja (ACP), David Lowery (DL),  
 
Apologies: Steve Iliffe (SI), Clare Leonard (CL), Fiona Waters (FW), Mark 
Griffin (MG), James Lee (JL), Lyn Strother (LS). 
 
Did not attend: Sue Ricketts (SR) 
 
1) Welcome & Introductions 
• CR welcomed and thanked attendees 
• As there was an imbalanced representation from the independent members 
of the steering group, it was discussed whether to go ahead with the meeting or 
reschedule it for another date. CR proposed to carry on with the meeting but to 
avoid making any important decisions at this instance.   JW suggested AP contacts 
Chris Bumstead (CNWL, Clinical Governance) regarding PPI involvement. KK 
suggested having a look at the Evidem self-referral list to identify possible PII 
representatives.  
 
2) Previous Minutes 
• CR took the group through the minutes of the previous meeting point by 
point. Previous minutes represented an accurate reflection of the meeting and 
were agreed by the group.  
 
o Previous Actions 
• DeNDRoN -ACP & DL met with Jose Trevino (DeNDRoN) on 26/02/2010, 
where Jose stated that he would enquire with his leads if he could assist 
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recruitment for the Evidem-E trial. Jose said that the Evidem studies would be 
included in the DeNDRoN pathways document. DL provided Jose with the 
information describing the Evidem studies. However, later on Jose informed DL 
and ACP that the Evidem studies have been dropped off the brochure. Jose said 
that he did not know the reason why. Jose also informed DL and ACP that he has 
been told by his managers that he cannot assist Evidem-E with recruitment. Action: 
CR to email Kath Mummery to clarify Evidem’s position with DeNDRoN. DL to 
contact DeNDRoN manager and enquire about DeNDRoN’s support to Evidem-E. 
CR to invite a representative from DeNDRoN to the next Steering Group Meeting. 
 
3) Recruitment 
• CNWL 
Recruitment in CNWL continues to be slow. Six people have been recruited into 
the trial since December 2009. ACP & DL are actively visiting teams in CNWL and 
providing clinicians with information about the trial as well as information packs for 
their clients/patients. NF suggested raising the issue in her monthly meetings with 
the nurse leads. Action: ACP to provide NF with information regarding packs sent 
to teams and patients. ACP and DL to attend the next meeting with NF and admiral 
nurses. NF, JW and CR to email all trust OA clinicians about trial importance and 
recruitment.  
 
Incentivising- CR enquired whether it is possible to present the champion team, 
who sends the most packs to participants, with a percentage of accrual rates from 
the money that goes to the trust. Action: JW to discuss with John Green.  
 
• WLMHT 
 ACP has completed a new SSI form, adding West London Metal Health Trust as a 
new participant identification site. ACP does not require an honorary contract as 
the R&D office will provide her with a Letter of Access as soon as all the checks 
have been carried out. The first SSI form was not accepted by the R&D office as 
there was no ample information in the form regarding the research team in 
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WLMHT. Discussions ensued regarding who will be part of the team in WLMHT, 
and about JL contract and indemnity. CR thinks That ITB and JL do not need to be 
included in the SSI. ACP and DL have met with Dr Regan (WLMH site PI) and her 
team, who are ready to recruit for the trial.  Action: CR to contact Lynis Lewis to 
clarify whom should we include in the SSI as working at the WLMHT site. 
 
• Registry 
DL informed CR that SI has emailed us the agreement letter regarding accruals. 
DL will email the letter to CR. Lisa Curry, the present manager can help with 
recruitment. CNWL will recruit for Demreg and Lisa Curry will act as coordinator for 
the site in the meantime. Action: DL and ACP to contact Lisa regarding recruitment 
for the trial. CR to ask Lisa to meet with JW regarding championing in his clinic to 
recruit for Demreg.  
• Other 
      CR suggested exploring recruitment with other trusts such as Barnet, Enfield 
and Haringey. Action: JW to discuss new recruitment pathways with Liz Sampson 
from Barnet, Enfield and Haringey NHS.  
             
4) Databases 
ACP- The Access database was abandoned as data collection in it seemed 
problematic. Another database was set up in Opinio, UCL based database. This 
was abandoned as well as it presented limitations in regards to double data entry. 
MG and ACP met and the team agreed to use Epi-data. Action: ACP to set up a 
new database in Epi-data, with MG’s help.   
 
5) Timeline 
DL explained that the study recruitment is running fairly late therefore, there is a 
slippage in timeline. CR set a target of having recruited a total of 16 participants in 
the trial by September.  
 
6) AOB  and date of next meeting 
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• Information sheets- ACP & DL were asked by clinicians of a team in CNWL 
to replace the word ‘dementia’ with ‘memory difficulties’. This was discussed in the 
group and it was decided that considering the forms were approved by the Ethics 
Committee, the wording remains the same.  
 
• ACP & DL- during a visit at IMPS team the physio lead talked about a 
validated intervention where walking is part of the intervention. Can we recruit from 
this group? Action: We can recruit after the client has been discharged from the 
intervention. 
 
• Adverse Events- One of our participants has, unfortunately, passed away. 
The death was unrelated to the trial. We have devised a letter to the GP to make 
sure the death was unrelated and to enquire whether there are any concerns about 
the trial. Action: AP to email the letter to CR.    
 
• JW thanked the group for a very productive meeting that filled him with 
enthusiasm.  
 
• The date of next meeting is 21 September 2010, 10:00-12:00. Venue to be 
booked 
 
 
 
 
 
 
 
 
 
3.2.4   21 September ‘10 
10:00 – 12:00   
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Cruciform Building (UCL), Gower St, Room B.01 
 
Attendees: Craig Ritchie (CR)(Chair), Kalpa Kharicha (KK), Arlinda Cerga-
Pashoja (AP), David Lowery (DL), Fiona Waters (FW), Sylvia Gupta (SG).  
Apologies: James Warner (JW), Steve Iliffe (SI), Clare Leonard (CL), Mark Griffin 
(MG), Lyn Strother (LS), Natalie Fox (NF). 
Did not attend: Sue Ricketts (SR) 
James Lee (JL) is no longer required to attend these meetings 
 
 Welcome & Introductions 
 CR welcomed and thanked attendees 
 
 Previous Minutes 
 CR took the group through the minutes of the previous meeting point by 
point. Previous minutes represented an accurate reflection of the meeting 
and were agreed by the group.  
 
a. Previous Actions 
 DeNDRoN: CR has emailed Dr Cath Mummery to clarify Evidem’s 
position with DeNDRoN. DL met with DeNDRoN manager and enquired 
about DeNDRoN’s support to Evidem-E. In the meeting it was agreed that 
we will receive support from DeNDRoN, and the Evidem studies will be 
included in its brochure.  
 Recruitment: AP has provided NF with information regarding packs sent 
to teams and patients. AP and DL attended the monthly meeting with NF 
and admiral nurses. The meeting went generally well, although some of 
the nurse leads seemed somewhat resistant to recruiting for the study. 
 NF, JW and CR have emailed all trust OA clinicians about trial 
importance and recruitment. This seems to have raised awareness and 
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there has been an increase in referrals as a result. 
 WLMHT: AP contacted the R&D department and updated the CSRI 
accordingly to include the WLMHT site. AP has also been issued with a 
Letter of Access for WLMHT. 
 Registry: AP has contacted Lisa and recruitment for the trial from the 
registry has commenced.  
 Databases: AP has set up a new database in Epi-data, with MG’s help.   
 Timeline: CR’s target of having recruited a total of 16 participants in the 
trial by September 2010 has been met. We have recruited 19 people so far.  
 Adverse Events: AP has emailed the adverse events letter to CR.    
 
 Recruitment: 
 
AP updated the group on accruals, expressions of interest and recruitment 
rates. AP     also feedback about different networks that have been 
supporting recruitment for Evidem-E: 
o North London Mental Health Research Hub has been supporting 
recruitment through two CSO’s: Amy Murphy and Antoinette McNulty. They 
have been actively meeting with OA teams in both CNWL and WLMHT, 
supporting the teams identifying eligible candidates and sending information 
packs to those eligible.  
FW said that the CSOs have visited her team and she believes way of 
recruitment works very well.  
o Demreg: AP has been sending invitations to people in the registry. CR 
explained to the group what Demreg is. CR raised his concern about people 
in the registry being contacted more than once through our different 
recruitment paths: from AP and from the CSOs. Action: AP and CSOs to 
make sure to use Demreg to exclude people that have been already 
invited into the study. CSOs need to have research passports for both 
CNWL and WLMHT. 
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o Living with Dementia and self-referrals. Our publication in Living with 
Dementia magazine arose interest about the trial and we received self-
referrals as a result, although most of them came from out of our 
geographical catchment area. SG suggested we consider posting on 
Talking Point Forum, which is part of Alzheimer’s Society website. Action: 
DL to contact Catherine Watt from the Alzheimer Society and to 
prepare material for publication on the forum.   
 
 Reporting and Dissemination 
o Newsletter: Content and frequency was discussed. It was agreed to 
produce it twice annually. CR suggested we ask people who have finished 
the trial about their experience in it. DL suggested we introduce the 
Steering Group members in our next newsletter.  
o Evidem-E Output strategy: DL discussed the themes for publications. CR 
enquired if there is a Cochrane review for BPSD and exercise and asked if 
would consider one.  
o Focus Group: DL and AP reported the attempt to run a few focus groups 
with professionals in order to explore barriers to recruitment and ways how 
to overcome the above. Although the groups did not happen as planned, we 
managed to hold one group and gathered some important views from 
clinicians. DL has prepared a draft, which we aim to publish as a letter in 
the International Journal of Geriatrics.  
 
 What is it like to be a control participant? 
Two participants have expressed dissatisfaction about being allocated in 
the control arm of the trial. AP and DL have amended the scripts to 
emphasize the probability of being allocated in the control arm. CR asked if 
could investigate motivation for participation in research prospectively, as 
people enter the trial and at the end of it.  
DL explained that one participant on the control arm has asked to come out 
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of the trial then re-enter it in order to receive the intervention. The group 
agreed that this would affect study’s rigidity and we can not take this 
approach. CR asked if we could offer exercise intervention at the end of the 
trial to people in the control group. DL explained that financial constraints 
do not allow us to provide intervention individually, but we may be able to 
provide a group approach. On the other hand, we are not sure if the 
intervention is beneficial and it would be presumptuous to offer intervention 
while we are still trialing this.  
 
 Time line 
DL has recalculated target numbers. We need to recruit 10 dyads a month, 
which puts us in a tight time schedule. KK advised that we take into account 
that the overall program ends in July 2013 and we need to contribute to its 
final report.   
KK asked if we can recruit from primary care. CR thought recruiting from 
primary care can be both time and effort consuming and most of the people 
diagnosed with dementia in primary care are being seen in secondary care 
as well.  
  
 AOB 
o SG emphasized the importance that different dementia subtypes react 
differently to interventions. People also deteriorate at different rates and 
experience different symptoms. SG asked how does the study account for 
this. CR explained that Evidem-E is a big trial with a large sample size, 
which should account for such differences. AP talked about the tools we 
use to capture data such as NPI, qualitative interviews and diaries. SG also 
asked about the effect of medication, and how we monitor this. AP 
explained that we monitor medication at baseline, week 6 and week 12 into 
the trial. The group suggested we also monitor it at week 26. Action: AP to 
send SG copies of the NPI and the diary. AP to add medication at 26-
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week interview.   
o DL enquired if the present Steering Group membership is working. Action: 
CR to contact Natalie Fox and Sue Ricketts to clarify their future 
involvement with the group.  
 
 date of next meeting 
14 December 2010, 10:00-12:00, Greater London House, Boardroom.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.2.5   14 December ‘10 
10:00-12:00 
Greater London House, Boardroom 
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Attendees: Craig Ritchie (CR)(Chair), Kalpa Kharicha (KK), Lyn Strother (LS), 
Clare Leonard (CL), Arlinda Cerga-Pashoja (AP), David Lowery (DL), Fiona 
Waters (FW)  
Apologies: James Warner (JW), Steve Iliffe (SI), Mark Griffin (MG), Natalie Fox 
(NF), Sylvia Gupta (SG). 
 
 Welcome & Introductions 
 CR welcomed and thanked attendees 
 
 Previous Minutes 
 CR took the group through the minutes of the previous meeting point 
by point. Previous minutes represented an accurate reflection of the 
meeting and were agreed by the group.  
 
a. Previous Actions 
 AP had advised the MHRN CSO’s to make sure there are no duplicate 
invitations to the study, thus avoiding overburdening people.  CSO’s 
have valid research passports for both CNWL and WLMH. 
 DL has contacted Catherine Watt from the Alzheimer Society and 
published material on the web-based Talking Point Forum. 
 AP has sent SG copies of the NPI and the diary. 
 AP has added medication info at 26-week interview. 
 
 Recruitment 
 
o AP updated the group on recruitment numbers, expressions of interest 
and recruitment rates: 38 participants recruited so far, 2 – waiting to be 
randomized, 22 - not eligible, 70 - declined participation. DP presented 
  367  
 
a chart of projected and achieved recruitment figures. Currently we are 
on target.  
  
AP  and DL feedback about different networks that are supporting 
recruitment for Evidem-E: 
 
o NHS Clinicians: Amy Murphy and Antoinette McNulty from MHR have 
been recruiting actively from CNWL and WLMH. There has been an 
increase in recruitment figures, however there is a risk these figures 
may start falling again with the exhaustion of the present resources. 
Action: AP to send NF recruitment information broken down per 
each CNWL team.  
AP has received a list of 111 people with dementia from Dr Regan 
(WLMHT) and has been sending information packs to everyone on the 
list.   
James Warner is negotiating with CNWL in order to generate a central 
list of everyone         in the trust with a diagnosis of dementia.  
 
o Care and nursing homes: A few independent care homes have 
expressed an interest to participate in the Evidem-E study. However, 
there is a concern over contamination of intervention and especially 
regarding the control group in such settings. The group suggested we 
should pursuit recruitment with the care homes, but should proceed 
slowly and carefully, i.e. just a couple of participants at a time.  
  
o East London Mental Health Trust: We may expand our recruitment to 
ELMHT. Rahul Bhattacharya who is a member of the study team is 
exploring with the trust the opportunity to set up a research site for 
Evidem-e within the trust.   
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o DeNDRoN:  As mentioned previously we are very grateful to the CSOs 
from MHRN for their invaluable support with recruitment. This support is 
to end and is being presently transferred to Jonathan Anderson a CSO 
from Dendron. Jonathan will provide support for Evidem-E recruitment 
for two day a week. He is presently setting up IRAS application to 
include Barnet Enfield and Haringey NHS Trust as a patient 
identification site.  
 
o Demreg: AP has sent invitation packs to 88 people on Demreg. 
Unfortunately the reponse has been disappointing: 3-recruited, 3-not 
eligible, 10-declined, 72-did not reply. CR explained that Sarah 
Gregory will be helping to populate the registry from CNWL and demreg 
numbers should increase.  CR asked if it would be difficult for AP to 
manage recruitment single-handed. This has not been a problem so far, 
we’ll monitor progress.  
 
o Self referrals : FW inquired about Talking Point publication and 
whether it raised to interest and self-referrals. DL said that he has 
posted a blog but no one has made any comments about it. LS 
suggested that the blog may need rewording and volunteered to 
contribute to this. Action: DL to revise Talking Point blog.  
 
 Reporting and Dissemination 
 
o Newsletter was circulated and amendments were suggested in relation 
to a typo.  
  
o Focus Group write up has been accepted as a letter to the editor, by 
the International Journal of Geriatric Psychiatry.  
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o SAPC: AP is presenting at the Society for Academic Primary Care 
conference in Madingley, Cambridge. The presentation is about 
Evidem-E recruitment challenges. 
  
o BPSD review paper will be submitted soon for publication 
 
 Qualitative work 
o AP presented topic guides for interviews with control and intervention 
participants, and raised the question: when should we start gathering 
the qualitative data. Considering AP is blinded to group allocation, she 
can only gather such data from participants she is already de-blinded. 
CR asked if we are excluding participants we get deblinded from. The 
answer is No. Considering this is a single blind, pragmatic trial we 
expected for deblinding to happen. AP gave examples of cases when 
she has been deblinded.  
o FW suggested if the qualitative interviews can be done by someone 
else, not AP, on the telephone. Action: The group suggested this 
methodological issue needs to be raised with the trial management 
group.   
 Date of next meeting 
 
18 March, 15:00-17:00 
 
Boardroom B  
Greater London House, 
Hampstead Road  
London NW1 7QY 
3.2.6   18 March ‘11 
15:00-17:00 
Boardroom B, Greater London House, Hampstead Road, London NW1 7QY 
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Attendees: Craig Ritchie (CR)(Chair), Steve Iliffe (SI), Clare Leonard (CL), 
Arlinda Cerga-Pashoja (AP), David Lowery (DL),  
 
Apologies: James Warner (JW), Kalpa Kharicha (KK), Natalie Fox (NF), Lyn 
Strother (LS), Sylvia Gupta (SG), Fiona Waters (FW). 
 
 Previous Minutes 
 CR took the group through the minutes of the previous meeting point 
by point. Amendments: In page 2, paragraph 6 change LS to SG.  
 
a. Previous Actions 
 AP has sent NF recruitment information broken down per each CNWL 
team.  
 DL has revised the Talking Point blog according to SG suggestions.   
 
 Recruitment 
 
o AP updated the group on recruitment numbers, expressions of interest 
and recruitment rates: 48 participants recruited so far, 27 - not 
eligible, 108 - declined participation. A chart of projected and 
achieved recruitment figures was presented. Currently we are lagging 
behind the revised target numbers.  
  
AP  and DL feedback about different networks that are supporting 
recruitment for Evidem-E: 
 
o NHS Clinicians:  
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o CNWL- JW will identify patients to invite to the study from his workload 
and start sending invitation packs to his patients.  
 
o WLMHT- AP has been visiting Brentford Lodge and several 
recruitments have happened as a result.  DL said that from his 
discussions with Sujoy Mukherjee, he suggested to visit other memory 
clinics in WLMH. Action: AP to arrange to meet with Sujoy.   
 
o East London Mental Health Trust: Agreements are with John Green 
to be signed. Preliminary advisory sessions for awareness raising with 
clinical teams are scheduled for early April. KK and DL to organize 
these sessions.   
 
o DeNDRoN:  Barnet Enfield and Haringey NHS Trust have been 
added as patient identification site.   
 
o Demreg:  Barnet Enfield and Haringey NHS Trust have been added 
as patient identification site. Recruitment from WLMHT is going 
very well.  
 
o Self referrals: DL has revised the Talking Point blog but it has not 
raised any interests as yet.    
 
o Housing 21: is an organisation that provides care, health and housing 
services for the elderly. Can we recruit from Housing 21? It was agreed 
that we can visit tenants’ meetings and discuss our study with tenants. 
Any referrals as a result with be considered as self-referrals. Action: DL 
to attend visits at Housing 21 homes.  
 
o Evidem-ED: SI agreed that people who finish their participation with 
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Evidem-ED can be invited to Evidem-E. This will be done during their 
final interview that Ingela is presently conducting. SI said that there are 
about 70 people that may be approached. Action: SI to clarify with 
Ingela.  
 
o GP’s: SI asked if we can recruit from the primary care and work through 
issues that may arise ethically and practically. Evidem-ED has worked 
with 20 GP practices and they have agreements in place for these 
practices. Action: SI to discuss with Priya regarding involving GP 
surgeries in Evidem-E recruitment.  
 
o Press: SI asked if we can advertise to the press. DL explained that he 
has been approached by BBC One about being interviewed in regards 
to exercise and dementia subject.  
 
o CR asked whether there was any possibility for the study to be 
extended. Unfortunately, this is not possible.  
 
 Reporting and Dissemination 
 
o Summer School: CNWL has committed to hold an event mainly for 
CNWL staff on Friday 7 October. It is planned that this year Evidem 
themed events will be delivered to Band 7 clinicians.  
 
o Dementia Care Congress: DL asked about ideas regarding our 
presentation at the Dementia Care Congress. CL suggested to set up 
several scenarios such as getting people to walk up and down the 
room, give them multiple tasks to carry out etc.  
 
AOB: Fiona Waters has left her position with CNWL and is no longer able 
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to participate in this group.   
 
 Date of next meeting 
6 October 2011 
12:00-14:00 
Room 3 
Greater London House, Hampstead Road, London NW1 7QY 
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3.2.7   6 October ‘11 
Boardroom B, Greater London House, Hampstead Road, London NW1 7QY 
 
Attendees: Craig Ritchie (CR)(Chair), Steve Iliffe (SI), James Warner (JW), Clare 
Leonard (CL), Arlinda Cerga-Pashoja (AP), Sylvia Gupta (SG) 
Apologies: Kalpa Kharicha (KK), Lyn Strother (LS), David Lowery (DL), Alison 
Gordon (AG) 
 Previous Minutes 
 
 CR took the group through the minutes of the previous meeting point 
by point.  
 
a. Previous Actions 
 
 AP has tried to arrange to meet with Sujoy Mukherjee, PI for WLMH, 
but has been unsuccessful.  
 DL has visited the Housing 21 homes and we’ve recruited a few 
participants as a result.     
 SI confirmed that Evidem-ED follow-ups are about to conclude and we 
shouldn’t be expecting many more referrals from it.  
 
 Extension of Evidem-E 
 
The trial has been granted a non-cost extension from NIHR for six 
months. Therefore we will be recruiting until June 2012. CR advised that 
we should inform Dendron as well as the Ethics Committee about the 
extension. Action: AP and DL to inform the above bodies about the 
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trial extension.    
 
JW explained that trial’s dropout rate has been 10%, which is lower than 
the 20% predicted rate used when power calculations were carried out. 
JW said that when using the actual dropout rate the recruitment target is 
120 dyads. JW asked the group if we should keep recruiting beyond 
120. CR said that as there is no risk involved we should carry on 
recruiting until we meet the initial target of 146 dyads or until the 
recruitment end date.  
 
 Recruitment 
 
o AP updated the group on recruitment numbers, expressions of interest 
and recruitment rates: 80 participants recruited, 44 - not eligible, 137 
- declined participation. A chart of projected and achieved recruitment 
figures was presented.  
 
o NHS Clinicians:  
 
o CNWL- JW has asked his PA to send invitation packs to his patients. 
AP has not received any interest so far. Action: JW to ask Sheila how 
many packs have been sent out.    
 
o WLMHT- Unfortunately, AP has not been able to contact Sujoy 
Mukherjee or arrange visits to his memory clinic. However, referrals 
from Brentford Lodge have been coming regularly, especially from 
Demreg.  
 
o East London Mental Health Trust: Recruitment at this site is going 
very slow. We have only recruited one dyad from this site.  
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o Demreg: Luton has been added as patient identification site. 
Recruitment to start soon.  
 
o Housing 21: DL has attended a few homes in the scheme and five 
dyads have been recruited as a result.   
 
o Evidem-ED: Four dyads have been recruited from Evidem-ED. Ingela 
said that we shouldn’t expect any new referrals.  
 
 Reporting and Dissemination 
 
o Summer School: CNWL has committed to hold an event mainly for 
CNWL staff on Friday 7 October. It is planned that this year Evidem 
themed events will be delivered to Band 7 clinicians, who will then 
cascade the information to their teams.  
 
o Dementia Care Congress: DL is presenting a session called: Providing 
People with Dementia and their Carers with Tools to improve their 
levels of Physical Activity. 
 
o Chartered Society of Physiotherapy Annual Congress “Liverpool”: 
DL and JL are co-presenting the pilot video kit in a session called: 
Physical Activity as a tool for improving outcomes for people with 
dementia: current clinical guidelines, research recommendations and 
gaps in our knowledge.   
 
o Gerontological Society of America Conference: Our abstract has 
been accepted for presentation at The Gerontological Society of 
America's 64th Annual Scientific Meeting. The title of the session is: 
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Factors Affecting Clinician Engagement in Recruitment for Dementia 
Trials. 
 
o AP has successfully converted from MPhil to PhD status.  
 
o CR stated that the trial’s dissemination strategy is very impressive.  
 
 Date of next meeting 
 
15 March 2012 
12:00-14:00 
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3.2.8   15 March ‘12 
 
12:00-14:00 
 
Alexander Fleming, Stephenson  House, 75 Hampstead Road, London NW1 
2PL 
Attendees: Craig Ritchie (CR)(Chair), Clare Leonard (CL), Arlinda Cerga-
Pashoja (AP), Gill Sargeant (GS), Jane Wilcock (JWC) 
Apologies: Steve Iliffe (SI), James Warner (JW) 
Previous Minutes 
 
CR took the group through the minutes of the previous meeting point by point.  
 
Recruitment (AP) 
Update on recruitment rates. CR said that WLMH will have a last drive to recruit 
as many participants as possible. Claudia Wald, consultant at Westminster 
Memory Service is very keen to recruit.  
J WC enquired about who is classified as ‘self-referred’. AP and DL explained 
they include participants from Housing-21 and Memory Cafés. 
 
Reporting & Dissemination (DL) 
Video toolkit and Alzheimer’s Society bid (DL) 
DL talked about his presentation at Dementia Care Congress where the video 
tool kit was piloted. This received good support from Congress participants. 
Useful suggestions to modifying it were also made. This work turned into an 
application for Alzheimer’s dissemination grant, which we’re waiting to hear 
about.  
SG members suggested the video can be disseminated through the Alzheimer’s 
Society website, DVD’s on request, YouTube, AgeUK, Demreg newsletter etc.  
JWC asked if there will be any feedback from those viewing the video. CR 
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suggested sending a card with the DVD, which people can tick and return to 
study team, or if the video is being played online to have a box popping out with 
a short feedback form.  
 
CR said that we may disseminate at memory clinics, but may need to wait until 
the outcomes are clear.  
GS said that she can put us in touch with AgeUK communication team. 
 
James Lee’s dissertation  
James Lee is attending his final BSc year and has proposed to utilize some of 
the physical data (Blood pressure). CR advised that this may compromise data 
integrity (blinding). It was agreed that JL will utilize the before and after data of 
the intervention group only. His findings will be submitted in the interim report.  
 
Alzheimer Disease International Conference 
We presented a poster on the Alzheimer Disease International Conference last 
week. The poster raised interest.  
 
Adverse events 
An incident has been reported to JL, who reported to DL. The incident was 
classified as not related to the trial and the participants have agreed to 
contribute their data in the follow ups.  
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3.2.9   17 December ‘12 
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